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ABSTRACT 
CD147, also known as basigin, extracellular matrix metalloproteinase inducer, 
neurothelin, tumour cell-derived collagenase stimulatory factor, M6, HT7, OX47 or 
gp42, is a transmembrane glycoprotein of the immunoglobulin super-family. It is 
expressed in many neuronal and non-neuronal tissues with high expression in the 
hippocampus, pre-frontal cortex, thyroid, heart, early erythroid, amygdala and placenta. 
This protein is involved in various cellular and biological functions such as lymphocyte 
migration and maturation, tissue repair, cancer progression, T and B lymphocyte 
activation and induction of extracellular matrix metalloproteinase. The CD147 protein 
interacts with with cyclophilin A, cyclophilin B, sterol carrier protein, caveolin-1 and 
integrins, and can influence beta amyloid peptide levels, a protein that is central to 
Alzheimer’s disease pathology.  
 
Mechanisms through which CD147 regulates bata amyloid levels still remain unclear, 
thus the current study investigated the impact of high cholesterol and beta amyloid 42 
loading on CD147 expression in rat primary cortical neuronal cultures. Its expression in 
human brain tissue from Alzheimer’s disease and non-Alzheimer’s disease dementias 
and APPswe transgenic mice fed on a high fat/high cholesterol diet were also 
determined. CD147 over expression experiments in rat primary cortical neuronal and 
SH-SY5Y cultures using recombinant adenoviruses (AdRSV-CD147 and AdRSV-
Empty) in the presence and/or absence of cyclophilin A were employed to determine 
level of proection against oxidative stress and toxicity. Finally sequencing of the CD147 
promoter region (-392 to -242 nucleotides) was perfomed to identify possible single 
neucrotide polymorphysims that may be linked to Alzheimer’s disease pathology.  
 
iv 
The in vitro experiments conducted in this study have shown that cholesterol and beta 
amyloid loading and oxidative stress result in increased CD147 expression in rat 
primary cortical neuronal cultures and that CD147 protects neuronal cultures from beta 
amyloid toxicity only in the presence of cylophilin A.  However in vivo experiments in 
animal model have shown that a high fat/high cholesterol diet does not affect brain 
CD147 levels as evidenced by unchanged expression levels in APPswe mice.  
 
Human studies have revealed a correlation between CD147 and γ-secretase complex 
components (nicastrin and presenilin 1) in the hippocampus. However, there is no 
difference in CD147 protein expression between hippocampus and frontal cortex from 
Alzheimer’s disease patients.  Sequencing of the CD147 promoter region, where sterol 
carrier protein binds to initiate CD147 transcription, has identified two novel single 
neucrotide polymorphysims (-61A>G and 37C>G). However, single neucrotide 
polymorphysims within this region are not associated with Alzheimer’s disease 
pathology. 
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Aβ  Amyloid beta peptide 
AD  Alzheimer’s disease 
ADAM A disintegrin and a metalloproteinase 
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ROS  Reactive oxygen species 
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RT  Room temperature 
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SD  Standard deviation 
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SE  Standard error 
SEM  Standard error of mean 
SLE  Systemic lupus erythematous  
SPE  Sperm integral membrane proteins 
StAR  Steroidogenic acute regulatory protein 
TACE  Tumour factor-α converting enzyme 
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TCSF  Tumour cell-derived collagenase stimulatory factor 
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CHAPTER 1 
Introduction 
1.1: Alzheimer’s disease (AD) 
  
In November 1901, a woman called Auguste Deter was admitted to a mental hospital by 
a German neuropathologist/psychiatrist Alois Alzheimer because of impaired memory, 
paranoia and disorientation complaints. Her condition deteriorated after a few years 
leading to language deficits, hallucinations and aggressive behaviour. Her physical and 
mental condition deteriorated considerably, consequently resulting in her death in 1906. 
After Auguste’s death, Alzheimer performed an autopsy on her brain and identified 
unusual formations which are now known as the characteristic hallmarks of Alzheimer’s 
disease, namely neurofibrillary tangles and amyloid plaques.  
 
Currently, dementia, of which Alzheimer’s disease (AD) is the most common form, is 
posing escalating social and financial burdens especially with the ageing population. 
Globally, it is estimated that there are about 26.6 million dementia cases with 
approximately 245,000 cases being in Australia, and of these, 50 – 70 % are AD cases. 
This is expected to rise to approximately 1.1 million by 2050 with an annual financial 
impact on the Australian community already exceeding $6.6 billion annually (Access 
Economic Report, 2003).  The disease is a progressive neurodegenerative disorder 
resulting in atrophy of the brain due to neuronal loss (Fig. 1.1B) and clinically, is 
characterised by memory impairment and behavioural changes. To date, post-mortem 
examination is still the most affirmative determination of AD, based on the presence of 
the pathological hallmarks. With advances in brain imaging technology such as 
magnetic resonance imaging (MRI), computed tomography (CT) and positron emission 
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tomography (PET), there is now an opportunity to diagnose and differentiate AD ante-
mortem from various other dementias. Over the past several years there has also been 
intensive research to identify biomarkers that can be used to diagnose AD with high 
sensitivity and specificity, prior to onset of symptoms. 
 
Although pathological hallmarks of AD (Fig.1.2 and 1.3) have been known for over a 
century, there is still no consensus on the chain of events that result in the onset and 
progression of AD.  A number of hypotheses have been postulated to account for 
neuronal dysfunction/loss in the AD brain. Of these, the most widely studied and 
accepted is the “amyloid hypothesis” which postulates that the aggregation and 
accumulation of a small peptide, termed amyloid-β (Aβ), triggers a cascade of events 
that include the generation of free radicals, oxidative damage and inflammatory 
processes, resulting in neurodegeneration.  The Aβ protein is a small 4-kDa peptide that 
is generated from the proteolytic processing of its parent molecule, the amyloid 
precursor protein (APP) (see below and Fig.1.5) (Yu et al., 2000, Jankowsky et al., 
2004, Krishnaswamy et al., 2009, Ionov and Pushinskaya, 2010, Perez et al., 2010, Guo 
et al., 2011, Kim et al., 2011).  
 
Dysregulated proteolytic processing of APP or impaired Aβ clearance are primary 
events that lead to the accumulation of Aβ within the AD brain. In familial cases, where 
genetic mutations are inherited in an autosomal dominant manner, the dysregulated 
proteolytic processing of APP is thought to lead to the accumulation of Aβ, whereas in 
the more common sporadic cases, the impaired clearance of Aβ from the CNS is 
thought to be a major contributor to AD pathogenesis.  One protein that has been 
implicated in both the production and clearance/degradation of Aβ is CD147. The 
CD147 protein is a transmembrane glycoprotein originally described for its ability to 
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activate metalloproteases and amongst its many functions has been recently thought to 
modulate Aβ levels. Discussed below is a general overview of AD pathogenesis and the 
implications for CD147 in modulating Aβ accumulation and neuronal functions that 
may be compromised in AD. 
 
1.2: Neuropathological Characteristics of Alzheimer’s disease (AD) 
 
As AD progresses, gross morphological changes occur, such as the widening of the 
sulci, narrowing of the gyri and enlargement of the ventricles of the brain, in the 
frontotemporal areas (Fig.1.1) (Wu et al., 2003, Wu et al., 2010).  During the early 
stages of AD there is atrophy of the medial temporal lobe, hippocampus, and the 
amygdala (Cahill and McGaugh, 1998).  Loss in brain mass due to degeneration is 
generalised.  The progression of brain atrophy starts from the temporal lobe and spreads 
to the frontal lobe and cerebral cortices (Baum et al., 1995).  Measurement of the medial 
temporal lobe has been used in diagnosis and in the monitoring of disease progression 
(Denihan et al., 2000). 
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Figure 1.1: Representative schematic diagram of post-mortem brain cross-sections.  
 Differential characteristics of health control brain (A) and Alzheimer’s disease patient 
(B). The AD brain is featured by severely enlarged ventricles and shrinkage of the 
cerebral cortical and hippocampal regions, which are responsible for memory and 
cognitive functions.  
(Image courtesy:http://knol.google.com/k/lara/alzheimer-s-disease/Ing3X-E/g1JpHQ). 
  
A B 
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The histopathological hallmarks of AD are senile plaques (SP), neurofibrillary tangles 
(NFTs) and congophillic amyloid angiopathy (CAA) (Vinters and Gilbert, 1983).  The 
early NFT and SP deposits are concentrated in regions of the brain mostly associated 
with memory and learning such as the hippocampus (Masters and Beyreuther, 1995, 
Gilman, 1997).   
 
1.2.1: Neurofibrillary tangles (NFT) 
 
A key characteristic of AD is the pattern of NFT lesions in the brain that is symmetrical 
in both hemispheres (Braak and Braak, 1997).  In healthy neurons, microtubules are 
parallel structures involved in cell motility, transport, shape and mitosis that are 
supported by tau proteins (Goedert, 1993, Avila et al., 2004).  The equilibrium between 
phosphorylation and de-phosphorylation of tau modulates the cytoskeleton influencing 
the morphology of the axon (Maccioni et al., 2001).  The hyper-phosphorylation of tau 
protein reduces the binding of tau to microtubules resulting in the formation of 
filamentous structures called paired helical filaments (PHF) which are the basic 
constituents of NFT (Fig. 3) (Goedert, 1993, Gilman, 1997).  
 
1.2.2: Senile plaques (SP) 
 
Senile plaques consist of a central core of radiating amyloid fibrils surrounded by 
dystrophic neurites and activated glial cells. Plaques may also appear as a diffuse 
amorphous deposition of Aβ (Eikelenboom et al., 2010, Hurtado et al., 2010, Perl, 
2010).  Silver staining reveals a central core of Aβ surrounded by swollen abnormal 
neurites (Fig. 1.2) (Anderton, 2002, Mathis et al., 2004).  Congo red staining reveals a 
characteristic birefringence seen under polarised light indicating the anti-parallel beta-
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sheet conformation of Aβ; this is the characteristic that makes it “amyloid”.  
Transmission electron microscopy reveals the fibrillary nature of the plaque cores that 
reflects the distinguishing pattern of Aβ aggregation (Morris, 1997).  The number of SP 
are greatly increased in AD (Mathis et al., 2004), compared to what can be found in an 
apparently normal person – it is thought that the presence of significant numbers of SP 
and NFT indicate pre-clinical AD, since by the time AD symptoms arise, 
neurodegeneration has been occurring for years. 
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Figure 1.2: Neurofibrillary tangles (NFT) and senile plaque (SP) 
Comparison of a normal brain (A) and pathological hallmarks of AD (B) showing NFT 
described as filamentous structures arranged in bundles within affected neurons and SP 
with the characteristic dense core of beta amyloid. (Image courtesy: http://ww.spice-of-
life.com). 
  
A B 
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1.2.3: Cerebral amyloid angiopathy (CAA) 
 
Congophillic amyloid angiopathy (CAA) is due to Aβ peptide accumulation in blood 
vessel walls within the brain (Fig.1.3) (Weller et al., 2000).  CAA increases the 
frequency of intracerebral haemorrhage as a result of vessel wall weakness.  Smooth 
muscle tissue is replaced by Aβ in the blood vessels.  This results in hindrance of 
arterial elasticity which plays a significant role in the clinical pathology of AD (Weller 
et al., 2000).  
 
 
 
Figure 1.3: Congophillic amyloid angiopathy 
Concentric cellular, eosinophilic thickening of penetrating cortical vessels with severe 
luminal narrowing, typical of advanced amyloid angiopathy (haematoxylin and eosin) 
(Weller et al., 2000) 
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1.3: Risk factors of AD 
 
Alzheimer’s disease can be classified broadly into two groups, late-onset AD (LOAD, 
occurring >65 yrs) and early onset AD (EOAD, occurring < 65 yrs). The more common 
sporadic late-onset cases are associated with many risk factors. Of these age and 
possession of the ε4 allele of the APOLIPOPROTEIN gene (APOE ε4) are the major 
risk factors for most populations globally (Roses, 1994, Martins et al., 1995, Roses, 
1997, Martins et al., 2006).  Many other potential risk factors for AD have been 
described which include, low levels of sex steroids (Pericak-Vance et al., 1991, Poirier 
et al., 1993, Strittmatter et al., 1993, Haskell et al., 1997, Lambert et al., 1998, Short et 
al., 2001), increased levels of gonadotropins (Smith et al., 1998, Bowen et al., 2000, 
Short et al., 2001), head injury, physical inactivity, stroke, diabetes, hypertension, and 
hypercholesterolemia. In addition to APOE ε4, recent genome-wide association studies 
in humans have identified a number of possible additional loci associated with increased 
risk for LOAD (Caselli et al., 2009). These have revealed associations of specific genes 
such as TOMM40, APOC1, CLU, CRI, PI-CALM, EXOC3L2, BIN1and APOC2 with 
LOAD (Bertram et al., 2007, Harold et al., 2009, Lambert et al., 2009, Seshadri et al., 
2010). Although these genes have had various, significant associations with LOAD, 
APOEε4 is still by far the strongest genetic risk factor of AD.  
 
The human APOE gene is located on the long arm of chromosome 19 (19q13.2) 
(Olaisen et al., 1982, Das et al., 1985).  It is 3.7 kb in length containing three exons and 
introns and encodes a 34kDa protein. There are three major polymorphisms of APOE 
(ε2, ε3, and ε4), which result from a single amino acid substitution at residues 112 
and/or 158 (Utermann et al., 1980, Rall et al., 1982, Weisgraber et al., 1982). Of these 
APOE alleles, the ε4 form is associated with an increased risk of developing AD with 
approximately 40-60% of sporadic cases carrying this allele. The APOE ε4 allele is 
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associated with a rapid decline in memory in individuals without dementia and in 
individuals considered to have mild cognitive impairment (Boyle et al., 2010). Further, 
the risk of developing AD markedly increases in individuals with increasing copy 
number of the ε4 allele.  Risk increases from 3.5 times when carrying one copy of ε4 
(heterozygous) to almost 15 times when carrying two copies of ε4 (homozygous) 
compared to those lacking ε4 (Breitner et al., 1998, Davidson et al., 2006).  Individuals 
who have AD and have two copies of the ε4 gene develop the disease earlier compared 
to those that do not possess this gene or have only one copy of this gene. Similarly, 
individuals with two copies of APOE ε4 also appear to have a more severe pathology. 
The APOE ε2 allele, on the other hand, associated with a reduced frequency in the AD 
population, is associated with a delayed age of onset of AD and is associated with a less 
severe pathology than that observed with AD patients harbouring APOE ε4. Thus the 
presence of the APOE ε2 allele is thought to exert a protective effect. 
 
The combination of APOE ε4 and other environmental or dietary risk factors for AD 
can increase the risk of developing the disease further. The presence of the APOE ε4 
allele in western society also increases the risk of other disorders associated with high 
fat/ high cholesterol intake, including type-2 diabetes, hypertension (high blood 
pressure), hypercholesterolemia (high cholesterol levels) and cardiovascular disease, all 
of which are also AD risk factors (Simons et al., 1998a).  Research reports have also 
shown evidence that a higher intake of calories and saturated fat may be associated with 
increased risk of AD in individuals with the APOE ε4 allele (Kalmijn et al., 1997, 
Refolo et al., 2000a, Mihovilovic et al., 2007, Torreggiani et al., 2009). Furthermore, 
individuals with type-2 diabetes possessing the APOE ε4 allele are at twice the risk of 
developing AD compared to ε4 carriers who do not have diabetes (Martins et al., 2006). 
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These studies provide evidence in support of an interaction between APOE ε4 and 
dietary factors enhancing the risk of AD.  
The major function of  apoE is to mediate the clearance of lipoproteins by interacting 
with the low-density lipoprotein (LDL) family on receptors in liver cells (Beisiegel et 
al., 1989). ApoE-containing lipoproteins initially bind to cell surface heparin-sulphate 
proteoglycans, and are subsequently transferred to the LDL receptor-like protein (LRP) 
or LDL receptor for endocytosis via clathrin coated vesicles (Ji et al., 1993, Havel, 
1998). Studies also suggest an important role for apoE in the uptake and redistribution 
of cholesterol within the CNS (Roheim et al., 1979, Pitas et al., 1987, Holtzman et al., 
1995).  
 
Several mechanisms of action of apoE have been proposed that may account for its 
association with AD.  These include modulating the metabolism of Aβ by influencing 
its clearance and aggregation rates (Bales et al., 2002). In animal models, apoE has been 
associated with brain cholesterol such that high cholesterol levels increase Aβ 
accumulation within the brain (Refolo et al., 2000a).  A study by Naslund et. al., 
(Naslund et al., 2000) showed that ApoE co-localised with Aβ in SP within brain tissue 
from AD cases.  ApoE has also been shown to enhance the aggregation of Aβ1-40 
(Sanan et al., 1994).  Conflicting results from various studies exist on the influence of 
the apoE ε4 isoform on cellular uptake of Aβ1-40 with some studies showing this 
isoform to be correlated with increased Aβ40 uptake.  Conversely other groups have 
shown that Aβ uptake is reduced in the presence of the apoE ε4 isoform compared to 
the other apoE isoforms (Yang et al., 1995, Cole et al., 1999).  These discrepancies have 
been explained by the fact that earlier studies showing enhanced aggregation of Aβ1-40 
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with apoE ε4 isoform used poorly lapidated apoE which compromised its function 
(Yang et al., 1995). 
 
 Recent studies have shown that apoE binds to Aβ and may modify its biological 
activities.  Wilhelmus and colleagues (Wilhelmus et al., 2005) evaluated the effect of 
apoE on Aβ-mediated toxicity of cerebrovascular cells.  Their results showed that 
cultured cells with ε4/ε4 genotype were more vulnerable to Aβ toxicity than those with 
ε3/ε3 or έ3/ε4 genotype (Wilhelmus et al., 2005).  Taken together, these outcomes 
suggest that apoE plays a direct isoform specific role in Aβ deposition.  This notion is 
supported by the findings in mouse models where differences in isoform specific action 
on Aβ aggregation and clearance by apoE ε4 and apoE ε2 respectively were identified 
(Smith et al., 1998).  
 
Increased levels of apoE have a detrimental influence on the neuronal cell system 
promoting cytotoxicity or neurite degeneration (Hashimoto et al., 2000).  However, low 
levels of plasma apoE are found in AD subjects (Veer et al., 2011). Current data suggest 
that one mechanism by which apoE may alter the risk for AD is isoform-dependent 
regulation of Aβ cytotoxicity.  It is thought that extracellular apoE binds to Aβ and 
thereby modifying Aβ -mediated cell toxicity (Wilhelmus et al., 2005).  This however 
changes with each apoE isoform where apoE ε2 is most protective and apoEε4 is least 
protective due to isoform specific differences in binding to Aβ (Mahley et al., 1996).  
ApoE is also thought to have isoform specific effects on microglia activation in AD 
brains (Egensperger et al., 1998) or an inhibitory effect on activation of cultured glial 
cells by Aβ peptides (Hu et al., 1998).   
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A role for apoE in the clearance of Aβ has also received attention. There are two major 
Aβ clearance mechanisms in the brain – firstly there is receptor mediated clearance by 
cells in brain parenchyma (microglia, astrocytes, neurons), along the interstitial fluid 
(ISF) drainage pathway, or through the blood brain barrier (BBB). Secondly Aβ can be 
cleaved by endopeptidases such as insulin degrading enzyme (IDE) and neprilysin 
which are both expressed in neurons and vascular cells, as well as other enzymes such 
as endothelin converting enzymes (Bu, 2009). Aβ peptide clearance in the periphery has 
been shown to be mediated by apoE. For example, Hone et al. demonstrated that Aβ is 
rapidly removed from plasma by murine peripheral tissues and that the rate of clearance 
is affected by apoE (Hone et al., 2003). In this study, C57 BL/6J and APOE knockout 
mice were intravenously injected with Aβ40 peptide and blood was taken from the 
retro-orbital sinus at various time-points. In the C57 BL/6J mice, it was observed that 
the liver had removed a large proportion (40.8%) of the injected Aβ followed by the 
kidney (4.4%) by 90 minutes, whereas these tissues had undetectable levels of Aβ in the 
APOE knockout animals (Hone et al., 2003). Recent findings have extended this work 
and have shown that the presence of apoE ε4 led to a reduced plasma clearance of Aβ 
and reduced uptake by two major peripheral organs that clear Aβ from the periphery, 
the liver and kidney (Sharman et al., 2010). It was also found that levels of the Aβ 
degradation enzyme, insulin degradation enzyme (IDE) were reduced in brain and 
kidney from mice harbouring the APOE ε4 allele. The decreased capacity of apoE ε4 to 
clear/degrade Aβ from the periphery and the associated lower levels of IDE, particularly 
in the brain, suggest an explanation for the greater brain Aβ accumulation and higher 
risk of AD in APOE ε4 carriers. Individuals carrying the APOE ε4 allele also bear some 
risk of developing the early-onset form of AD. However there are also some familial 
AD subjects that are not associated with either APP, PS1 or PS2 mutations or APOEε4 
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inheritance that suggests that other underlying factors may be responsible for such 
familial forms of AD.  
 
Overall, EOAD accounts for only a small percentage of AD cases but is the most severe 
form of the disease. The majority of EOAD cases are familial forms of AD showing 
autosomal dominant inheritance.  Familial AD (FAD) is typically associated with an 
early age of onset (reviewed by (Martins et al., 2009). Most of our knowledge of the 
molecular events underlying the development of AD comes from FAD since we can use 
genetic analysis to identify the genes and proteins involved.  Mutations at only three 
loci are known to cause FAD although other loci may yet be found (Caselli et al., 2009). 
One locus hosts the gene for the Amyloid Precursor Protein (APP) from which Aβ is 
cleaved by the action of two “secretases”; β-secretase and γ-secretase (see section1.5.1). 
Mutations in APP alter these cleavages so that Aβ  production is increased or more 
aggregation-prone forms of Aβ are formed (reviewed by (Martins et al., 2009). The 
remaining two loci host the presenilin genes PSEN1 and PSEN2 with mutations in these 
genes accounting for 50-70% of EOFAD cases (Zhang et al., 2010a, Stevens et al., 
2011). The presenilin proteins form the catalytic core of protein complexes with γ-
secretase activity (see section1.6). Mutations in the presenilins also appear to alter the 
rate of Aβ production (see section1.6.1). The role of Aβ in AD pathogenesis and its 
production are described in detail below. 
 
1.4: Beta Amyloid protein (Aβ) 
 
As described before in section 1.2.2.2 SPs containing amyloid deposits are 
neuropathological hallmarks of the AD brain. The accumulation and aggregation of Aβ 
is central to the amyloid hypothesis and has a major role in AD pathogenesis (Maccioni 
et al., 2001).  The Aβ protein is a proteolytic fragment of the amyloid precursor protein 
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(APP) (Fig.1.6) (Hartmann et al., 1996).  There are two major forms of Aβ, Aβ40 which 
terminates at Val40 of the Aβ sequence and the longer and more pathogenic form Aβ42, 
which terminates at Ala42 of the Aβ sequence.  Aβ42 forms aggregates more quickly 
resulting in the formation of senile plaques (SP) (Iwatsubo et al., 1994) 
Immunochemical studies suggest that the deposition of Aβ42 precedes Aβ40 (Iwatsubo et 
al., 1994, Lippa et al., 1998).  It is estimated that approximately 90% of Aβ found in the 
sporadic AD brain is Aβ40, with the remaining 10 % Aβ42 (Chapman et al., 2001).  Aβ 
in cerebrospinal fluid (CSF) and blood is secreted by neuronal/glial cells and 
accumulates in cerebral capillaries, arterioles and venules.  Furthermore, blood platelets 
are key contributors of secreted Aβ in the periphery (Maccioni et al., 2001, Borroni et 
al., 2002).  Increased levels of soluble form of Aβ40 are more strongly correlated with 
AD than amyloid plaque load (Fonte et al., 2001, Hemar and Mulle, 2011, Lewczuk et 
al., 2011).  Furthermore, recent evidence has shown that small aggregates of Aβ, termed 
oligomers or protofibrils are the major neurotoxic species rather than the amyloid fibrils 
or the senile plaques themselves (Goedert and Spillantini, 2006a, b, Spillantini et al., 
2006).  These aggregated forms of Aβ in the brain parenchyma trigger a cascade of 
pathological events that lead to AD pathology, neuronal loss and the associated 
cognitive decline (Hardy and Higgins, 1992, Small et al., 2001).  Several factors are 
involved in the process of Aβ aggregation and toxicity that contribute to AD pathology 
some of which are discussed below.  
 
1.4.1: Aβ mediated toxicity 
 
The soluble forms of Aβ aggregates have been implicated in disruption of several 
cellular functions including mitochondrial activity (Dyrks et al., 1992, Butterfield et al., 
2001 , Palmblad et al., 2002, Lustbader et al., 2004a), oxidative stress (Martins et al., 
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1986, Butterfield et al., 2001 ), receptor mediated functions (Yaar et al., 1997, Wei et 
al., 2002 , Fuentealba et al., 2004, Pereira et al., 2004, Bhaskar et al., 2009), disruption 
of Ca2+ homeostasis (Mattson et al., 1993, Hartmann et al., 1994), membrane 
depolarization and disorder (Muller et al., 2001, Verdier et al., 2004) and microglia 
activation (Giulian et al., 1996). Most studied mechanisms of Aβ induced toxicity are 
described below. 
 
1.4.2: Mitochondrial dysfunction 
 
Neurons are highly differentiated cells that need large amounts of Adenosine tri-
phosphate (ATP) and depend on mitochondrial function and oxygen supply to survive 
(Ames, 2000, Erecinska et al., 2004). As a result neuronal function and survival are very 
sensitive to mitochondrial dysfunction (Fiskum et al., 1999, Nicholls and Budd, 2000). 
Neuronal death and loss in AD may be attributed to an intracellular interaction between 
Aβ and Aβ binding alcohol dehydrogenase (ABAD) which in turn alters the enzyme’s 
active site and prevents native dehydrogenase activity (Lustbader et al., 2004b, 
Caspersen et al., 2005). This is evidence of the presence of a mitochondrial pool of Aβ 
within the AD brain that disrupts normal mitochondrial function. This is supported by 
the finding of Aβ accumulation within mitochondria from brains of AD patients, rodent 
models, and neuronal cells over expressing APP (Caspersen et al., 2005, Crouch et al., 
2005, Manczak et al., 2006). Since APP and γ-secretase components are present in 
mitochondria, Aβ could be generated within mitochondria (Anandatheerthavarada et al., 
2003, Hansson et al., 2004, Devi et al., 2006) which may in turn significantly impact the 
functions of the mitochondrial electron transport chain which is essential for the cell’s 
energy requirement (Casley et al., 2002, Crouch et al., 2005) leading to neuronal death 
due to oxidative stress. 
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1.4.3: Oxidative stress 
 
Oxidative stress is a major contributor to neuronal cell loss in a number of 
neurodegenerative disorders including AD, and there is strong evidence linking 
oxidative stress to Aβ. Oxidative stress occurs due to over and/or under production of 
reactive oxygen species (ROS) via oxidative phosphorylation within the mitochondria 
that exceeds antioxidant defence systems, leading to oxidative damage of cellular 
components. ROS are by-products of ATP generation as the CNS consumes 20% of the 
total oxygen supply. This notion is supported by the findings of Martins et al (Martins et 
al., 1986) who reported an increase in activity of enzymes from the hexose 
monophosphate pathways in post-mortem AD brain samples compared to age-matched 
controls. This increased activity of the hexose monophosphate enzymes reflected the 
increased oxidative stress in the AD brain. Several subsequent reports have also 
confirmed the original finding and have shown extensive oxidative damage in AD, 
including lipid peroxidation (Sayre et al., 1997, Butterfield et al., 2002), oxidized 
proteins (Bissette et al., 1991, Smith et al., 1991) nucleic acid damage (Gabbita et al., 
1998, Lovell et al., 1999) and advanced glycation end-products (AGE) (Markesbery and 
Lovell, 1998, Perry et al., 2003). Oxidative damage in AD may be a direct result of Aβ 
peptide accumulation which cause neurotoxicity by production of ROS (Behl et al., 
1994) through interaction with metals, mainly copper (Cu) (Curtain et al., 2001, Dong et 
al., 2003). Aβ-Cu combination generates hydrogen peroxide (H2O2) that has been shown 
to cause oxidative damage of lipids and intracellular proteins. These findings clearly 
show that Aβ mediated generation of ROS contributes to neuronal cell death in AD.  
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1.4.4: Synaptic toxicity 
 
Cognitive impairment in AD is often attributed to synaptic dysfunction and neuronal 
cell loss in the hippocampus which is one region of the brain crucial for memory 
(Hyman et al., 1984, Davies et al., 1987 ). Depleted neurotransmitters and synaptic 
connections  are indicators of  synaptic loss ((Whitehouse et al., 1982, Small et al., 
2001) and impact learning and memory skills by affecting signal transmission between 
neurons. There is now evidence that naturally secreted low molecular weight Aβ 
oligomers and synthetically derived oligomeric Aβ42 disrupt signal transmission in the 
hippocampus leading to loss of hippocampal plasticity (Nagerl et al., 2004, Zhou et al., 
2004). The biochemical mechanism by which soluble oligomers bind to synaptic plasma 
membranes and interfere with signalling molecules that are required for synaptic 
plasticity is unclear. Studies show that Aβ oligomers can interact with membranes to 
induce a cascade of structural changes such as opening of ion pores, enhancing 
membrane permeability or ion conductance by modulating a wide array of ion channels  
and affecting osmotic flux (Mattson and Chan, 2003, Demuro et al., 2010). Disrupted 
cellular homeostasis affects neuritic dystrophia and blockage of intra-neuronal 
signalling essential for cognitive functions that may consequently lead to synaptic 
dysfunction (De Fusco et al., 2003, Lingrel et al., 2007, Moseley et al., 2007). There is 
also data that has shown that intracellular Aβ accumulation and soluble Aβ oligomers 
can induce synaptic dysfunction and dendrite loss. However, the molecular mechanisms 
that underline the loss of synapses and ensuing decline in memory related functions 
caused by Aβ are complex. Neurodegeneration in AD is specific to particular regions of 
the brain, but it is still not clear what makes the particular subset of neurons and their 
processes more vulnerable to the effects Aβ toxicity.  
 
 40 
 
1.5: The Amyloid Precursor Protein (APP) and its proteolytic processing 
 
The amyloid precursor protein (APP) is highly expressed primarily in the brain but is 
also found in non-neural cells from many different tissues such as liver, kidney and 
muscle though the level of expression in most peripheral tissues is markedly lower 
(Turner et al., 2003).  The function(s) of APP is still not fully understood but there is 
evidence to indicate that it plays an important role in an intricate protein signalling 
network and associated with the regulation of non-neuronal cell mitosis (Nishimoto et 
al., 1993, Popp et al., 1996).  APP is thought to maintain nerve cell growth, morphology 
and functional plasticity and plays a role in learning and memory (Janus et al., 2000, 
Morgan et al., 2000, Bayer et al., 2001).  The localisation of APP within synapses 
suggests that APP plays a role in neuronal communication (Chapman et al., 2001).  The 
non-neuronal isoform of APP which contains the Kunitz protease inhibitor domain 
(KPI) may be involved in cellular adhesion and inhibition of serine proteases  (Festoff 
et al., 2001). The major neuronal form of APP is a glycoprotein comprised of 695 
amino acids, characterized by a large ectodomain, a transmembrane domain and a small 
endodomain (reviewed in (Sisodia and Price, 1995).  The APP gene is encoded on 
chromosome 21.  Six different APP isoforms have been identified and are generated 
from the alternative splicing of exons 7, 8 and 12.  These APP isoforms are broadly 
divided into two groups, either containing KPI (KPI-APP) or lacking KPI (non KPI-
APP) (Hook et al., 1999).  The KPI-APP group include APP563, APP751, and APP770.   
The non KPI-APP includes APP695, APP365, and APP714 and dominates in neuronal 
cells.  The latter group lacks the KPI domain due to splicing out of exon 7 during 
transcription (Ponte et al., 1988). 
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Figure 1.4: Amyloid Precursor Protein.  
Schematic diagram of APP showing the three main sections: ectodomain, 
transmembrane and cytoplasmic domain.  
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1.5.1: Amyloid precursor protein (APP) processing 
 
The APP protein undergoes proteolytic cleavage by enzymes termed BACE, α, and γ-
secretases which act via two competing pathways (reviewed in Krishnaswamy et al., 
2009). The non-amyloidogenic pathway involves the cleavage of APP by α- secretase 
which precludes Aβ formation whereas the alternative amyloidogenic pathway involves 
APP cleavage by β and γ-secretase resulting in the Aβ production. These two competing 
pathways are discussed below. 
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Figure 1.5: Proteolytic Processing of Amyloid Precursor Protein (APP). 
The two competing APP pathways and the enzymes involved in each pathway. 
Non-amyloidogenic and Amyloidogenic pathways (adapted from(Barron et al., 
2006)). 
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1.5.1.1: α-secretase cleavage of APP 
 
The non-amyloidogenic pathway involves the cleavage of APP by α- secretase between 
residues 16 and 17 of the Aβ sequence thus precluding Aβ formation.  Cleavage by α-
secretase results in the liberation of a secreted form of APP (α-APPs) and a membrane 
bound C-terminal fragment of APP which contain residues 18-42 of the Aβ domain 
(Sisodia and Price, 1995). The membrane bound C-terminal fragment is further cleaved 
by γ-secretase, at the C-terminal end of Aβ, to liberate non-amyloidogenic fragments.  
Cleavage of APP by α-secretase is regulated by protein kinase C or other factors such as 
hormones (Buxbaum et al., 1993, Bayer et al., 2001).  
 
Tumour necrosis factor-α converting enzyme (TACE), a disintegrin and a 
metalloproteinase, which belong to The ADAM family of type-1 transmembrane 
glycoproteins, (ADAM9, ADAM 17 and ADAM 10) have all been shown to have α-
secretase activity.  These metallo-proteases are involved in cellular activities such as 
cellular adhesion and membrane protein shedding (Black et al., 1997).   These metallo-
proteases have been shown to process APP in a number of in vitro and in vivo studies.  
In vitro co-expression of ADAM9 with APP resulted in increased production of αAPPs 
(Koike et al., 1999). Its activity has also been demonstrated in the plasma membranes 
and the protein secretory pathway (Kuentzel et al., 1993, Refolo et al., 1995, De 
Strooper, 2007).  Over-expression of ADAM10 has been shown to facilitate α-cleavage 
of APP whereas knock down precludes endogenous α-cleavage activity in cell lines 
including primary neurons (Lammich et al., 1999, Lopez-Perez et al., 2001, Kuhn et al., 
2010). There is data that suggest that ADAM10 is the constitutive α-secretase that is 
active at the cell surface as evidenced by reduced ADM10 protein levels in platelets of 
sporadic AD patients which correlate with reduced sAPPα levels (Colciaghi et al., 
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2002). This has also been confirmed in neurons from mice with neural ADAM10 
knock-out which resulted in significant reduction of sAPPα production to negligible 
levels (Jorissen et al., 2010). 
 
1.5.1.2: βeta-site APP cleaving enzyme 
 
 Beta site APP cleaving enzyme (BACE), formerly known as β-secretase, is a 501 
amino acid trans-membrane protein consisting of signal, trans-membrane, luminal and 
cytosolic domains (Vassar et al., 1999).  Two isoforms of β-secretase (BACE 1 and 2) 
which belong to the aspartyl-protease family have been identified (Vassar, 2004).  In the 
amyloidogenic pathway BACE cleaves APP at the N- terminus of the Aβ domain to 
release a β-APPs product and a membrane bound C-terminal fragment (β-CTF).  
Subsequent cleavage by γ-secretase releases Aβ40 or Aβ42 and the APP intracellular 
domain (AICD). (Naslund et al., 2000).  The BACE gene is located on chromosome 
11q23.3, near a region recently identified as having increased lode scores for AD 
(Hussain et al., 1999, Vassar et al., 1999).  The biological functional and genetic 
association studies indicate that polymorphisms in the BACE1 gene might be a genetic 
risk factor for late-onset AD (Kan et al., 2005).  
 
Unlike BACE2, which is highly expressed in heart, kidney and placenta tissue (Yang et 
al., 1995), BACE1 is highly expressed in the brain with relatively low amounts in most 
peripheral tissues with the exception of the pancreas (Vassar et al., 1999).  Over-
expression of BACE correlates with increased cleavage of APP and its activity increases 
with age (Li et al., 2000b).  Furthermore BACE1 levels are elevated in AD brain 
especially in regions vulnerable to neurodegeneration (Li et al., 2000b, Holsinger et al., 
2002).  In addition BACE1 knockout mice crossed with APP transgenic mice have low 
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cerebral Aβ levels (Luo et al., 2001), providing further evidence that BACE1 accounts 
for the majority of β-secretase activity in the brain.   
 
1.5.1.3: γ-Secretase cleavage of APP 
 
 Following APP cleavage by BACE, the last step in Aβ generation is the cleavage of the 
β-CTF by γ-secretase at the C-terminal end of the Aβ region. This final cleavage by γ-
secretase releases Aβ40 or Aβ42 (Naslund et al., 2000).  The complete structure of the γ-
secretase enzyme has not yet been fully identified but it is well established that the 
presenilins together with anterior pharynx defective (APH-1), nicastrin, and presenilin 
enhancer (PEN-2) are the core members of the enzyme complex. (Xia et al., 1997, Zhou 
et al., 2005).  It has been originally proposed that two different γ-secretases termed γ40-
secretase and γ42-secretase exist which are responsible for the generation of Aβ40 and 
Aβ42 respectively (Citron et al., 1996). However, more recently a model has been proposed to suggest a single γ-secretase enzyme with a broad range of activity, performing multiple cleavages sequentially along the APP-C99 fragment. The 
“successive cleavage” model, originally proposed by Ihara and colleagues (Qi-Takahara 
et al., 2005, Takami et al., 2009) provides a sequence of cleavage events by γ-secretase 
that occurs within the C-terminal fragment of APP (C99) to generate Aβ40 and Aβ42. 
In this model, after BACE cleavage of APP (to form the N-terminal of Aβ) the 
remaining C-terminal part of APP-C99 is first cleaved within the transmembrane 
domain at the epsilon (ε)-site nearest the cytosol to release the AICD. Cleavage 
proceeds progressively in increments towards the N-terminal of Aβ at zeta (ζ) and γ 
sites respectively. This model also proposes that Aβ40 and Aβ42 are generated from a 
different cleavage process and depends on the initial position of ε-cleavage 
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The γ-secretase enzyme is a high molecular weight aspartyl protease that cleaves type I 
transmembrane proteins within the hydrophobic environment of the lipid bi-layer.  In 
addition to cleaving APP to release Aβ, γ-secretase also cleaves other substrates such as 
Notch to release the notch intracellular domain (NICD) fragment (Esler and Wolfe, 
2001, Lee et al., 2002).  Notch is a type I transmembrane protein which is first acted 
upon by a distintegrin and metalloprotease within the extra-cellular region, followed by 
γ-secretase mediated cleavage within the trans-membrane domain to liberate NICD.  
This fragment translocates to the nucleus where it co-activates the transcription of the 
genes involved in many developmental pathways (Ray et al., 1999).   Th e γ-secretase 
enzyme also cleaves sterol regulatory element binding protein (SREBP), an integral 
membrane protein located in the endoplasmic reticulum consisting of N- and C-terminal 
domains after being acted upon by sterol sensitive protease in the luminal loop (Sakai et 
al., 1996). SREBP plays a significant role in cholesterol homeostasis by stimulating 
transcription of sterol-regulated genes and plays a role in the activation of proteins 
involved in cholesterol biosynthesis (Leonard et al., 1986, Wang et al., 1994, Brown 
and Goldstein, 1997). There are several other γ-secretase substrates. Examples include 
epithelial (E) and neural (N) cadherins, involved in cell adhesion, CD44 that acts as a 
signal transduction molecule and activates transcription in the nucleus, and Erb-B4, 
which plays a significant role in neuronal development by regulating cell proliferation 
and differentiation (Okamoto et al., 2001, Yarden and Sliwkowski, 2001, Marambaud et 
al., 2003). Due to the large number of substrates γ-secretase has been a difficult target to 
develop inhibitors and/or modulators of its activity. 
 
1.6: The γ-secretase complex components 
 
The γ-secretase complex is a multimeric protein complex composed of Presenilin 1 
(PS1), Nicastrin (NCT), anterior pharynx defective-1a (APH-1a), and Presenilin 
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enhancer-2 (PEN-2) (Kimberly et al., 2003) (Fig.1.6).  Its molecular weight has been 
reported to be different in some studies.  One study reported it to be ~2MDa, whereas 
others reported it to be ~250KDa and ~500KDa (Li et al., 2000a, Edbauer et al., 2002, 
Farmery et al., 2003, Kimberly et al., 2003, Li et al., 2003b). PS1/2 which is the 
catalytic components of the γ-secretase share 67% of the overall protein sequence 
(reviewed in (Krishnaswamy et al., 2009). There is also evidence of the existence of 
distinct PS1 and PS2 complexes where PS1 containing complexes produce both Aβ40 
and Aβ42 whereas PS2 containing complexes only produce Aβ42 (Lai et al., 2003, 
Mastrangelo et al., 2005). Other proteins that are involved in modulating Aβ levels such 
as CD147 (Fig.1.6) but do not appear to be core components of the complex have also 
been identified (Winkler et al., 2009).  
 
1.6.1: Presenilins 
 
The Presenilins (PS1 and PS2) are transmembrane proteins consisting of 8-10 
hydrophobic domains (Sherrington et al., 1995, Lehmann et al., 1997).  The gene spans 
more than 50 to 75kb and is organized into 12 exons, the first two corresponding to 5’ 
untranslated regions (Alzheimer’s Disease Collaborative Group, 1995; (Mitsuda et al., 
1997).  Two presenilin genes have been identified; presenilin 1 (PS1) located on the 
short and long arms of chromosome 14 and presenilin 2 (PS2) found on the long arm of 
chromosome 1.   The PS1-holoprotein is composed of 467 amino acids with a molecular 
weight of 45 kDa (Sherrington et al., 1996, Lehmann et al., 1997). PSI is similar in 
structure to sperm integral membrane proteins (SPE) which play a role in membrane 
trafficking in the organelles within the Golgi (L'Hernault and Arduengo, 1992, Levitan 
and Petersen, 1995).  The similarity to SPE may suggest that PS1 is also involved in 
protein trafficking.  Other roles for PS1 include signal transduction during development, 
apoptosis and cellular calcium ion homeostasis (Marjaux et al., 2004). However, its role 
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in APP metabolism and processing has received the most attention. Initial evidence 
comes from many in vivo and in vitro studies which have shown that mutations in PS1 
increase the production of the longer more pathological Aβ species (Martins et al., 
1995, Guo et al., 1997, Xia et al., 1997, Jankowsky et al., 2004). A subsequent study 
provided evidence that presenilins may have γ-secretase activity and represents the core 
catalytic subunit of the enzyme. Many reports have shown that presenilin ablation or 
mutagenesis of two highly conserved aspartate residues within transmembrane domains 
6 and 7 result in a reduction in Aβ levels in vitro and in vivo (De Strooper et al., 1999, 
Steiner et al., 1999, Wolfe et al., 1999, Esler et al., 2000). Furthermore, aspartyl 
protease inhibitors and transition state analogue inhibitors designed to target the active 
site of the protease, all reduce Aβ40 and Aβ42 levels and have been shown to have 
affinity label and bind to PS1 (Esler et al., 2000, Li et al., 2000a, Seiffert et al., 2000). 
In addition, physical interactions between presenilins and γ-secretase substrates have 
been identified (reviewed in (Verdile et al., 2004)). Although initial evidence strongly 
implicated presenilins in γ-secretase catalytic activity they do not exhibit typical 
aspartyl protease structural characteristics, in particular they lack the typical D(T/S)G 
motif required for the active site of an aspartyl protease. However, presenilins do 
contain the two aspartyl residues (e.g.: D257 and D385 for PS1) which are either critical 
for the active site on the γ-secretase complex or constitute the active site. The formation 
of this aspartyl catalytic site could result from one or multiple presenilin molecules. The 
full length PS1 protein is rapidly endoproteolytically cleaved within its characteristic 
large hydrophilic loop into amino- and carboxyl-terminal fragments (NTF/CTF) of ~27 
and ~17 kDa, respectively (Borchelt et al., 1996, Thinakaran et al., 1996, Podlisny et al., 
1997). These fragments are thought to interact with each other to form the catalytic 
component of γ-secretase (Levitan et al., 2001, Laudon et al., 2004a, Laudon et al., 
2004b). The stoichiometry and the nature of the interaction between these fragments 
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remain unclear. It has also been shown by many studies that the NTF:CTF form a 
heterodimer in mammalian cells (Seeger et al., 1997, Grunberg et al., 1998, Yu et al., 
1998, Beher et al., 1999) leading to suggestions that this heterodimer is the active γ-
secretase. However, Cervantes and colleagues 2001 (Cervantes et al., 2001) provided 
evidence that the presenilin fragments can form a tetramer by identifying heterodimers 
as well as NTF and CTF homodimers in yeast. Evidence for heterodimer and NTF 
homodimer (but not CTF homodimer) formation has been provided by photo affinity 
labelled cross linking studies (Schroeter et al., 2003). This formation provides a core of 
aspartyl residues required for aspartyl protease activity. However, it has yet to be 
established whether the hypothetical “core” is formed between fragments from one PS1 
molecule or multiple molecules within the complex. 
 
The PS proteins (PS1 and PS2) share 62% amino acid identity and several lines of 
evidence suggest that these proteins have quite distinct functions. Mice lacking PS1 die 
before birth and the embryos display severe skeletal and brain deformities, whilst mice 
lacking PS2 develop mild pulmonary fibrosis and haemorrhages with age (Shen et al., 
1997, Steiner et al.,1999, Rozmahel et al., 2002). Neuronal cultures isolated from PS1 
ablated mice, when compared to those isolated from PS2 knockout mice, exhibit higher 
Aβ production and are less sensitive to γ-secretase inhibitors (Lai et al., 2003). Lai and 
colleagues also provided evidence suggesting the existence of distinct PS1 and PS2 
containing complexes (Lai et al., 2003). Evidence exists that these complexes may have 
a differential capacity to generate Aβ, whereby PS1 containing complexes produce both 
Aβ40 and Aβ42, and PS2 containing complexes are involved in Aβ42 (but not Aβ40) 
generation (Mastrangelo et al., 2005). Placanica et al.,  (Placanica et al., 2009) provided 
further evidence for distinct PS1 and PS2 γ-secretase complexes in the generation of Aβ 
where they are in dynamic equilibrium, possibly under control of pen-2 expression. It 
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has also been suggested that PS2 is less efficient at generating Aβ peptide than PS1 
(Bentahir et al., 2006, Placanica et al., 2009). 
 
Evidence for different capacities for PS1 and PS2 to process other γ-secretase substrates 
comes from a study that has shown that notch defects in PS1 null mice can be rescued 
with wild-type PS2, but fails to rescue APP processing (Mastroangelo et al., 2005). 
These findings suggest that PS2 is capable of facilitating Notch processing but is 
associated with only very low levels of Aβ production. Although the presenilins share 
some sequence identity (67%), there are domains within these proteins that show 
sequence divergence, where transmembrane (TM) 3 and 4 and the large cytoplasmic 
domains show 38% and 68% sequence divergence. This information could be used to 
identify critical areas between these two proteins responsible for their activities. 
 
A very large number of missence mutations have been isolated in the human presenilin 
genes from families with EOAD (>190 mutations in PS1, and 23 in PS2, 
http://www.molgen.ua.ac.be/ADMutations).  A large number of these mutations are 
missense mutations involving substitution of a single amino acid. Others include small 
deletions, insertions or splice mutations (De Strooper, 2007).  The I4Sev5 and 
Glu318GLY mutations are exceptions because they exhibit incomplete penetrance 
(Rossor et al., 1996, Helisalmi et al., 2000).  Mutations in the presenilins are known to 
be scattered throughout these proteins and it has been proposed that these mutations 
may all be hypomorphic – i.e. they decrease γ-secretase activity (Wolfe, 2007). The 
decreased presenilin/γ-secretase activity as a result of mutations might shift the ratio of 
Aβ production from shorter forms (e.g. Aβ40) that are less toxic (or possibly even 
protective) towards production of longer forms (predominantly Aβ42) that have a 
greater tendency to form toxic oligomers .  
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1.6.2: Nicastrin (NCT) 
 
Nicastrin is a type 1 transmembrane glycoprotein which was identified as a component 
of the γ-secretase enzyme complex when it was found to co-immunoprecipitate with 
PS1 and APP (Yu et al., 2000).  It is comprised of a 670 amino acid long hydrophilic N-
terminal domain, a trans-membrane domain, and a relatively short cytoplasmic C-
terminus of 20 amino acid residues (Yu et al., 2000).  The protein is synthesized as an 
endoglycosidase-H-sensitive glycosylated precursor protein which is an immature form. 
It is then modified by complex glycosylation in the Golgi apparatus and by sialylation 
in the trans-Golgi network to generate the mature nicastrin molecule (Yu et al., 2000).  
NCT is physically associated with presenilin and has a major role in stabilization and 
proper localization of presenilin to the membrane-bound γ-secretase complex (Kopan 
and Goate, 2002).   NCT plays a role as a scaffold for the assembly of the γ-secretase 
enzyme complex that binds APH-1 to form the first sub-complex (Morais et al., 2003, 
Periz and Fortini, 2004). It is also thought that NCT plays a role in the assembly of the 
γ-secretase complex within the endoplasmic reticulum and intracellular trafficking of 
the complex to the cell surface (Shah et al., 2005, Zhang et al., 2005).  Evidence has 
also been provided to suggest that NCT is essential for the interaction between the γ-
secretase complex and APP-C99 (Shah et al., 2005).   
 
1.6.3: Anterior Pharynx defective homolog-1 (APH-1) 
 
The Aph-1 molecule is a 30 kDa transmembrane protein comprising 308 amino acids 
(Goutte et al., 2002).  Two human homologues of APH-1 genes exist, APH-1a and 
APH-1b located on chromosome 1 and 15 respectively.  APH-1a exhibits isoforms, 
APH-1aS and APH-1aL, generated through alternative splicing of a single transcript 
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(Lee et al., 2002, Gu et al., 2003, Saito and Araki, 2005).  APH-1a and APH-1b are 
expressed in certain human and mice tissues such as hippocampus, cortex, medulla, 
testes, lung and the large intestines (Saito and Araki, 2005, Coolen et al., 2006), 
whereas APH-1aS is expressed more than APH-1aL (Saito and Araki, 2005). Both 
APH-1a and APH-1b are multi-pass membrane proteins with seven transmembrane 
domains (Fortna et al., 2004) whereas APH-1aS and APH-1aL have different C-
terminal sequences (Lee et al., 2002, Gu et al., 2003).  In vitro evidence has shown that 
down-regulation of APH-1a and APH-1b alters the formation of the multimeric 
complex and strongly reduces the production of Aβ (Luo et al., 2003).  Knock down 
experiments of APH-1a result  in impaired maturation of NCT and decreased expression 
of PS1, PS2, and PEN-2 proteins (Saito and Araki, 2005).  In vivo experiments have 
provided evidence that complexes containing different isoforms of aph-1 may also have 
different functionality. Mice lacking APH-1a are embryonic lethal whilst those lacking 
APH-1b appear to be normal phenotypically (Ma et al., 2005, Serneels et al., 2005, 
Serneels et al., 2009), suggesting that aph1a complexes are essential for Notch 
signalling during embryogenesis. In the absence of APH-1a an active γ-secretase 
complex formation is disrupted (Ma et al., 2010). Collectively these data suggest that 
complexes containing aph-1a are active and those containing aph-1b maybe redundant. 
 
However, aph-1b complexes have been shown to have a role in neuregulin-1 (Nrg-1) 
signalling. Aph-1b knockout mice show signs of schizophrenia including 
hypersensitivity to psychiatric drugs, sensory motor gating abnormalities and working 
memory deficits (Dejaegere et al., 2008). In addition, subsequent findings show that 
inactivation of aph-1b γ-secretase complexes led to a reduction in AD pathology 
without altering Notch related signalling (Serneels et al., 2009), suggesting the 
existence of different complexes that selectively process certain substrates.  
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Apart from the scaffolding function it shares with nicastrin, aph1 also interacts with the 
mature forms of PS1, nicastrin and pen-2 (Lee et al., 2002, Hansson et al., 2004, 
Hansson et al., 2005) on the cell surface where it binds the γ-secretase substrates and 
facilitates cleavage (Hansson et al., 2005). Structural and functional similarities between 
aph-1 and other proteases that possess the ability for intra-membranous cleavage such as 
rhomboid, (Urban et al., 2001, Lee et al., 2003a) suggests that it may also have catalytic 
activity, though there is yet no direct evidence for this.  
 
1.6.4: Presenilin Enhancer 2 (PEN-2) 
 
The Presenilin Enhancer 2 (PEN-2) is a ~12 kDa protein with 101 amino acids and 
consists of two trans-membrane domains with its N- and C- termine facing the lumen of 
the endoplasmic reticulum (Crystal et al., 2003).  Interaction of PEN-2 with other 
proteins aids the stability of the γ-secretase complex which is otherwise degraded by the 
proteasome in the absence of this interaction (Crystal et al., 2003, Prokop et al., 2004). 
PEN-2 is required for stabilization of the presenilin N- and C-terminal fragments within 
the γ-secretase complex and also contributes to the maturation of nicastrin.  Further, 
PEN-2 is thought to contribute to the endo-proteolysis of the presenilin holoproteins 
into N- and C-terminal fragments (Prokop et al., 2004).  Interaction of PEN-2 with 
APH-1 and NCT in drosophila increases the formation of presenilin fragments and 
promotes γ-secretase activity (Takasugi et al., 2003).  Knockout and knockdown 
experiments of PEN-2 expression have shown a marked decrease in PS1 endo-
proteolysis and Aβ production, suggesting  that PEN-2 is essential for both PS1 
fragment formation and γ-secretase activity, (Steiner et al., 2002, Takasugi et al., 2003).  
PEN-2 has been shown to bind to PS1 and the “DYLSF” domain of PEN-2 and a “NF” 
motif on trans-membrane 4 of PS1 have been shown to be critical for this interaction 
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(Hasegawa et al., 2004, Kim and Sisodia, 2005). The C-terminal fragment of PEN-2 has 
been shown to be critical for γ-secretase activity, where altering the length of the PEN-2 
CTF (Naruhashi et al., 1997) or introducing loss of function mutations into the CTF 
(Hasegawa et al., 2004, Prokop et al., 2004) reduces Aβ40 and Aβ42 levels.  
 
Although PS, NCT, aph1 and Pen2 are known to be the core-components of γ-secretase 
there are a number of other proteins that interact with components of the γ-secretase 
enzyme or APP  to modulate Aβ production (Zhou et al., 2005, Chen et al., 2006). One 
such protein is CD147. As a major focus in this study the sections below will describe 
the structure, function and roles in neuronal homeostasis and in regulating Aβ levels 
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Figure 1.6: Assembly of γ-secretase enzyme complex to form the active enzyme.  
NCT and APH-1 binds to form NCT: APH -1 sub complex, presenilin binds to this sub 
complex forming a trimeric complex that is transported to the cell surface after the post-
translational modification of NCT, wherein PEN-2 attaches to the complex.  Following 
the BACE cleavage of APP molecule, γ-secretase cleaves APP-C99 releasing Aβ1-40 or 
Aβ1-42 (adapted from (Verdile et al., 2007)). 
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1.7:CD147 is a multifunctional protein that modulates Aβ levels 
 
The CD147 protein has been identified in various species and assigned different names 
(Table 1.1). Initially termed tumour cell-derived collagenase stimulatory factor (TCSF) 
because of its ability to induce matrix metalloproteinase (MMP) expression in 
fibroblasts, the CD147 cell membrane receptor protein is now classified as a trans-
membrane glycoprotein belonging to the immunoglobulin super-family (IgSF) (Biswas 
and Vonderhaar, 1987, Fossum et al., 1991, Miyauchi et al., 1991, Kasinrerk et al., 
1992, Biswas et al., 1995), that has been shown to induce the production of several 
MMPs (Kataoka et al., 1993, Biswas et al., 1995, Guo et al., 1997).  It has been 
classified as a member of a small family of related proteins, including the 
teratocarcinoma antigen GP70 and the synaptic glycoprotein SDR1, that share the 
features of two Ig-like extracellular domains, a short cytoplasmic tail, and a single trans-
membrane domain (Fossum et al., 1991, Shirozu et al., 1996). In addition to playing a 
vital role in foetal development, CD147 is critical to the development of the nervous 
system, spatial learning and memory, sensory inputs and retinal functions (Naruhashi et 
al., 1997, Muramatsu and Miyauchi, 2003, Zhou et al., 2005). The CD147 protein has 
been linked to cancer, tumour progression and arthritis. More recently this protein has 
been implicated in AD pathogenesis (Nabeshima et al., 2006a, Winkler, 2008, 
Nahalkova et al., 2010), in particular regulating Aβ levels (Zhou et al., 2005, Vetrivel et 
al., 2008b). The following sections provides a detailed discussion on CD147 protein 
structure, expression and function with particular focus on neuronal functions and its 
role in neurodegenerative diseases such as AD. 
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Table 1.1: CD147 nomenclature 
Designated name Species Reference 
Extracellular Matrix 
Metalloproteinase-Inducer 
(EMMPRIN) and M6 
Human (Kasinrerk et al., 1992) 
Neurothelin, 5A11 and HT7 Chicken (Seulberger et al., 1990, Fadool and 
Linser, 1993, Schlosshauer et al., 1995) 
OX47 and CE9 Rat (Fossum et al., 1991, Nehme et al., 1995) 
CD147, gp42 Human 
and Mouse 
(Altruda et al., 1989, Miyauchi et al., 
1991, Miyauchi et al., 1995) 
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1.7.1: Protein structure and expression. 
CD147 is composed of an extracellular domain of 187 residues, a 24-residue trans-
membrane domain and a 40 amino acid cytoplasmic region (Biswas et al., 1995). Its 
extracellular region has two Ig domains (Domain1 and Domain 2) and an N-terminal 
domain with several enzyme catalytic sites. The trans-membrane (TM) domain contains 
a glutamic acid residue thought to be important in protein-protein association (Fig.1.7) 
(Miyauchi et al., 1990, Fossum et al., 1991).  
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Figure 1.7: Human CD147 protein. 
Structure showing the signal peptide sequence (SP), consensus asparagines-linked 
glycosylation sites (N), extracellular domains (0, 1 and 2), transmembrane domain 
(TM), and cytoplasmic domain (Cyto-domain)  (adapted from (Belton et al., 2008)). 
 
 
 
 
 
 
 
 
 
Domain 0 Domain 1 Domain 2 Cyto-domain SP TM
N N N
Extra-cellular Intra-cellular
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Although, the CD147 protein is expressed in most tissues, it is relatively highly 
expressed in tumours where it has been demonstrated to participate in tumour invasion 
and metastasis (Reimers et al., 2004, Tang et al., 2004, Tang et al., 2005, Nabeshima et 
al., 2006b).  It is also highly expressed on activated T and B lymphocytes, dendritic 
cells, monocytes, macrophages, heart, early erythroid, thyroid, pre-frontal cortex and 
placenta (Kasinrerk et al., 1992, Kochi and Ushio, 1999, Liang et al., 2005). Patients 
with systemic lupus erythematous (SLE) exhibit elevated CD147 levels in activated 
CD3+ T Cells compared to healthy donor, suggesting its involvement in the progression 
of SLE (Pistol et al., 2007).  In the brain CD147 is highly expressed in neurons within 
the cornu ammonis (CA) region and dentate of the hippocampus (Fan et al., 1998). 
Other brain areas that express CD147 include the upper layers of the cortex, with the 
CA region of the hippocampus and neuronal processes showing weak expression 
(Vetrivel et al., 2008b). 
 
CD147 can also be detected in conditioned media from tumour cell cultures (Biswas, 
1984, Tang et al., 2004, Hanata et al., 2007), in supernatant of lipid loaded macrophages 
(Yue et al., 2009) and more recently detected in human serum (Moonsom et al., 2010) 
indicating that CD147 can be secreted and is present in a soluble form. The function(s) 
of soluble CD147 remain unclear, however, it has been shown to stimulate stromal 
fibroblast cells to express metalloproteases (MMPs), facilitating matrix degradation, 
tumour invasion and metastasis (Tang et al., 2004). Similar functions have been 
suggested for soluble CD147 in atherosclerotic plaque destabilization (Yue et al., 2009).    
 
1.7.2: Functions of CD147 
In non-diseased tissue CD147, has been shown to interact/associate with several 
proteins. Its trans-membrane and cytoplasmic domains play a critical role in protein-
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protein interactions associated with the plasma membrane (Kirk et al., 2000). In 
pathology, CD147 is implicated in some diseases such as cancer where it facilitates its 
metastasis through MMPs induction and systemic lupus erythematous (SLE) (Biswas, 
1984) that is characterized by activated T Lymphocytes. The CD147 protein also has 
important roles in the central nervous system and more recently has been implicated in 
neurodegenerative diseases such as AD (Nahalkova et al., 2010). The following sections 
will discuss some of the more established neuronal and non-neuronal roles for CD147.   
 
1.7.3: Non neuronal functions of CD147 
 A number of functions for CD147 appear to be due to its ability to regulate metallo-
proteinases (MMPs), a family of proteolytic enzymes which are capable of degrading 
molecules of the extracellular matrix (Sanderson et al., 2005). In reproduction, 
degradation of the endometrium after embryo implantation is facilitated by MMPs, 
which is influenced by CD147 expression in fibroblasts (Li et al., 2001, Chen et al., 
2007). Induction of MMPs by CD147 in human placenta promotes parturition by 
inducing foetal membrane rupture and detachment from the uterus.  Roles for CD147 in 
reproduction also appear to extend to fertilization where CD147 knock-out mice are 
infertile, due to deficiencies in spermatogenesis (Igakura et al., 1998) and roles in 
sperm-egg interaction (Sexena et al., 2001).  
 
CD147 facilitated induction of MMPs also appears to have a role in stromal cells of 
cancer tumours where it maintains extracellular matrix integrity and cell communication 
through association with intergrins (Curtin et al., 2005). Integrins are cell surface 
receptors composed of alpha and beta chain heterocomplexes that serve as bi-directional 
transducers of extracellular and intracellular signals during cell adhesion, proliferation, 
differentiation and tumour progression. The structural and functional properties of both 
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intergrins and CD147 provide a conducive environment for the interaction of the two 
proteins.  
 
Tumorigenic cells expressing CD147 induce MPP expression by neighbouring 
fibroblasts facilitating cancer cell migration (Biswas, 1982, Kataoka et al., 1993, Biswas 
et al., 1995, Heppner et al., 1996). Further evidence that CD147 regulates MMP 
expression during cancer metastasis is provided by studies in human breast cancer and 
glioblastoma cell lines where suppression of CD147 by antisense RNA decreased MPP-
2, MPP-9 and also down-regulated vascular endothelial growth factor (VEGF) (Liang et 
al., 2005, Tang et al., 2005). The consequences of CD147 induction of MMP extends to 
tissue repair where diseased eye corneas have elevated levels of CD147 localized to 
those areas of greatest MMP expression (Gabison et al., 2005). The mechanism by 
which CD147 regulates MMP production is largely unclear, although its glycosylation 
is necessary for its action as de-glycosylated CD147 induces MMP secretion from a 
breast cancer cell line (Sun and Hemler, 2001, Tang et al., 2004).  One possible 
mechanism is through the mitogen-activated protein kinase (MAPK) signalling pathway 
which is known to regulate MMP production. Knock-down of CD147 by siRNA has 
been shown to inhibit phosphorylation of the MAPK signalling molecules SAPK/JNK, 
suggesting a possible mechanism by which CD147 regulates MMP levels (Qian et al., 
2008).  
 
Evidence also exists that CD147 has a role in transport of products from the glycolytic 
pathway. The monocarboxylate transporter (MCT) protein catalyses the protein linked 
monocarboxylates including lactate and pyruvate, glucose metabolites necessary for the 
maintenance of metabolic homeostasis within most cells (Halestrap and Price, 1999, 
Kirk et al., 2000).  Of the four isoforms, only MCT1 and MCT4 interact with CD147 
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and this association facilitates the expression of both MCTs and CD147 (Kirk et al., 
2000).  These two isoforms require direct interaction with CD147 for their transport to 
the plasma membrane (Kirk et al., 2000) in order to mediate lactate transport across the 
plasma membrane (Wilson et al., 2002).  Deficiency in MCT 1 and MCT 4 in the retina 
affects the photoreceptor cells due to reduced lactate transport resulting in blindness. 
Similarly CD147 absence or depletion leads to impaired surface expression of MCT1, 
which results in the death of photoreceptor cells due to lack of lactate transport (Philips 
et al., 2003). Taken together these findings indicate that CD147 acts as a chaperone for 
MCT1 and MCT4 translocation to the plasma membrane.  
 
The identification that CD147 is a signalling receptor for cyclophilin A (CyPA) 
provided a novel function for this transmembrane glycoprotein (Yurchenko et al., 
2002). CyPA is an ubiquitously expressed intracellular protein belonging to the 
immunophillin family, and is known to function as a ligand for the immunosuppressive 
drug, cyclosporine (Liu et al., 1991, Colgan et al., 2005) and shown to also regulate 
protein trafficking in cells (Brown et al., 2001, Chklovskaia et al., 2001, Ansari et al., 
2002, Huang et al., 2002).   Elevated cyclophilins levels have been reported in several 
inflammatory conditions including severe sepsis (Tegeder et al., 1997), vascular smooth 
muscle cell disease (Jin et al., 2000), and rheumatoid arthritis (Billich et al., 1997). 
These inflammatory effects may be mediated by cyclophilins-CD147 interactions which 
initiate/progress the recruitment of leucocytes, which express CD147 receptor, 
(Yurchenko et al., 2001, Yurchenko et al., 2005) into inflamed tissues (Sherry et al., 
1992, Xu et al., 1992, Allain et al., 2002). 
 
The roles of CD147 in cell development, tumour progression, cell metabolism and 
signalling have been well studied. However, its role in the CNS has received less 
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attention. Cell signalling and its ability to interact with a number of proteins, including 
cyclophilins, has suggested roles for CD147 in neuroprotection and in the pathogenesis 
of neurodegenerative diseases such as AD. These roles are discussed further below.    
 
1.7.4: Neuronal functions of CD147 
Expression of CD147 (Basigin) has been shown to be extensively expressed in a 
number of regions of the mouse CNS (Fan et al., 1998). The regions include: mitral 
cells in the olfactory bulb; limbic system including the amygdala and piriform cortex; 
hypothalamus including the paraventricular nucleus and the ventromedial nucleus, the 
Purkinje cells in the cerebellum; the pontine nucleus in the pons; thalamus; retina 
including the outer and inner granular layers and ganglion cells (Fan et al., 1998). Such 
extensive expression in many regions of the CNS suggests a number of functions and 
particularly the relatively high expression in the limbic system (Fan et al., 1998), would 
suggest functions in memory and behaviour. This was addressed by Naruhashi and 
colleagues (Naruhashi et al., 1997) where a number of behavioural tasks were carried 
out in mice lacking CD147. Compared to wild-type and heterogeneous (Basigin +/-) 
mice, the CD147 null mice (Basigin -/-) performed worse in memory and learning tasks 
(e.g. Y-maze and water finding tasks). In addition CD147 null mice were less sensitive 
to light, pain, and induced electric shock, reflecting the importance of CD147 in sensory 
functions.   
 
Through its interaction, the CD147 receptor has been proposed to mediate neuro-
protection mediated by CyPA (Boulos et al., 2007) which is abundantly expressed in the 
brain, primarily localized to neurons (Goldner and Patrick, 1996) and co-localises with 
neuronal CD147 receptor in the hippocampus and cortex of rodents (Lad et al., 1991, 
Goldner and Patrick, 1996, Fan et al., 1998). Although its role in the CNS is undefined, 
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CyPA has been implicated in neuronal differentiation (Hovland et al., 1999, Chiu et al., 
2003, Song et al., 2004), cortical plasticity (Arckens et al., 2003) and embryonic 
neuronal growth and development (Nahreini et al., 2001). CyPA is also up-regulated in 
neuronal cultures following pre-conditioning treatments (Meloni et al., 2005).  Over-
expression of CyPA in primary cortical neuronal culture has been shown to attenuate 
neuronal death induced by oxidative stress or ischemic insults (Boulos et al., 2007). 
Similar protection was also achieved with the addition of exogenous human CyPA 
protein to neuronal cultures. Activation of the CD147 receptor by CyPA was shown to 
stimulate the phosphorylation of ERK1/2, which activates the anti-apoptotic proteins 
Bcl-2 (Riccio et al., 1999) and Bag-1 (Perkins et al., 2003) and phosphorylation-
mediated inactivation of pro-apoptotic proteins such as Bim (Biswas and Greene, 2002) 
and Bad (Bonni et al., 1999, Zhu et al., 2002).  These downstream pro-survival 
signalling events may be one mechanism through which CyPA/CD147 interaction 
protects neurons from toxic insults.  Although a role for CD147 in neuronal protection 
has been reported, its involvement in neurodegenerative diseases has been directed at 
AD, where it appears to control levels of Aβ. 
 
1.7.5: CD147 interactions with γ-secretase and modulating beta 
amyloid levels. 
 
A role for CD147 in modulating Aβ levels came about following the observation that 
knock-down of CD147 resulted in increased levels of secreted Aβ40 and Aβ42 from 
cells (Zhou et al., 2005, Vetrivel et al., 2008b) (Fig.1.8B). The mechanism by which 
CD147 modulates Aβ accumulation is unclear, with two studies proposing different 
mechanisms of action. Zhou and colleagues (Zhou et al., 2005) showed that CD147 is 
possibly a regulatory component of the γ-secretase complex. In their study it was 
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observed that CD147 depletion using RNAi resulted in elevated Aβ40/42 production, 
without affecting expression levels of NCT, pen-2, aph-1 and PS1(Zhou et al., 2005). 
However, Vetrivel and colleagues (Vetrivel et al., 2008b) showed that CD147 did not 
interact with the other γ-secretase complex components and concluded that it was not an 
integral part of the complex. Instead, the authors showed that CD147 mediates the 
degradation of Aβ possibly via stimulating the production of the MMPs, which have 
previously been shown to degrade Aβ (Backstrom et al., 1996, Nalivaeva et al., 2008, 
Kong et al., 2010). The discrepancies between these two studies could be due to 
methodological differences and it is possible that CD147 may have varying functions in 
different cell lines. Vetrivel and colleagues used HEK-293 (compared to CHO cells 
used in the Zhou et al study) in over-expressing CD147. Nahalkova and colleagues 
(Nahalkova et al., 2010) recently provided further evidence that CD147 interacts with γ-
secretase components and may influence Aβ production. The authors showed that the 
sub-cellular distribution of CD147 was altered from a cell surface localisation in PSwt 
and PS1-/- cells, to a peri-nuclear localisation in PS2-/- cells. This study not only 
indicated that specific components of γ-secretase interact with CD147, but also implied 
that CD147–γ-secretase interaction may occur in mitochondria-associated membranes 
(MAM), the cellular fraction where the majority of γ-secretase activity is proposed to be 
localized (Area-Gomez et al., 2009, Schon and Area-Gomez, 2010).   
 
Purification and biochemical characterization of interactors of endogenous γ-secretase 
in HEK-293 cells showed that CD147, together with TMP21 a member of the p24 
cargo-protein family, which functions in quality control and protein transport in the ER 
and Golgi (Li et al., 2000a), co-purified in a high molecular complex with γ-secretase 
(Winkler et al., 2009). However, these proteins could not be affinity captured with γ-
secretase inhibitors, indicating that they are not part of the active γ-secretase complex. 
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These findings support the notion that both CD147 and TMP21 may act to control Aβ 
levels (Fig.1.8A) within the cell but they most likely are not part of the core 
components of the γ-secretase complex, thereby affecting Aβ levels indirectly.  
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Figure 1.8: The γ-secretase complex proteins.  
Proteins of the γ-secretase complex (Psn, Nct, APH-1 and PEN-2) with CD147 as a 
regulatory subunit of the γ-secretase complex showing reduced generation of Aβ 
peptides (A) and without CD147 showing increased generation of Aβ peptides (B). 
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1.7.6: CD147 expression in AD. 
 
Considering the roles of CD147 in neuro-protection and modulating Aβ levels, it would 
be conceivable that modulating CD147 transcription or its expression would impact on 
its activity. Apart from in vitro over-expression and knock-down studies in proof-of-
concept studies, the effects of modulating CD147 transcription/expression on AD 
pathology have not been explored. Indeed, whether CD147 transcription or protein 
expression is altered in AD has not been fully examined.  Only one study has 
investigated CD147 protein expression levels in different brain regions in a small 
number of control and AD brain samples (Nahalkova et al., 2010). The numbers used 
(n=3/group) were too small to show significant differences in CD147 levels, however 
qualitative analysis of immunostained tissue sections revealed that CD147 staining was 
more intensive in the neurons and capillaries in both frontal cortex and thalamus of AD 
compared to control brain. More detailed, quantitative analysis in a larger number of 
tissue samples is required to determine if CD147 protein expression is significantly 
altered in AD. In addition, correlations with plaques and NFTs would be required to 
determine if CD147 expression is significantly associated with AD pathology.  
 
Evidence also exists that CD147 may be modulated at the transcription level. One study 
investigated the presence of natural anti-sense transcripts (NATs) in AD associated 
genes including PRESNILINS, BACE1/2, APP, APOE, TAU, NICASTRIN, PEN2, 
APH1A/B as well as CD147 (Guo et al., 2006). The exact function of NATs remain 
unclear, however they are thought to play a role in suppressing gene expression (Yelin 
et al., 2003, Alfano and Poli, 2005). The authors showed that NATs were present in 
CD147 and 3 other genes, namely APP, BACE2, and APH1A critical for Aβ 
production. These results suggest that NATs may have a role in modulating Aβ 
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production, by controlling expression of genes important in APP metabolism including 
APP itself, components of Aβ generating enzymes and CD147. Polymorphisms or other 
genetic variations in the CD147 gene and associations with AD have yet to be 
investigated; however if such variations exist, particularly in the promoter, they may 
impact on Aβ accumulation. Such variations may alter binding of transcription factors 
such as sterol carrier protein 2 (SCP-2), which is known to control CD147 expression 
by binding its promoter region, in turn altering γ-secretase activity (Ko and Puglielli, 
2007).  Accumulated evidence presented above, indicates a role for the multifunctional 
CD147 receptor in AD pathogenesis, possibly by modulating Aβ levels through altering 
production or clearance. However, its involvement in AD pathogenesis may not be 
limited to Aβ.   
 
Many pathological conditions involving inflammation are associated with increased 
CD147 expression in tissues and cells. These include lung inflammatory diseases (Foda 
et al., 2001, Hasaneen et al., 2005), rheumatoid arthritis (Konttinen et al., 2000, Tomita 
et al., 2002, Zhu et al., 2006, Yang et al., 2008, Damsker et al., 2009), systemic lupus 
erythematosus (SLE) (Pistol et al., 2007), chronic liver diseases induced by hepatitis C 
virus (HCV) (Shackel et al., 2002), atherosclerosis (Spinale et al., 2000, Choi et al., 
2002, Yoon et al., 2005, Siwik et al., 2008) and ischemia (Boulos et al., 2007, Waldow 
et al., 2009).  Inflammatory mediated increases in CD147 levels are thought to be a 
mechanism by which MMPs are activated and potentiate tissue repair and or 
remodelling, for example in instances of myocardial infarction (Spinale et al., 2000, 
Siwik et al., 2008, Nie et al., 2009) or destabilization of atherosclerotic plaques (Yoon 
et al., 2005).  CyPA- CD147 interactions also appear to play important roles in 
inflammation. The up-regulation of CD147 expression observed in most inflammatory 
diseases, overlap with an up-regulation of CyPA. This is thought to contribute to the 
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recruitment of immune cells to sites of inflammation via a chemokine-like activity 
(Yurchenko et al., 2005). Pro-inflammatory leucocytes have been reported to have 
increased expression of CD147, compared to non-inflammatory cells (Zhu et al., 2005). 
This may facilitate the interaction between leucocytes and thereby further promoting 
leukocyte recruitment. Recent evidence for this was shown by Damsker and colleagues 
(Damsker et al., 2009), where activated CD4+ T cells showed enhanced CD147 
expression. The CyPA- CD147 interaction may also contribute to MMP production. In 
an apoE deficient mouse model of atherosclerosis, knock-down of CD147 and the 
presence of cyclophillin inhibitor during cell differentiation, hindered up-regulation of 
MMPs. Whereas the presence of CyPA up-regulated MMPs and both CD147 and CyPA 
were found in atherosclerotic plaques in these mice. The results suggested that 
CyPA/CD147 pathway may have a role in atherosclerotic plaque pathology.  
 
The presence of CD147 mRNA transcripts in microglia (Inoue et al., 1999) and 
astrocytes (Meeuwsen et al., 2003) suggests a potential role for this protein in 
inflammatory processes mediated by these cells. Indeed, it may have a similar role as it 
has in the periphery where it could facilitate chemokine-mediated recruitment of 
inflammatory cells. However, at present there is no evidence that CD147 can mediate 
release of cytokines from astrocytes or microglia. The presence of CD147 in astrocytes 
may also mediate other functions. Since CD147 is up-regulated in astrocytes in a mouse 
model of permanent focal cerebral ischemia and co-localises with MMP-9 suggests its 
participation in neurovascular remodelling (Kleene et al., 2007) through ATPase in 
astrocytes which bound to CD147 and facilitated lactate transport via the astroglial 
monocarboxylate transporter 1 (MCT1) (Maekawa et al., 2008). Astrocytic lactic 
transport facilitated by MCT and activated by CD147 has important implications in 
maintaining glucose metabolism “glycolytic flux” in the brain (Gandhi et al., 2009).  
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This has implications in AD, as brain glucose metabolism is impaired in AD individuals 
with mild cognitive decline (MCI) and transgenic mouse models of AD (Bigi et al., 
2003, Hooijmans et al., 2007). 
 
1.8: Regulating CD147 expression.  
 
1.8.1 Control of CD147 expression by Sterol carrier protein (SCP) 
 
The expression of CD147 is controlled by sterol carrier protein 2 (SCP-2), a protein that 
is involved in trafficking and intracellular utilization of cholesterol and other lipids. The 
SCP protein plays a key role in cholesterol metabolism as it facilitates in cholesterol 
uptake (Hirai et al., 1994, Colles et al., 1995, Lipka et al., 1995, Moncecchi et al., 1996, 
Schroeder et al., 1998, Atshaves et al., 1999), intracellular transport (Puglielli et al., 
1995), esterification (Murphy and Schroeder, 1997) and oxidation (Chanderbhan et al., 
1986, Yamamoto et al., 1991).  In addition it has been shown to remodel lipid 
composition, structure and function of lipid rafts (Schroeder et al., 2007). The levels of 
SCP are altered in a number of diseases where lipid metabolism is abnormal, including 
diabetes and zellweger syndrome, where patients lack SCP-2 and are deficient in fatty 
acid oxidation and normal lipid metabolism (reviewed in (van Heusden et al., 1990, 
Wirtz, 1997)). In the neurodegenerative disease, Niemann-Pick Type C disease, where 
there is failure of cholesterol trafficking within the endosomal-lysomal pathway caused 
by mutation in the NPC protein (Nixon, 2004, Lo et al., 2010, Gallala et al., 2011), there 
is a marked reduction in levels of the 13KDa SCP-2 protein and accumulation of lipids 
in the lysosomes and Golgi (Roff et al., 1992). Interestingly, some intriguing parallels 
exist with NPC and AD, such as NFT formation, lysosomes dysfunction and 
accumulation of Aβ (reviewed in (Nixon, 2004).  
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The SCP-2 gene is part of a fusion gene that contains two initiation sites encoding a 
15.4 kDa (pro-SCP-2) and a 58.9 kDa (SCP-x) protein (Ohba et al., 1994, Ohba et al., 
1995). The 58.9 kDa SCP-x protein undergoes a post-translational cleavage process to 
yield a mature 12.9 kDa SCP-2 where it has been shown to translocates to the nucleus 
and activate CD147 transcription (Ko and Puglielli, 2007). In contrast, expression of 
pro-SCP-2 has been shown to abolish activity of 12.9 kDa SCP-2 and inhibit CD147 
transcription, resulting in an increase in Aβ production. SCPx/SCP-2 expression and 
synthesis has been shown to be regulated by hormones (McLean et al., 1989, Mendis-
Handagama et al., 1998), hypolipidemic drugs, lipid rich conditions (Kraemer et al., 
1995) and during development. (Trzeciak et al., 1987, Baun, 1993, Mori et al., 2009). 
Although over-expression and knockdown studies have revealed that SCP-2 can 
regulate CD147 levels, impacting on Aβ production, whether regulating SCP-2 levels 
impacts on CD147 expression has yet to be determined. 
 
1.8.2: Regulation of SCP and γ-secretase activity by cholesterol 
 
The largest pool and concentration of cholesterol in the body exists in the brain where it 
is a constituent of cell membranes and myelin. Cholesterol is important for normal brain 
function and defects in cholesterol metabolism are associated with serious neurological 
and mental dysfunctions (Tint et al., 1994). Brain cholesterol is efficiently protected 
from exchange with circulating lipoproteins by the blood-brain barrier (BBB) and thus 
most of the cholesterol found in the brain is synthesized locally, although at a low rate. 
Alterations in cholesterol metabolism occur with age and have been implicated in both 
increased AD risk and progression of this disease (Jarvik et al., 1995, Igbavboa et al., 
1996). Cardiovascular risk factors such as hypercholesterolemia, increased LDL and 
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reduced HDL levels, hypertension, obesity and type II diabetes make important 
contributions to the risk of developing AD. These risk factors also impact on disease 
pathogenesis and are known to modulate the levels of key AD associated proteins 
including Aβ. In neurons and other cell lines cholesterol levels modulate APP 
metabolism modulating secretase activity (Racchi et al., 1997, Simons et al., 1998b, 
Galbete et al., 2000a, Kojro et al., 2001, Runz et al., 2002).  Evidence exists that cellular 
sites that are rich in cholesterol and siphingolipid-rich membranes microdomains (so 
called lipid rafts; (Lee et al., 1998, Wahrle et al., 2002), contain BACE1 and the γ-
secretase complex, promoting Aβ production at these sites (reviewed in (Cheng et al., 
2007)). Knowing that SCP has a role in nearly all aspects of cholesterol metabolism and 
also facilitates CD147 transcription, it is conceivable that changes in cholesterol 
homeostasis (i.e. under cholesterol loading) will alter levels of SCP, thereby impacting 
on CD147 levels. Indeed cholesterol enrichment in rat aortic smooth muscle cells 
resulted in an increased SCP mRNA and protein levels of SCPx and SCP-2 protein 
(Kraemer et al., 1995), providing evidence that cholesterol and its derivatives can 
regulate SCP expression. Whether this results in changes in CD147 levels, thereby 
impacting on Aβ levels remains to be determined.  Given the apparent relationship 
between cholesterol and Aβ it is important to investigate factors involved in cholesterol 
transport and metabolism such as sterol carrier protein (SCP).   
 
1.12: Hypothesis 
 
Alzheimer’s disease is a very heterogeneous and a multifactorial ageing disorder of the 
nervous system. Accumulation and toxicity of the Aβ protein are key mediators of 
neurodegeneration in AD and its levels can be modulated through altering its production 
and clearance. A number of factors and cellular pathways (and proteins within these 
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pathways) are known to influence the production and or clearance of Aβ. The CD147 
protein has recently been implicated in AD pathogenesis, in particular regulating Aβ 
levels.   The roles of CD147 in cell development, tumour progression, cell metabolism 
and signalling have been well studied. However, its role in the CNS has received less 
attention. Cell signalling and its ability to interact with a number of proteins, including 
cyclophilins, has suggested roles for CD147 in neuroprotection and in pathology of 
neurodegenerative diseases such as AD.  Considering the roles of CD147 in neuro-
protection and modulating Aβ levels, it would be conceivable that modulating CD147 
transcription or its expression would impact on its activity. Apart from in vitro over-
expression and knock-down experiments in proof-of-concept studies, the effects of 
modulating CD147 transcription/expression on AD pathology have not been explored. 
Indeed, whether CD147 transcription or protein expression is altered in AD or in the 
presence of risk factors has not been fully examined.  One such factor is cholesterol 
metabolism, which could impact on CD147 expression through regulating one of its 
major transcription regulators, Sterol Carrier Protein (SCP-2).  
 
1.13: Aims 
This thesis explores the effects of modulating CD147 expression on neurodegeneration 
and AD pathogenesis and addresses the following specific aims: 
 
1. To determine if cholesterol and Aβ accumulation alters CD147 protein levels in 
vitro and alter neuronal toxicity.  
2. To determine if cholesterol alters CD147 levels in a mouse model of AD. 
3. To determine if CD147 protein levels are altered in AD brain. 
4. To determine if polymorphisms within the promoter region of CD147 are 
associated with AD and correlate with Aβ accumulation. 
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CHAPTER 2 
Materials and Methods 
2.1: Materials 
 
Table 2.1: Commonly used chemicals 
CHEMICAL SUPPLIER 
Ammonium persulphate (APS Bio-Rad Irvine, CA.- USA 
Acrylamide Bio-Rad Irvine, CA.- USA 
Aprotonin Sigma Saint Lous, MO - USA 
Ammonium chloride (NH4CL) Sigma Saint Lous, MO - USA 
Adenosine triphosphate (ATP) Sigma 
Agarose (Biotechnology grade) Ameresco 
Ampicillin (sodium salt) Sigma 
Agar Amresco 
Bacto-tryptone Difco 
Bacto-Yeast extract Difco 
Bis-tris Bio-Rad Irvine, CA.- USA 
Bicine Bio-Rad Irvine, CA.- USA 
Bradford reagent Bio-Rad 
Calcium chloride BDH 
Dithiotreitol (DTT) Sigma Saint Lous, MO - USA 
D-(+)-Glucose BDH 
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Dimethylsulphoxide (DMSO) Sigma 
Di-sodium hydrogen orthophosphate Sigma 
DNA molecular weight marker standard 
(1.0 kb ladder) 
Promega 
DNA molecular weight marker standard 
(Lambda HindIII digest) 
Promega 
Deoxynucleotide triphosphates (dNTPs) Promega 
Ethylenediaminetetra acetic acid (EDTA) BDH chemicals Pty. Ltd., Vic. - Australia 
Ethylphenyl-polyethylene glycol (NP40) ICN Biomedicals, Inc. Aurora, Ohio - 
USA 
Ethanol BDH chemicals Pty. Ltd., Vic. - Australia 
Ethidium bromide Sigma 
Glacial acetic acid BDH 
Glycine Bio-Rad Irvine, CA.- USA 
Glycerol Sigma 
Human recombinant cyclophilin A 
(hrCyPA) 
Biomol 
Hydrochloric acid BDH 
Isopropyl alcohol BDH 
Isopropylthio-β-D-galactoside (IPTG) Boehringer Mannheim 
  
Kanamycin sulphate Sigma 
Leupeptin Sigma Saint Lous, MO - USA 
Methanol BDH chemicals Pty. Ltd., Vic. - Australia 
Magnesium chloride BDH 
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M-MLV Reverse transcriptase, RNase H 
minus Point mutant 
Promega 
  
N,N,N,N,N’-Tetra-methyl thylenediamine 
(TEMED) 
Bio-Rad Irvine, CA.- USA 
N1N-dimethylformamide BDH 
  
Phenylmethyl-sulfonyl fluoride (PMSF) Sigma Saint Lous, MO - USA 
Phosphate buffered saline (PBS) Fisher Biotech International Ltd., Perth - 
Australia 
Potassium chloride BDH 
Protein molecular weight marker Invitrogen 
Protease inhibitors Roche 
Pfu DNA polymerase Promega 
RNasin ribonuclease Inhibitor Promega 
Sodium dodecylsulfate (SDS) Bio-Rad Irvine, CA.- USA 
Restriction enzymes Promega, New England (NEB) Biolabs 
Sodium acetate BDH 
Sodium dihydrogen orthophosphate Sigma 
Sodium dodecyl sulphate (SDS) Sigma 
Sodium hydroxide BDH 
Trizol reagent Invitrogen 
Trizma base Sigma 
Tween20 Sigma 
T4 DNA ligase Promega 
 
 80 
 
 
 
Table 2.2: Preparation of buffers/solutions and reagents 
SOLUTION PREPARATION 
Acrylamide/bis (49.5%/3%) A stock solution was made by dissolving 96g of 
acrylamide and 6g of bis-acrylamide in double 
distilled water (DDW) making up to 2 litres and the 
stock solution stored at 4 oC. 
Ammonium persulfate (10% w/v 
APS) 
A stock solution was made by dissolving 1g APS 
powder in DDW making the final volume to 10 ml, 
Aliquoted (1ml) and stored at -20oC 
Anode Buffer (10x  stock 
solution) 
A stock solution was made by dissolving 242.2g 
Tris-chloride in DDW making up to 1 litre  
Ampicillin A stock solution was made by dissolving 50 mg/ml 
stock in WFI, sterilised by microfiltration (0.2 µm) 
and stored at -20°C 
Aβ42  Aβ42 was prepared by dissolving 1mg in 180μl 
20mM NaoH, 630μl Baxter water and 90μl 10x 
PBS pH7.4 and sonicate for 5 minutes. Centrifuge 
and transfer supernatant into a new tube. Measure 
absorbance on a Shimadzu UV/VIS 
Spectrophotometer at 214nm (1:24 dil.). Calculate 
concentration by multiplying OD by the correction 
(15.45) and dilution (25) factors. 
Cholesterol (5mg/ml) Cholesterol working solution was prepared by 
dissolving 40mg/ml cholesterol stock in 6 ml sterile 
Baxter water  
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Cathode Buffer (10x  stock 
solution) 
A stock solution was made by dissolving 121.1g of 
Tris, 179.2g tricine and 10g SDS in DDW, making 
the final volume to 1 litre.  
Carbonate/Bicarbonate Buffer 
(50mM) 
50mM carbonate/bicarbonate buffer consisted of 
0.26g of Na2CO3, 0.21g of NaHCO3, with addition 
of DDW made up to 50ml and adjusted to pH 9.6 
using HCl. 
DNA loading dye 6x stock prepared in 1 x TAE buffer and containing 
bromophenol blue (0.25%), xylene cyanol ff 
(0.25%) and 30% glycerol 
dNTPs (10 mM stock solution) A stock solution was made by mixing 100 µl of 
each constituent (dATP, dTTP, dCTP and dGTP 
each at 100 mM) with 600 µl of WFI, dispensing 
100 µl aliquots and stored at -20°C 
Ethidium bromide Prepared as 10 mg/ml stock with WFI.  Stored in 
the dark, at 4°C 
ELISA Blocking Buffer Blocking Buffer was prepared by dissolving 0.25g 
of bovine serum albumin (BSA: Sigma Chemical 
Co., USA) into 25ml of PBST. 
ELISA Standards (Aβ40) Standards were prepared by diluting 1mg/ml Aβ40 
stock with PBST to concentrations ranging from 
15.625 pg/ml to 1μg/ml 
ELISA  Detection antibody solution were prepared by 
diluting 0.125g BSA in 12.5ml of PBST and 12.5µl 
of secondary antibodies (R208) (1:1000) for each 
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plate. The Neutravidin HRP solution was prepared 
by the addition of 1.25µl of nHRP and 12.5ml of 
PBST (1:10000).  
MgCl2 (1M) MgCl2 (1M) was prepared by dissolving in WFI 
and sterilised by microfiltration/0.2 µm 
MgSO4 (1M) MgSO4 (1M) was prepared by dissolving in WFI 
and sterilised by microfiltration/0.2 µm 
MOPS SDS running buffer Supplied as 20x stock (Invitrogen) and composed 
of MOPS (1 M); Tris Base (1 M); SDS (69.3 mM); 
EDTA (20.5 mM) made up in ultrapure water. 
Unadjusted 1x buffer is pH 7.7 
NuPAGE lauryl dodecyl sulphate 
(LDS) sample buffer 
Supplied as 4x stock (Invitrogen) and composed of 
glycerol (4 g); Tris-Base (0.682 g); Tris HCl (0.666 
g); LDS (0.8 g); EDTA (0.006 g); Serva Blue G250 
(0.75 ml of 1% solution); phenol red (0.25 ml of 
1% solution) made up in 10ml of ultrapure water.  
Unadjusted 1x buffer is pH 8.5 
NuPAGE transfer buffer Supplied as 20x stock (Invitrogen) and composed 
of bicine (500 mM); Bis-Tris (500 mM); EDTA 
(20.5 mM); chlorobutanol (1 mM) made up in 
ultrapure water.  Unadjusted1x buffer is pH 7.2 
Oligonucleotides (Custom) Synthetic oligonucleotides were ordered as 
250ng/ml solutions from Proligo (USA) and stored 
at -20°C 
Phosphate buffered saline (PBS) 10x stock was prepared by dissolving 11.5 g of di-
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pH7.5 sodium hydrogen orthophosphate anhydrous (80 
mM), 2.96 g sodium dihydrogen orthophosphate 
(20 mM), 5.84 g sodium chloride (100 mM) in 
Milli-Q water to1000 ml 
  
Sodium acetate Prepared as 3 M solution (pH 5.2) in Milli-Q, 
adjusted with glacial acetic acid and autoclaved 
TAE A one litre, 50x stock solution was prepared by 
combining Trizma base (242 g), 57.1 ml of glacial 
acetic acid and 100 ml of 0.5 M EDTA (pH 8.0) 
with Milli-Q water 
TB Buffer HEPES (10 mM), CaCl2 (15 mM), KCl (250 mM) 
were dissolved in WFI and the pH adjusted to 6.7 
with KOH, prior to adding MnCl2 (55 mM).  The 
solution was sterilised by microfiltration/0.2 µm 
and stored at -4°C 
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        Table 2.3: Special equipment list 
EQUIPMENT COMPANY 
Dry Block Heater Ratek Instruments Australia 
Electrophoresis Power Supply Amersham Pharmacia Biotech 
FLUOstar Optima Spectrophotometer BMG Labtech 
Florescent Microscope Olympus 
Gene Pulser Xcell Bio-Rad 
IBlot Invitrogen 
Mastercycler Gradient  Eppindorf 
Qp RT-PCR (BioRad) Bio Rad – South Africa 
Scanner, UMAX 1220S UMAX Technologies Inc., CA.- USA 
Sonifier 450 Branson 
UVmini-12 Spectrophotometer Shimadzu – Japan 
VI-CellTM XR Cell Viability Analyser Beckam Coulter- USA 
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Table 2.4: Reagents for mammalian cell culture 
REAGENT SUPPLIER 
B27 supplement Invitrogen Carlsbad, CA - USA 
β-mercaptoethanol Sigma 
D-Glucose Sigma 
Dulbecco’s modified Eagles medium 
(DMEM) 
ICN Biomedical, Costa Mesa, CA - USA 
Foetal calf serum (FCS) JRH Biosciences Lexan, KS - USA 
Gentamycin Invitrogen  
Glutamax Invitrogen  
Hanks balanced salt solution (HBSS Invitrogen  
Hibernate E media Brain Bits, Springfield IL - USA 
L-glutamine Sigma 
Neurobasal medium without L-glutamate Invitrogen  
OPTI-MEM and DMEM ICN Biomedical,  
Poly-D-Lysine Sigma 
Penicillin Sigma-Aldrich Pty. Ltd., Sydney- 
Australia 
Streptomycin Sigma 
Trypsin, 0.25% (1X) with EDTA 4Na Trace Biosciences Pty Ltd., Vic.- 
Australia 
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Table 2.5: Bacterial culture media 
MEDIA PREPARATION 
F-12 Medium Dissolve 1 packet of media in a litter of dH2O, add 2.4g sodium 
bicarbonate and 2g D-glucose and adjust pH to 7.2. Filter 
sterilized and add 5%FCS.  
2x YT Medium Dissolve 16g bacto-tryptone, 10g bacto-yeast extract and 5g 
sodium chloride in 900 ml deionised H2O, make up to 1000ml 
and sterilize at 15 lb.sq.in on liquid cycle 
SOB++ Bacto-tryptone (20 g), Bacto-yeast (5 g), NaCl (0.5 g) and KCl 
(0.186 g) dissolved in WFI to a final one litre volume and 
sterilised.  Prior to use, 20 ml of MgCl2 (1 M stock) and MgSO4 
(1 M stock) was added to a final concentration of 10 mM 
Terrific Broth Dissolve 12g bacto-tryptone, 24g bacto-yeast extract and 4ml 
glycerol in 900ml-deionised water. Add 0.17M KH2PO4 and 
0.72M K2HPO4 solution prepared by dissolving 2.31g KH2PO4 
and 12.54g K2HPO4 in 90ml dH2O adjusted to 100ml. 
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Table 2.6: PCR Reagents 
REAGENT SUPPLIER 
DNA and Gel purification systems Promega Corporation, Madison, WI - USA 
DNA loading dye Promega  
dNTPs Qaigen ,Victoria – Australia 
KAPA SYBR FAST RT-PCR master mix BioRad, Cape Town - South Africa 
KpnI Promega  
Xhol Promega  
1kb DNA ladder Promega  
T4 ligase Bio-Labs, - New England 
T4 ligase buffer Bio-Labs, - New England 
 
 
Table 2.7: Test Kits 
KIT SUPPLIER 
Amyloid Beta Assay Kit Covance- USA 
Cholesterol Assay Kit Cayman Chemical company,  MI- USA 
LDH Cytotoxicity Assay Kit Cayman Chemical company,  MI – USA 
Micro BCA Pierce Protein Assay Kit Pierce, Rockford, IL., USA 
Light Shift Chemiluminescent EMSA Kit Pierce, Rockford, IL., USA 
7-Deaza-2’-Deoxy-Guanosine Kit Jena Bioscience, Jena - Germany 
 
 
 
 
 
 88 
 
 
Table 2.8: List of antibodies 
ANTIBODY USE DILUTIO
N 
SOURCE SUPPLIER 
Anti-EMMPRIN 
(Allain et al.) 
MAB2623 
Immunohis
tochemistry 
1:200 Mouse 
monoclonal 
Chemicon, California – 
USA 
Anti-Human βeta 
amyloid 1-40/42 
polyclonal 
antibody (AB-
5076) 
Immunohis
tochemistry 
1:200 Rabbit 
polyclonal 
Millipore, New South 
Wales – Australia 
Biotinylated Rabbit 
Anti-Mouse 
Immunohis
tochemistry 
1:200 Mouse 
monoclonal 
DAKO, Glostrup – 
Denmark 
β-Actin (AB8229) Western 
blot 
1:5000 Mouse 
monoclonal 
Abcam, Waterloo – 
Australia 
C1/1.6 Western 
blot 
1:5000 Mouse 
polyclonal 
Kindly provided by Dr 
Paul Mathews, NYU 
Donkey anti- 
Rabbit HRP 
Western 
blot 
1:10000 Donkey Amersham, 
Buckinghamshire – UK. 
Donkey anti-Goat 
(HRP) 
Western 
blot 
1:20000 Goat Santa Cruz – USA 
Donkey anti-
Mouse (HRP) 
Western 
blot 
1:5000 Mouse Chemicon – USA 
M42 – Aβ42 ELISA 1:1000 Mouse kindly provided by Pankaj 
Mehta, NY- USA 
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M40–Aβ40 ELISA 1:1000 Rat kindly provided by Pankaj 
Mehta, NY- USA 
Nicastrin Western 
blot 
1:500 Rabbit 
polyclonal 
Sigma 
Presenilin Western 
blot 
1:2000 Mouse 
monoclonal 
Kindly provided by Dr 
Paul Mathews, NYU 
PEN 2 Western 
blot 
1:2000 Rabbit 
polyclonal 
Sigma 
SC-9754 (Human) Western 
blot 
1:5000 Goat 
polyclonal 
Santa Cruz biotechnology 
Inc – USA 
SC-9757 (Rat) Western 
blot 
1:5000 Goat 
polyclonal 
Santa Cruz biotechnology 
Inc – USA 
Sheep anti- Mouse 
HRP 
Western 
blot 
1:10000 Mouse  Amersham, 
Buckinghamshire – UK. 
SCP-2 (NB100-
93459) 
Western 
blot 
1:5000 Goat 
monoclonal 
Novus Biologicals, CO - 
USA 
WO2 Western 
blot 
1:2500 Mouse 
polyclonal 
Kindly provided by Dr 
Colin Masters, University 
of Melbourne 
4G8 Rodent Aβ ELISA 1:1000 Mouse 
monoclonal 
Sigma, Sydney – 
Australia 
6E10 Human/pig 
Aβ 
ELISA 1:400 Mouse 
monoclonal 
Covance- USA 
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2.2: Methods 
2.2.1: Cell Cultures 
2.2.1.1: Culturing Primary Rat Neurons 
 
All animal experiments were approved by the University of Western Australia (UWA) 
and Edith Cowan University (ECU) Animal ethics committees. Establishment of 
cortical cultures was as previously described (Meloni et al., 2005). Briefly, cortical 
tissue from E18 to E19 Sprague-Dawley rats were dissociated in Dulbecco’s modified 
Eagle medium (DMEM; Invitrogen supplemented with 1.3mM L-cysteine, 0.9mM 
NaHCO3, 10U/ml papain (Sigma , USA) and 50U/ml DNase (Sigma) and washed in 
cold DMEM/10% horse serum. Culture plates (6-well) were coated with poly-D-Lysine 
(50μg/ml; 70-150K; Sigma) and incubated overnight at room temperature. The poly-D-
Lysine was removed and replaced with Neurobasal Media (containing 2% B27; 4% 
FCS; 1% horse serum; 62.5μM glutamate; 25μM 2-mercaptoethanol and 30μg/ml 
penicillin). Neurons were plated at a density of 3 x 106 cells per well and cultures were 
maintained in a CO2 incubator (5% CO2; 95% air balance and 98% humidity) at 37oC. 
On DIV 4 half the media was removed and replaced with fresh NB/2% B27 containing 
the mitotic inhibitor cytosine arabinofuranoside (Cara), one third of the culture media 
was removed and replaced with fresh NB2° on day in vitro (DIV) 9, and the cultures 
were maintained at 37oC in 5% CO2.  
 
2.2.2: Cell viability assessment 
 
Cell viability was assessed by measuring lactate dehydrogenase (LDH) release using the 
Cayman Chemicals test kit (Cayman Chemical Company, MI – USA) according to 
manufacturer’s instructions. Differences between groups were determined by ANOVA 
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with p < 0.05 considered statistically significant. Unless otherwise stated, all 
experiments were conducted at least three times. 
 
2.2.3: Cholesterol Treatment of Rat Primary Cortical Neuronal Cultures 
 
Rat primary cortical neuronal cultures were seeded in 6-well plates in NB2 media 
(4ml/well). Prior to treatment, 2ml media was removed and treatment prepared in the 
equal volume and added back to the respective wells. Cholesterol concentration of 0, 5, 
10, 15, 20 and 30µg/ml water soluble-cholesterol (5mg/ml stock) were used to treat the 
neurons at DIV12 and used at DIV14 and DIV14 for western blot and LDH analysis 
(see section 2.6.3., below)  
 
2.2.4: Aβ Treatment of Rat Primary Cortical Neuronal Cultures 
  
Freshly prepared Aβ42 peptide (10μM) was added to appropriate wells in neuronal 
cultures at DIV 7 for the CD147 over expression experiments. Neuronal cultures were 
treated with 0, 1, 2.5, 10 and 15 μM Aβ42 at DIV14 at 37oC for 48 hours.  
 
2.3: In vivo Experiments 
2.3.1: APPswe mice 
 
The APPswe mice were purchased from Animal Resources Centre (ARC) (WA, 
Australia). Two groups of APPswe mice were fed on normal or high fat/high cholesterol 
diet for 60 days. Animals were weighed once a week. The experiment group (18 
animals) comprising 9 males and 9 females were fed on a high fat/high cholesterol diet 
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SF08-033 (comprised of 10% fat, 0.75% cholesterol, 0.3% cholate and additional 
vitamins). The control group (18 animals, 9 males and 9 females) were maintained on 
normal chow. Animals were sacrificed at 90 days and tissue samples (liver, kidney and 
half of the brain) were collected and snap frozen in liquid nitrogen and stored at – 80oC. 
The other half of the brain was fixed in 10% formal-saline and kept at RT whereas the 
plasma was kept at -80oC until further processing.  Tissues were homogenized in PBS 
cocktail containing protease inhibitor (Roche) prior to protein determination and 
western blot analysis.  The levels of CD147, FL-APP, and APP-CTF were measured in 
all tissue homogenates whereas Aβ40/42 levels were only measured in plasma and brain 
samples. 
 
2.3.2: Human Subjects 
 
Brain samples (frozen and 10% formal-saline fixed) of AD, Lewy body disease, 
frontotempral dementia and controls were obtained from the West Australian Brain 
Bank Network (WABBN). Frozen tissues were homogenized as described in section 
3.3.3 and used for protein determination and western blot analysis. Paraffin-embedded 
tissue section (0.5μ) were prepared from fixed tissues and used for 
immunohistochemistry analysis. 
 
2.3.3: Homogenisation of Tissues 
 
Frozen human hippocampal and frontal cortex tissues and rat brain, kidney and liver 
tissue were kept on dry ice prior to being homogenized. Tissue fragments (approx. 100 
mg) were homogenised in 300µl of tissue homogenising buffer containing protease 
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inhibitor (Roche) using a hand-held Kinematica polytron homogeniser (KPH). Samples 
were aliquoted (25 µl) and stored at -80°C for further analysis. 
 
2.4: Protein Procedures 
2.4.1: Protein Extraction from Cultures 
 
Culture media was removed from 6-well plates and 150µl of RIPA lysis buffer (1M 
Tris-HCl pH7.5, 5M NaCl, 0.5M EDTA, 0.5ml of 10% SDS and 125ul Igepal) 
containing protease inhibitor (20ul of protease inhibitor in 1ml of lysis buffer) was 
added to each well and the resulting lysate transferred to a new eppindorf tube, 
vortexed, and centrifuged at 14000 rpm at 4oC for 30 minutes. The supernatant was 
collected, aliquoted and stored at -80oC until further analysis.  
 
2.4.2: SCP-2 Protein Generation 
 
SCP-2 protein was generated using KRX E.coli cell line. The cells were transformed 
with pro-SCP and SCP-x DNA (1ul) and subcultured on Kanamycin agar plates over 
night. Following the transformation of chemically competent KRX cells with expression 
vectors, colonies were inoculated into 2ml tubes containing 2x YT media; fitted with 
Eppendorf LidBac membrane filters and incubated overnight at 37°C with shaking 
(1400rpm). Two hundred millilitres of Terrific Broth (containing 50µg/ml kanamycin) 
was inoculated with 2ml of the overnight culture. The flask of KRX cells containing the 
required plasmid vector was incubated at 37°C in a conical flask (2L) with shaking 
(275rpm), until OD600 reached 0.8-1.0. The flask was transferred to room temperature 
with shaking (275rpm) until the OD600 reached approximately 1.3 (1.2 - 1.5). Protein 
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expression was induced by the addition of 1mM IPTG and 0.1% Rhamnose. The 
cultures were incubated at room temperature with shaking (275rpm) for approximately 
18 hours. 
 
Cultures were transferred to a 250ml pre-cooled centrifuge bucket and centrifuged at 
10000g for 10 minutes at 4°C. The supernatant was discarded and the pellet was stored 
at -20°C.  Pellets were re-suspended in 25ml Lysis buffer. The cell suspension was 
subjected to three passages of homogenization using a French press, followed by 
centrifugation at 10000g for 10 minutes. Inclusion bodies containing the desired protein 
were recovered from the homogenate as a pellet. The lysate was retained and further 
processed to recover recombinant proteins localized to the cytoplasm. 
 
2.4.3: Cytoplasmic Protein Purification 
 
The purification of pro-SCP and SCP-x cytoplasmic protein was achieved through 
Immobilized Metal Ion Affinity Chromatography (IMAC). The lysate was treated with 
1ml of Ni-NTA agarose beads (Qiagen) and gently mixed at 4°C for 1 hour. The 
combined solution was centrifuged at 2000g for 5 minutes, and the supernatant 
removed. Four millilitres of wash solution was then mixed with the remaining beads, 
followed by centrifugation at 2000g for 5 minutes. This step was repeated 4 times. To 
elute the protein, 1ml of elution buffer was added to the beads, centrifuged for 5 
minutes at 2000g and the supernatant collected. This step was repeated using 1ml, 
followed by 0.5ml of elution buffer. In total approximately 2.5ml of protein solution 
was collected using this method. 
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The protein solution was transferred to dialysis tubing and dialysed against three 2 litre 
volumes of dialysis buffer solution at 4°C, over a 24 hour period. The protein solution 
was then removed from the cellulose tubing, combined with glycerol (10%), filter 
sterilised (0.2µM) and stored at -80oC. 
 
2.4.4: Determination of Protein Concentration 
 
The Micro BCA Pierce protein assay kit (Pierce) was used to determine the protein 
concentration in each sample. Sample blanks (PBS), samples and standards (100µl) 
were transferred to a 96-microplate wells and 100µl of detection reagent (prepared 
according to the manufacturer’s instructions) was added and incubated at 56°C for 15 
minutes. Absorbance was measured at 595nm using a microplate reader (Bio-Rad 
Model 3550) and protein concentration (μg/ml) were extrapolated from a standard 
curve.  
 
2.5: Immunobloting 
 
Protein (25µg/ml) was separated by SDS-PAGE, transferred to nitrocellulose 
membranes and analysed by immunobloting (Peano et al., 2011). Membranes were 
incubated in blocking buffer (TBS containing skim milk 5% w/v) at RT for 1 hour then 
incubated with primary antibody in TBST (containing skim milk 0.5% w/v) (SC-9753 
and SC-9754 for mouse and human EMMPRIN respectively, C1/1.6 for FL-APP and 
CTF, NT1 for PS1, ant-PEN2, β-actin and ant-nicastrin) RT for a further 2 hours. 
Membranes were washed three times for 10 minutes in TBST and incubated with 
secondary antibodies at RT for a further one hour. Membranes were washed three times 
for 10 minutes in TBST with a final wash with TBS to remove the Tween 20. Following 
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treatment with luminal enhancer solution diluted 1:1 with stable peroxidase solution 
(Pierce, Rockford, IL., USA) at RT for 2 minutes; membranes were exposed on 
Amersham Hyperfilm-ECL film at RT for up to 10 minutes until the desired signal 
intensity was attained.  
 
Films of western immunoblots were scanned and optical density determined through the 
Bio-rad, Quantity-One software (GS-800 Calibrated Densitometer – BioRad). 
Specifically film backgrounds were subtracted from optical density of individual protein 
bands. An internal control was run on each gel for inter-gel normalisation. Levels for 
the proteins of interest were represented as a ratio of to the β-actin, to control for inter 
sample loading differences and presented in scatter plots. Western blots for all 
individual data points are presented in next to their corresponding scatter plots. 
  
2.6: Enzyme Linked Immunosorbent Assay (ELISA) 
2.6.1: Aβ1-40/1-42 ELISA 
 
Brain homogenates were prepared in Paul Mathew’s homogenisation buffer (250mM 
sucrose, 20mM Tris-HCL, 1mM EDTA, and 1mM EGTA pH 7.4). In brief 
homogenized brain tissues were centrifuged at 4oC (100,000g) for one hour and the 
supernatants were again centrifuged at 4oC (30,000g) for one hour and stored at -80oC. 
Aβ levels were measured in supernatants using ELISA method. In brief, primary 
antibody (6E10; 1:400; Covance- USA) was incubated in 96-well plate at 4°C overnight 
and washed with phosphate buffered saline with PBST. Plates were incubated in 
blocking buffer at RT for 1 hour and washed with PBST. Samples and standards 
(250µl/well in duplicates) were loaded and incubated at RT for 2 hours followed by an 
overnight incubation at 4°C. Plates were washed with 100µl/well PBST and 100µl/well 
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of detection antibody solution (containing antibody R306; 1:1000; Covance- USA) was 
added and incubated at RT for 1.5 hours and unbound detection antibody was removed 
by washing with PBST. Thereafter 100µl/well neutravidin-HRP solution (nHRP; 
1:10,000 in PBST) was added and incubated  at RT for 1 hour before washing with 
PBST followed by addition of 100µl TMB/KGP reagent to each well and incubated at 
RT in the dark for 10 – 15 minutes. The reaction was stopped by addition of 100µl stop 
solution 1M (H3PO4) to each well and the absorbance read at 450nm on a Bio-Rad 
Model 3550 Microplate reader. 
 
2.6.2: Plasma Cholesterol ELISA 
 
Total plasma cholesterol was measured using the cholesterol assay kit (Cayman 
Chemical Company, MI- USA) according to the manufacturer’s instructions. In brief, 
50ul of plasma and standards were added to appropriate wells in a 96-well plate 
followed by the addition of 50 μl assay cocktail (containing 4.745ml assay buffer, 150μl 
cholesterol detector, 50μl HRP, 50μl cholesterol oxidase and 5μl cholesterol esterase) 
incubated for 30 minutes at RT and the fluorescence measured at excitation 580nm and 
emission 595nm wavelengths using a FLUOstar Optima spectrophotometer (BMG 
Labtech). Cholesterol concentration (mM) was calculated using the formula below: 
 
  
 
 
Sample adjusted fluorescence – (y – intercept)
slope
X  sample dilution X  0.001][
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2.6.3: CytoTox 96® Non-Radioactive Cytotoxic Assay (LDH Assay) 
 
Lactate dehydrogenase (LDH) is a stable cytosolic enzyme released from dead cells 
following plasma membrane degradation. The CytoTox 96® Non-Radioactive 
Cytotoxic Assay (Promega) is a colorimetric assay which quantitatively measures LDH. 
In brief, lactate dehydrogenase released by cells is measured following the enzymatic 
LDH mediated conversion of the tetrazolium salt (INT) substrate into its red formazan 
product, which is detected spectrophotometrically at 490nm. The amount of formazan 
produced is proportional to the number of lysed cells in culture. Differences between 
groups were determined by ANOVA where p< 0.05 was considered statistically 
significant. Unless otherwise stated, all experiments were conducted at least three times. 
 
2.7: Maintenance of bacterial cells 
 
For long-term storage, both recombinant and non-recombinant bacterial cells were 
resuspended in 2xYT medium containing 15% glycerol, aliquoted out into sterile 2 ml 
cryotubes (Nunc), snap frozen in liquid nitrogen and stored at -70°C.  Cells were 
recovered from slightly thawed frozen aliquots using sterile loops or micropipette tips 
and used to inoculate agar or liquid culture media. 
 
2.8: Competent Cells 
2.8.1: Preparation of Chemically Competent KRX Cells 
 
KRX cells were thawed slowly on ice, and 5µl was inoculated into 1 ml of 2x YT 
media, and incubated on Thermo mixer Comfort (Eppendorf) incubator at 37°C for 1 
hour with shaking (300rpm). A 100µl aliquot of the broth mixture was plated onto a 
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pre-dried 2x YT agar plate, and incubated at 37°C overnight. Two colonies were 
inoculated into two 2ml tubes containing 2x YT media; fitted with Eppendorf LidBac 
membrane filters and incubated overnight at 37°C with shaking (1400rpm).  
 
Three millilitres of overnight KRX broth was inoculated into 500ml of fresh SOB 
medium, and incubated at 28°C with shaking at 225rpm. Once the OD600 of KRX 
broth reached 0.4, the culture was transferred to nice slurry for 10 minutes, and then 
centrifuged at 3,000g in a pre-cooled bucket rotor for 10 minutes. The cell pellet was 
gently resuspended in 100ml of ice cold TB, incubated on ice a further 10 minutes, and 
re-pelleted by centrifugation at 3,000g for 10 minutes. The cell pellet was gently 
resuspended in 18.6ml of TB, mixed with 1.4ml of DMSO, and incubated on ice a 
further 10 minutes. Aliquots of the cell mixture (0.6ml) were transferred to 1.5ml 
microfuge tubes, snap frozen in liquid nitrogen and stored at -80°C. 
 
2.8.2: Assessment of Chemically Competent KRX Cells 
 
Freshly prepared competent cells were assessed for their competency in the following 
manner. Two microlitres of freshly thawed competent cells were transformed with 
0.1ng of pGEM 3Z plasmid DNA. A 100µl aliquot of the transformation mix was plated 
onto agar plates (containing ampicilin; 50µg/ml) and incubated at 37°C overnight. The 
colonies were then counted and the transformation efficiency was calculated according 
to the following formulation.  
  90cfu     ×   103   =   9 × 106 colony forming units (CFUs)/µg of plasmid DNA 
 0.01ng    
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2.8.3: Transformation of Chemically Competent KRX Cells 
 
An aliquot of KRX cells was thawed on ice. Eight microlitres of DNA was added to 
1.5ml microfuge tubes containing 50µl of competent cells, gently mixed and incubated 
on ice slurry for 10-30 minutes. The transformation mix was heat shocked at 42°C for 
30-45 seconds; returned to ice for 2 minutes, and 900µl of pre-warmed 2x YT was 
added, followed by incubation at 37°C for 1 hour with gentle shaking (300rpm). 
Transformation mixes were plated on 2x YT agar plates (containing the appropriate 
antibiotic) and incubated at 37°C overnight.  
 
2.9: Preparation of Recombinant Adenovirus 
 
Recombinant RSV-Empty and RSV-CD147 viruses were prepared according to the 
method of (He et al., 1998), with some modifications. Briefly pShuttle plasmid DNA 
was linearized by Pmel digestion and introduced into E.coli strain BJ5183 carrying 
pAdeasy (Zeng et al., 2001) by electroporation (Gene Pulser II, Biorad). Recombinants 
were selected on media containing 50μg/ml kanamycin, and their plasmid DNA 
checked by PacI digestion. HEK-293 cells grown to 90% confluence in 25cm2 flasks 
were transfected with 3μg of PacI linearized recombinant plasmid DNA using 
Lipofectamine2000 (Invitrogen, USA) Viral plaques appeared within 5 – 10 days and 
viral material used to for subsequent amplification of the virus in HEK-293 before 
purification and concentration using the Adeno-X virus purification kit (BD 
Biosciences, USA). Viral titres were determined by end-point dilution assay, as 
indicated by EGFP reporter expression 
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2.10: RNA/DNA methods 
2.10.1: General handling 
 
All plastic ware, solutions and buffers used in conjunction with DNA or RNA were 
either certified free of DNases or RNases as supplied by the manufacturer or prepared 
in-house and sterilised appropriately.  In general, preparations of oligonucleotides, DNA 
and RNA were reconstituted in sterile WFI and stored at -20°C.  For analytical or 
preparative work, oligonucleotides, DNA or RNA samples were handled aseptically, 
and were thawed and maintained on ice when in use. 
2.10.2: RNA extraction 
 
Total RNA was extracted from tissue cultures or animal tissue samples using TRIZOL 
Reagent, a mono-phasic solution of phenol and isothiocyanate and used according to the 
manufacturer’s instructions.  Total RNA was resuspended in sterile water for injection 
(WFI) at 0.2 to 1.0 µg/ml and stored at -80°C 
 
2.10.3: Genomic DNA extraction 
 
Total genomic DNA was extracted from cells grown in culture using the MasterPure 
Complete DNA and RNA Purification Kit from Epicentre Technologies.  Total genomic 
DNA was resuspended in sterile WFI and stored at -20°C. 
 
2.10.4: Plasmid extractions 
 
Small-scale isolation of purified plasmid DNA from E.coli was performed with the 
Wizard Plus SV Minipreps DNA Purification System Kit (Promega).  Single colonies 
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were inoculated into 1.8 ml of 2xYT medium (containing an appropriate antibiotic) in 
microfuge tubes fitted with a PTFE membrane lid (LidBacEppendorf) and grown 16-18 
hours at 37°C with shaking at 1400 rpm.  Cells were pelleted by centrifugation and 
plasmid DNA was recovered by following the manufacturer’s instructions.  Plasmid 
DNA was eluted from the mini-column in 80-100 µl sterile WFI. 
 
2.11: Cloning of the PCR Products and Cell Transformation 
 
Cloning was performed by adding 0.5 - 4μl PCR product, 1μl salt solution, 1μl sterile 
water and 1μl TOPO vector in a final volume of 6μl. The mixture was then incubated at 
room temperature for 5 minutes and placed on ice ready for transformation. 
KRX cells were thawed on ice for 5 minutes or till completely thawed and 200μl of 
cells transferred to chilled tubes on ice. DNA (8μl) was added to the cells and incubated 
for 15 minutes. The cells were heat shocked on Thermo mixer Comfort (Eppendorf) for 
45-50 seconds at 42oC and immediately placed on ice for 2 minutes. 2YT medium 
(900μl) was added to each tube and incubated on Thermo mixer Comfort (Eppendorf) at 
37oC for 60 minutes with shaking at 225rpm. Tubes were centrifuged for 1 minute at 
14000rpm and pellet suspended in 100µl media. Cells were cultured on Kanamycin agar 
plates and incubated at 37oC overnight.  The following day colonies (one colony per 
tube) were suspended in 1.800ml 2YT medium with Kanamycin and incubated 
overnight on Thermo mixer Comfort (Eppendorf) incubator with shaking speed set at 
14000rpm. 
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2.12: Restriction enzyme digestion 
 
Restriction enzyme reactions were performed on plasmid DNA for both preparative and 
analytical purposes.  In general, restriction digests comprised DNA (0.2-3.0 µg) in 
sterile WFI and combined in a 20-80 µl reaction volume with 1x restriction enzyme 
buffer (supplied as a 10x stock by the enzyme manufacturer) and at least 4 Units of 
enzyme per µg of DNA.  Reactions were allowed to proceed for at least 2 hours at the 
temperature specified by the manufacturer.  For double or triple digests, reactions were 
either conducted separately followed by purification (as described in section 2.3.2.6) or 
simultaneously if enzyme buffer conditions were compatible.  Linearization of plasmid 
vector DNA by restriction digestion was performed for 12-18 hours using excess 
restriction enzyme.  For directional cloning into expression vectors, whereby the use of 
two different restriction enzymes was necessary, digests were always performed 
sequentially. 
 
2.13: Ligations 
 
For ligation reactions, insert DNA (100-250 ng) was combined with sterile WFI in a 
volume of 25 µl with: 1x T4 DNA ligase ligation buffer (supplied as a 10x stock by the 
enzyme manufacturer, Promega); linearised plasmid vector DNA (25-50 ng) and T4 
DNA ligase 4.5 Units.  Ligation mixtures were incubated at room temperature for 12-18 
hours and stored at -20°C.  Insert to plasmid DNA ratios were kept at a minimum of 3:1. 
 
2.14: Quantitation of DNA 
 
Where necessary, DNA and RNA samples were quantified spectrophotometrically by 
measuring absorbance at two wavelengths, 260 nm and 280 nm.  The instrument used 
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for this purpose was the NanoDrop (Analytical Technologies) and the protocols 
followed were described by the manufacturer.  The concentration and purity of nucleic 
acid in the sample is automatically calculated by the instrument, and whilst 
concentrations were dependent on the quantity of starting material, pure preparations of 
RNA and DNA routinely gave OD260/OD280 ratios of approximately 1.8. 
 
2.15: Agarose gel electrophoresis 
 
Plasmid DNA, RNA, restriction enzyme fragments and PCR products were mixed with 
DNA loading dye and electrophoresed in agarose gels (0.7-2.5% w/v) using a TAE 
buffer system.  Gels were pre-stained with ethidium bromide (0.5 µg/ml) and bands 
were visualised by UV transillumination (Foto/UV21, Fotodyne transilluminator), sized 
against DNA molecular weight markers and imaged/digitised following capture with a 
digital camera (brand, Kodak). 
 
2.16: DNA sequencing 
 
The ABI PrismBig Dye Terminator version 3.1 reaction ready fluorescent labelling 
sequencing mix, employing Ampli Taq DNA polymerase, was used to sequence 
double-stranded DNA.  Briefly, 2.0 µl of stock reaction mixture was combined with: 25 
ng of DNA oligonucleotide sequencing primer; 500-750 ng of purified double-stranded 
plasmid DNA template and made up to 10 µl with WFI.  Cycling conditions used were: 
initial denaturation at 96°C for 1 minute, followed by 25 amplification cycles (96°C for 
30 seconds, 50°C for 30 seconds and 60°C for 4 minutes) and a final 11°C hold.  To 
precipitate the resulting DNA product, samples were mixed with 20 µl of WFI, 3 µl of 
sodium acetate (pH 5.2) and 75 µl of ice-cold 100% ethanol.  The samples were held at 
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room temperature (protected from light) for 20 minutes, and centrifuged at 14000 rpm 
for 30 minutes.  The entire supernatant was carefully aspirated and discarded.  Two 
hundred and fifty microlitres of 75% ethanol were added to the tube containing the 
DNA pellet.  The tube was gently inverted several times and centrifuged at 14 000 rpm 
for 10 minutes.  The entire supernatant was carefully aspirated and the DNA pellet dried 
at 65°C for 2 minutes.  Dried samples were submitted to the Department of Clinical 
Immunology (Royal Perth Hospital) or the Australian Neuromuscular Research Institute 
(Queen Elizabeth II Medical Centre) sequencing facilities.   
  
2.17: Human CD147 promoter amplification and sequencing 
2.17.1: Slowdown PCR for amplifying GC-rich sequences 
 
Slowdown PCR was performed as described by Frey et al (Frey et al., 2008). In brief 
the reaction  contained  2μl each primer (forward 5’ CCAGAAAGGTAACCGCCAGC 
and reverse 5’ GCCATGATTCCTATTCCTCGC; Gene Works, AU), 1.6μl MgCl2, 2 μl 
DNA, 0.2 μl Taq polymerase, 4 μl 10x PCR buffer (Phusion), 1.5 μl 7-Deaza-dGTP, 2 
μl dNTPS and 9.7 μl dH2O.  The thermal cycle conditions are as follows: 
1 cycle of 95oC for 5min., setting heating ramp to 2.5oC-1 and the cooling ramp rate for 
reaching anneaniling temperature to 1.5oCs-1 
48 cycles of 95oC x 30 sec denaturation. 30secannealing with a progressively lowered 
temperature from 70-53oC at a rate of 1oC every third cycle and a primer extension of 
40 sec at 72oC. 15 cycles of 58oC, 4oC hold. The 360bp product (which covers the 
region of interest -392 to -242 nucleotides) was verified by agarose electrophoresis and 
viewed under UV on Biorad Gel doc. 
2.17.2: Amplification of the CD147 promoter 
 
Human genomic DNA samples (health controls; n=100 and AD cases, n=100) were 
sourced from the Australian Biomarker and Lifestyle (ABIL) study (Perth and 
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Melbourne – Australia). Sequencing of the CD147 promoter region was done at Applied 
Genetic Diagnostics (APG), Department of Pathology-University of Melbourne.  The 
~30-50ηg genomic DNA was amplified by PCR in a reaction containing 400nM each 
primer (forward 5’ AGGCTCTGGGAGTACAGACG and reverse 5’ 
CCGGGAGGAACCTCTAGTC), 1mM MgCl2, 200uM dNTPs, 8% DMSO and 2U of 
AmpliTaq Gold (Applied Biosystems).  The thermal cycle conditions are as follows: 
1 cycle of 94oC for 5min  
35 cycles of 94oC x 45sec, 60oC x 45sec, 72oC x 45sec 
 1 cycle of 72oC x 10min, 4oC hold. 
 
2.17.3: Sequencing of the CD147 promoter 
 
The 709bp product (which covers the region of interest -392 to -242 nucleotides) was 
verified by agarose electrophoresis before pre-sequencing cleanup using EXOSAP-IT 
(GE Healthcare) and a sequencing reaction with 5uM forward primer and Big Dye V3.1 
terminators (Applied Biosystems).  The Qiagen DyeEx kit was used to clean up the 
product before capillary electrophoresis on an ABI3130xl Genetic Analyser with POP7 
polymer. The product was amplified by PCR and sequenced by capillary electrophoresis 
on an ABI 3130xl Genetic Analyser and compared to the reference sequence 
NG_007468.1 using Mutation Surveyor Software.   Results were confirmed by repeat 
PCR and sequencing. 
Analysis and visualization of LD and haplotype maps was undertaken using the 
Haploview V4.2 software (Barrett et al., 2005). Generated data files were then analyzed 
in SPSS using student T-test and One Way Anova. 
 
 
 107 
 
2.18: Immunohistochemistry of Human Brain Tissue – Paraffin Embedded 
Sections 
 
  Frozen and formalin fixed frontal cortex and hippocampal tissues were sourced from 
the Western Australian Brain Bank Network (WABBN) in conjunction with the 
National Neural Tissue Resource Centre (NNTRC) and the Australian Brain Bank 
Network (ABBN). Paraffin sections were prepared in our laboratory. Paraffin sections 
were de-parafinized in 3 changes of xylene for 15 minutes followed by hydration in 3 
changes of alcohol and distilled water for 2 minutes then rinsed in water. Antigen 
retrieval (EDTA pH8) was achieved by boiling sections for 20 minutes. This was 
followed by peroxidise blocking (3% Hydrogen Peroxide) for 30 minutes. Non-specific 
binding was blocked by 10% normal goat serum for 10 minutes, and exposed to anti-
CD147 (Santa Cruz; 1:400) diluted in PBS for 90 minutes at room temperature. 
Preparations were washed three times in PBS prior to the addition of the secondary 
antibody and incubated for 20 minutes.  Tissues were washed three times followed by 
the addition of Streptavidin for 20 minutes at room temperature. This was followed by 
counterstaining with Haematoxylin for 5 minutes, dehydrated and cleared then mounted 
with DPX.  Slides were viewed and pictures taken using fluorescence microscopy 
(Olympus IX70) with Olympus DP70 digital camera. 
 
2.19: Statistical Methods 
2.19.1: Linkage, allelic and haplotypic analysis 
 
Linkage Dysequilibrium was estimated by D’ and r2 as implemented in Haploview V4.2 
software (Barrett et al., 2005). Allelic and haplotypic associations with clinical 
classification were undertaken using chi-squared (χ2) tests as implemented in 
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Haploview. Corrections for multiple testing were considered if mandatory, 1000 
permutations as implemented in Haploview.  Genotype associations were then analyzed 
using IBM SPSS® Statistics version 19.  Analysis of association with categorical 
variables (i.e. clinical classification) was undertaken using χ2 analysis, whilst continuous 
variables were analyzed using either the Student’s T-test or One Way ANOVA, where 
appropriate. 
 
2.19.2: Additional statistical analysis 
 
The resulting data was analysed using the statistical analysis system software ‘SPSS 
V17.0 for windows using One-Way ANOVA, Independent Sample T-test, and 
correlation analysis. The mean and standard deviation were used to report the data 
distribution and independent group ANOVA was used to compare differences among 
groups. All p-values reported are two-tailed and the significant level is 0.05. 
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CHAPTER 3 
 
Cholesterol modulates CD147 expression in vitro. 
 
 
3.1: Introduction 
 
Factors associated with an increased risk of developing Alzheimer’s disease (AD), 
which is related to toxic Aβ peptide accumulation in the brain include diet, obesity, old 
age, genetic profile (e.g. ApoE allele- isoform ε4), age-dependent reproductive hormone 
changes and head trauma (Sparks et al., 1990, Sparks, 1997).  In addition, high 
circulating plasma cholesterol levels and pre-existing cardiovascular diseases can also 
increase the risk of AD (reviewed in (Martins et al., 2006)). Furthermore, 
epidemiological findings linking diet and AD in humans are supported by animal 
dietary experiments. For example, high fat/high cholesterol diets in rabbits, cynomolgus 
monkeys and APPswe transgenic mice leads to increased Aβ brain deposition (Sparks et 
al., 1994b, Sparks et al., 2002, Wu et al., 2003, Schmechel et al., 2004). Taken together, 
these studies link high fat/high cholesterol diets with increased Aβ accumulation.  
 
Aβ peptides are generated by the sequential cleavage of amyloid precursor protein 
(APP) by the beta amyloid cleaving enzyme (BACE) followed by the γ-secretase 
enzyme (Li et al., 2000a, Naslund et al., 2000). The γ-secretase enzyme occurs in a 
complex with presinilin-1 (PS1), APH-1, presinilin-2, PEN-2 and Nicastrin. Recently, 
the CD147 receptor was found to co-fractionate with members of the γ-secretase 
complex, and proposed to modulate Aβ formation, via an as yet undescribed regulatory 
mechanism (Biswas et al., 1995, Zhou et al., 2005, 2007). However, follow-up studies 
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have  indicated that instead of regulating Aβ production, CD147 has a role in its 
degradation and clearance (Vetrivel et al., 2008b). Regardless of the mechanism, both 
studies support a role for  CD147 negatively modulating Aβ peptide levels (Zhou et al., 
2005, Vetrivel et al., 2008b), where reductions result in Aβ accumulation (Zhu et al., 
2005).   
 
The CD147 cell membrane receptor protein is a transmembrane glycoprotein belonging 
to the immunoglobulin super-family (IgSF) (Biswas and Vonderhaar, 1987, Fossum et 
al., 1991, Miyauchi et al., 1991, Kasinrerk et al., 1992, Biswas et al., 1995), which can 
induce the production of several MMPs, inducing MMP9 which is up-regulated in AD 
Brain (Kataoka et al., 1993, Biswas et al., 1995, Guo et al., 1997).  CD147 is also a 
member of the small family of related proteins that includes the teratocarcinoma antigen 
GP70 and the synaptic glycoprotein SDR1 (Fossum et al., 1991, Shirozu et al., 1996). 
Cell signalling and its ability to interact with a number of proteins, including 
cyclophilins, has suggested roles for CD147 in neuroprotection and in pathology of 
neurodegenerative diseases such as AD. (Kirk et al., 2000, Yurchenko et al., 2002, 
Wilson et al., 2005, Ko and Puglielli, 2007).  
 
The sterol carrier protein 2 (SCP-2) has a major role in cholesterol metabolism and 
trafficking (Baum et al., 1997, Zanlungo et al., 2000), where it facilitates the rapid 
translocation of lipids such as cholesterol between membranous organelles, into cells 
and tissues such as liver and blood (Baum et al., 1997, Zanlungo et al., 2000).  
Importantly, SCP 2 regulates CD147 transcription (Ko and Puglielli, 2007), suggesting 
that CD147 expression is influenced by cholesterol metabolism.  Knowing that SCP has 
a role in nearly all aspects of cholesterol metabolism and also facilitates CD147 
transcription, it is conceivable that changes in cholesterol homeostasis (i.e. under 
 111 
 
cholesterol loading) will alter levels of SCP, thereby impacting on CD147 levels. This 
chapter determines whether CD147 expression in primary rat neurons is altered under 
conditions of cholesterol loading or accumulated Aβ.  
 
3.2: Aims 
 
Specific aims: 
Determine if addition of exogenous cholesterol or Aβ alters the expression of CD147 
and full length APP protein in rat primary cortical neuronal cultures 
1) Determine if cholesterol affects the viability of rat primary cortical neurons in 
cultures. 
2) Determine if cholesterol affects CD147 levels in rat primary cortical neuronal 
cultures. 
3) Determine if Aβ treatment affects CD147 protein and FL-APP levels in rat 
primary cortical neuronal cultures. 
4) Determine if adenoviral mediated CD147 protein over expression with or 
without CyPA can protect rat primary cortical neurons and SH-SY5Y cells 
against Aβ42 mediated toxicity.  
 
3.3: Material and methods 
3.3.1: Neuronal cultures 
 
 Primary cortical rat neuronal cultures were established in 6 well plates from E18 
embryos as described in section 2.2.1.1. Neurons were plated at a density of 3 x 106 
cells per well and cultures were maintained in a CO2 incubator (5% CO2; 95% air 
balance and 98% humidity) at 37oC. On day in vitro four (DIV4) half the media was 
removed and replaced with fresh NB/2% B27 containing the mitotic inhibitor cytosine 
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arabinofuranoside (Cara), one third of the culture media was removed and replaced with 
fresh NB2° on DIV9, and the cultures were maintained at 37oC in 5% CO2.  
 
3.3.2 Cholesterol and Aβ treatment of primary cultures 
 
Cultures were treated on DIV12 with water soluble cholesterol (Sigma) for 48 hours. 
Prior to treatment, 2ml media was removed and replaced with an equal volume media 
containing cholesterol. Cholesterol concentration consisted of 0, 5, 10, 15, 20, and 
30µg/ml prepared from a stock of water soluble cholesterol (5µg/ml).  
 
Rat primary cortical neuronal cultures were exposed to increasing levels of Aβ42  for 48 
hours and/or hydrogen peroxide (H2O2) (3µM). Freshly prepared Aβ42 peptide (10μM 
oligomeric Aβ) was added to neuronal cultures at DIV 7 to determine CD147 
expression induction levels. Neuronal cultures were treated with 0, 1, 2.5, 10 and 15 μM 
Aβ42 at DIV14 at 37oC for 48 hours. CyPA protein was prepared in house. 
 
3.3.3: Preparation of pRSV-shuttle vectors encoding human CD147 
 
Total RNA was isolated from the human glioma cell line U251, reverse transcribed and 
amplified by PCR using gene specific primer pairs containing unique restriction sites 
(bold) and a Kozak sequence (underlined) as follows: - forward (Kpn1) 
5’ggtaccgccaccatggcggctgcgctgttc3’  and reverse (Xho1) 5’ctcgagtcaggaagagttcctc3’. 
 The resulting PCR products were gel purified, ligated into pGEM-Teasy (Promega, 
USA) and sequence verified. For sub cloning, the CD147 cDNA fragment was released 
by restriction enzyme digestion and ligated into the modified shuttle plasmid 
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pRSV/WPRE/CMV: EGFP (Boulos et al., 2006) to generate the pShuttle vector pRSV: 
CD147. 
 
3.3.4: Adenoviral vector construction 
 
Recombinant adenoviruses were prepared according to the method of He et al. (1998), 
with some modifications (Boulos, Meloni et al. 2006). Briefly, pShuttle plasmid DNA 
was linearized by PmeI digestion and introduced, by electroporation (Gene Pulser II, 
Biorad) into the Escherichia coli strain BJ5183 carrying pAdeasy (Zeng, Smith et al. 
2001).  Recombinants were selected on media containing 50 μg/ml kanamycin, and their 
plasmid DNA checked by PacI digestion.   HEK-293 cells grown to 90% confluence in 
25cm2 flasks were transfected with 3μg of PacI linearized recombinant plasmid DNA 
using Lipofectamine 2000 (Invitrogen, USA).  Following the appearance of viral 
plaques (5 – 10 days) culture lysates were used for viral amplification in HEK-293 cells. 
 Adenoviral particles were purified and concentrated from cell lysates using the Adeno-
X kit (BD Biosciences, USA).  Viral titers were determined by end-point dilution assay, 
as indicated by enhanced green fluorescent protein (GFP) reporter expression.  
 
3.3.5: Hydrogen peroxide treatment 
 
Neuronal cultures were exposed to 3μM H2O2 for 30 minutes, media removed and 
replaced with fresh NB2 and further maintained in CO2 incubator at 37oC for 24 hours. 
Neuronal lysates were collected after 24 hours and CD147 expression determined by 
western blot analysis. 
 
 
 114 
 
3.3.6: Western blot analysis 
 
The levels of CD147 and full length APP (FL-APP) were determined by western blot as 
described in section 2.5. The EMMPRIN SC-9757 (Santa Cruz) and C1/6.1 (kindly 
provided by Collin Masters) primary and anti-goat and anti- mouse secondary 
antibodies were used to probe for CD147 and FL-APP respectively from protein 
collected culture lysates. Following immunobloting, CD147 and FL-APP protein bands 
were quantified using the GS-800 Calibrated Densitometer (BioRad). Cell viability (in 
the presence and/or absence of CyPA, 100ηg/ml) were determined by LDH release 
assay as described in section 2.2.2. 
3.4: Results 
 
3.4.1: Cholesterol treatment increases CD147 expression in primary neuronal 
cultures in a dose dependent manner 
 
To determine if cholesterol influences CD147 expression in neurons, rat primary 
cortical neuronal cultures at DIV12 were treated with increasing doses of soluble 
cholesterol (0, 5, 10, 15, 20, 25, 30ug/ml).  At 48 hours post-cholesterol addition, cell 
homogenates were collected and subjected to Western blot analysis to determine CD147 
(Fig.3.1) and FL-APP protein levels (Fig.3.2). Cholesterol treatment increased CD147 
protein expression in a dose dependent manner from 5 μg/ml, reaching a statistically 
significant peak at 20μg/ml (p<0.001), then dropping below untreated control levels at 
30μg/ml. (Fig.3.1; n=6 independent experiments). Western blot analysis revealed a 
steady, dose dependent decline in FL-APP protein levels with increasing cholesterol, 
which dropped below untreated control levels at 25μg/ml (p< 0.005) and 30ug/ml 
(p<0.001; Fig.3.2).  
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Figure 3.1: Cholesterol increases CD147 expression in primary cortical neuronal 
cultures  
 Representative Immunoblots (run in duplicates) from rat primary cortical neuronal 
culture lysates following treatment with cholesterol for 48 hours. Membranes were 
probed with anti-CD147 and ant-β-actin antibodies (A). CD147 values were normalized 
against beta actin and calculated as a percent of the control. Densitometry and statistical 
data analysis of CD147 protein levels (B). Values are expressed as mean ±SD (from 6 
independent experiments). *p < 0.001 and *p < 0.05). Compared to controls, neuronal 
cultures treated with 20μg/ml cholesterol showed significant increase of CD147 
expression while those treated with 30μg/ml cholesterol showed significant decrease of 
CD147 expression levels. 
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Figure 3.2: Cholesterol decreases FL-APP expression in primary cortical neuronal 
cultures  
 Representative Immunoblots (duplicate samples) from rat primary cortical neuronal 
culture lysates following treatment with cholesterol for 48 hours. Membranes were 
probed with anti- anti-FL-APP and ant- β-actin antibodies (A). FL-APP values were 
normalized against beta actin and calculated as a percent of the control. Densitometry 
and statistical data analysis of FL-APP (B). Values are expressed as mean ±SD (from 6 
independent experiments). *p < 0.005 and ***p < 0.001).  
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3.4.2: Cholesterol increases LDH release in rat primary cortical neuronal cultures  
 
In the previous experiment (4.4.1) I observed a dramatic decline in both CD147 and FL-
APP, at the two highest cholesterol concentrations, 25ug/ml and 30ug/ml.  Why this 
occurred is not known but toxic Aβ peptide accumulation (Notkola et al., 1998, Refolo 
et al., 2000a, Oksman et al., 2006) and free cholesterol loading is associated with 
widespread mitochondrial dysfunction and apoptosis (Yao and Tabas, 2001, Matsuda et 
al., 2002). Furthermore, protein translation can be suppressed in cells undergoing 
environmental stress (Hara et al., 2011, Nilsson and Sunnerhagen, 2011, Koponen et al., 
2012). Thus I next investigated if cell viability was affected by cholesterol loading. In 
these experiments increased cholesterol levels appeared to induce cell stress as indicated 
by cell rounding and degeneration (data not shown).   To determine if cholesterol 
increases cellular stress, we measured lactate dehydrogenase (LDH) release in the 
supernatants from cholesterol treated cultures.  I chose LDH because it is a reliable 
marker of mitochondrial function, and hence, cellular health (Ying (Salahudeen et al., 
2001, Sawane et al., 2002, Ying and Gervay-Hague, 2005, Aras et al., 2008). I found 
that compared to untreated cells, LDH release increased in a dose dependent manner in 
response to cholesterol treatment (48 hours post addition), (p=0.001; Fig.3.3).  
 
 
 
 
 
 118 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Cholesterol treatment increases LDH release in primary 
neuronal cultures  
LDH release in rat primary cortical rat neuronal cultures exposed to cholesterol 
at DIV14 for 48 hours. The chart represents data from 6 independent 
experiments and values are expressed as mean ±SD, *** p<0.001. 
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3.4.3: Oxidative stress induces CD147 expression and affects cell viability in rat 
primary cortical neuronal cultures in a dose dependent manner  
 
Oxidative stress is an important contributing factor in a number of neurodegenerative 
disorders including AD, and strong evidence links Aβ mediated neurotoxicity and 
oxidative stress. Oxidative stress occurs when reactive oxygen species (ROS), which are 
by-products of mitochondrial phosphorylation, exceed the cells antioxidant defence 
systems (Huang et al., 1999, Zhu et al., 2002, Lustbader et al., 2004b). Reactive oxygen 
species such as H2O2 and OH- damage proteins, DNA, and cell organelles leading to 
cellular death.  
 
Thus, as oxidative stress is known to induce CD147 expression in cardiac myocytes 
(Seko et al., 2004), I wondered if Aβ treatment could similarly increase CD147 
expression in neuronal cultures. As part of this study, I first confirmed that hydrogen 
peroxide (H2O2), an oxidative stress inducer, induces CD147 protein expression 
(Fig.3.4).  Compared to control, results from these experiments have shown that 
cultures exposed to 3μM H2O2 showed increased CD147 expression and LDH release 
(Fig.3.4).   
 
Next I sought to determine if Aβ42 induces CD147 expression (Fig.3.5), I treated rat 
primary cortical neuronal cultures on DIV12 with increasing concentrations of Aβ42 
peptide (0, 1, 2.5, 5, 10 and 15µM). I first measured LDH release and as expected, 
observed a significant increase in neuronal cultures exposed to higher Aβ42 (p<0.001) 
(Fig.3.5). Finally I measured CD147 and FL-APP levels using western blot analysis of 
lysates which revealed that CD147 protein levels increased in response to Aβ in a dose 
dependent manner, reaching statistical significance at 5 - 15μM compared to controls 
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(p<0.001 respectively) (Fig 3.6). By contrast, high Aβ concentrations (≥5μM) caused 
FL-APP expression to decline (p<0.001) compared to untreated controls (Fig 3.7).  
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Figure 3.4: Hydrogen peroxide (H2O2) treatment of rat primary neuronal cultures 
increases CD147 levels and LDH release  
Representative immunoblots from rat primary cortical neuronal culture lysates 
following treatment with 3μM H2O2 for 24 hours. Membranes were probed with anti- 
anti-CD147 and ant- β-actin antibodies (A). Densitometry and statistical data analysis of 
CD147 (B). Values are expressed as mean ±SD (from 3 independent experiments) **p 
< 0.01).  
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Figure 3.5: Aβ42 treatment of rat primary neuronal cultures increases LDH 
release  
LDH release in rat primary cortical rat neuronal cultures exposed to Aβ42 at 
DIV14 for 48 hours. The chart represents data from 6 independent experiments 
and values are expressed as mean ±SD, *** p<0.001. 
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Figure 3:6: Differential CD147 expression in neuronal cultures following treatment 
with Aβ42 peptide.  
Western blot analysis of rat primary cortical neuronal culture lysates harvested 48 hours 
after Aβ42 treatment; A) representative immunoblot probed with anti-CD147 and anti-
β-actin antibodies. B) Densitometry and statistical analysis of CD147 expression. The 
chart represents data from 6 independent experiments and values are expressed as mean 
±SD, *** p<0.001. 
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Figure 3:7: Differential FL-APP expression in neuronal cultures following 
treatment with Aβ42 peptide.  
Western blot analysis of rat primary cortical neuronal culture lysates harvested 48 hours 
after Aβ42 treatment; A) representative immunoblot probed with anti-FL-APP and anti-
β-actin antibodies. B) Densitometry and statistical analysis of FL-APP expression. The 
chart represents data from 6 independent experiments and values are expressed as mean 
±SD, *** p<0.001. 
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3.4.4: Adenoviral mediated CD147 over expression does not affect cell viability in 
rat primary neuronal cultures. 
 
To determine if elevated CD147 expression can cause cell death, I transduced rat 
primary cortical neuronal cultures with a recombinant adenovirus expressing human 
CD147 (AdRSV-CD147) and control recombinant adenovirus (AdRSV-Empty) at 100 
moi. Approximately 70% of the neurons were transduced as indicated by GFP reporter 
expression GFP (Fig.3.8). CD147 levels were determined by western blot analysis using 
human EMMPRIN SC-9757 monoclonal antibody. As expected the results clearly show 
the absence of human CD147 expression in the AdRSV-Empty transduced neuronal 
cultures and expression of human CD147 protein in neuronal cultures transduced with 
AdRSV-CD147 (Fig.3.9A). Over expression of CD147 did not alter FL-APP levels 
(Fig.3.9A) or decrease cell viability as indicated by LDH release (Fig.3.9B). 
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Figure 3.8: Recombinant adenoviral transduction of neuronal cultures 
 Fluorescent microscopy of rat primary cortical neuronal cultures transduced 
with adenoviral constructs AdRSV-Empty and AdRSV-CD147 at 100 moi for 
72 hours. GFP reporter expression indicating successful adenoviral transduction 
of cortical neuronal cultures.  
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Figure 3.9: CD147, FL-APP and LDH release levels in recombinant 
adenoviral transduced neuronal cultures 
 Rat primary cortical neuronal cultures transduced with adenoviral constructs 
AdRSV-Empty and AdRSV-CD147 at 100 moi for 72 hours. Immunoblots 
probed for human CD147, FL-APP, and β-actin loading control (A) and 
corresponding LDH release in culture (B).  
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3.4.5: Adenoviral mediated CD147 expression protected rat primary cortical 
neuronal cultures against Aβ42 toxicity only in the presence of cyclophilin A 
(CypA) 
 
Studies have shown that cyclophillin A (CypA)/CD147 receptor-mediated ERK1/2 
signalling protects neurons against oxidative stress and ischemic injury (Boulos et al., 
2007). These findings prompted me to determine if increased CD147 expression, in the 
absence and/or presence of CyPA, is responsible for protecting neuronal cultures 
against Aβ42 toxicity. Rat primary cortical neuronal cultures were transduced with 
AdRSV-Empty and AdRSV-CD147 adenoviruses (Fig.3.10). Prior to Aβ42 (20μM) 
exposure, cultures were treated with recombinant CyPA (100ng/ml) or protein vehicle 
for 30 minutes. I measured LDH release in culture supernatants to determine the level of 
cell viability. Visual inspection of the cultures showed that CyPA provides protection 
against Aβ42 injury (Fig.3.10). However, analysis of LDH release in cultures 
transduced with AdRSV-CD147 and CyPA showed statistically significant protection 
against Aβ42 toxicity (p<0.05) (Fig.3.11B). However AdRSV-Empty transduced 
cultures treated with CyPA showed protection trend against Aβ42 toxicity (Fig.3.11A). 
This outcome was possibly due to low CD147 expression in AdRSV-Empty transduced 
cultures as cells exhibiting low level expression are reportedly unresponsive to CyPA 
(Trachtenberg et al., 2011). 
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Figure 3.10: Rat primary cortical neuronal cultures transduced with recombinant 
adenoviruses and exposed to Aβ42 in the presence and absence of CyPA 
Rat primary cortical neuronal cultures transduced with AdRSV-Empty (A, B and C) and 
AdRSV-CD147 (D, E and F) at a moi of 100. Cultures exposed to 20μM Aβ42 (B, C, E 
and F) without (B and E) and with (C and F) CypA (100ng/ml). Compared to untreated 
control cultures (A and D), cultures without CyPA pre-treatment (B and E) showed 
induced increased neuronal death compared to those pre-treated with CyPA (C and F). 
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Figure 3.11: Aβ42 toxicity in neuronal cultures transduced with recombinant 
adenoviruses 
LDH release in rat primary cortical neuronal cultures transduced with AdRSV-Empty 
(A) and AdRSV-CD147 (B) at moi of 100 and exposed to 20μM Aβ42 with and without 
CypA (100ng/ml) pre-treatment. Values are expressed as mean ±SE (n=3) and indicate 
that CD147 protected neuronal cultures against Aβ42 toxicity in the presence of CyPA 
(p<0.05). 
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3.4.6: Adenoviral mediated CD147 expression protected SH-SY5Y cell cultures 
against Aβ42 toxicity only in the presence of cyclophilin A (CypA) 
 
In order to consolidate the findings from rat primary cortical neuronal cultures, I 
performed additional experiments in SH -SY5Y human neuroblastoma cell line. I chose 
SH-SY5Y cells because they have low CD147 expression and are of human origin, and 
unlike mixed neuronal cultures are more of purely neuronal cell type. This eliminates 
potentially indirect effects of CyPA protection to demonstrate if CyPA acts through 
CD147 to mediate neuroprotection that has not been confirmed in neurons. SH-SY5Y 
cultures were transduced with adenoviral constructs (AdRSV-Empty and AdRSV-
CD147) at moi 40. Compared to controls (Fig.3.12 B and C) positive adenoviral 
transduction was confirmed by GFP reporter expression in AdRSV-Empty (Fig.3.12B) 
and AdRV-CD147 (Fig.3.12C) cultures.  Next cultures were exposed to Aβ42, CyPA 
and CyPA+ Aβ42 and LDH release was measured with a cell viability marker. The 
results showed that AdRSV-CD147, in the presence of CyPA, protected SH-SY5Y 
cultures against Aβ42 toxicity (p<0.001) (Fig.3.13B). These results are similar to those 
from rat primary neuronal cultures, providing further confirmation that adenoviral 
mediated CD147 protects neurons against Aβ42 induced oxidative stress in the presence 
of CyPA. Just as in the rat primary neuronal culture experiments, SH-SY5Y cultures 
transduced with AdRSV-Empty showed protection trend against Aβ42 induced toxicity 
(Fig.3.13A). 
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Figure 3.12: SH-SY5Y cultures transduced with recombinant adenoviruses  
Fluorescent microscopy images of SH-SY5Y cultures transduced with AdRSV-Empty 
and AdRSV-CD147 at moi of 40. GFP reporter expression indicating over 80% of 
neurons transduced with recombinant adenoviruses. 
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Fig. 3.13: Aβ42 Toxicity in SH-SY5Y human neuroblastoma cultures transduced 
with recombinant adenoviruses 
LDH release in SH-SY5Y human neuroblastoma cultures transduced with AdRSV-
Empty (A) and AdRSV-CD147 (B) at moi 40 and exposed to 20μM Aβ42 with and 
without CypA (100ng/ml) pre-treatment. Values are expressed as mean ±SE (n=3). 
Results indicate that CD147 protected SH-Y5Y human neuroblastoma cells against 
Aβ42 toxicity in the presence of CyPA (**p<0.001). 
 
 
 
 
**
LD
H
 R
el
ea
se
  
0 
0.1 
0.2 
0.3 
LD
H
 R
el
ea
se
  
 
0 
0.1 
0.2 
0.3 
0.4 
0.4 
0.5 
0.5 
AdRSV-EMPTY 
AdRSV-CD147 
A 
B 
AdRSV AdRSV+ CyPA AdRSV+ Aβ42 AdRSV+ CyPA+Aβ42 
 134 
 
3.5: Summary of results 
 
Overall the in vitro results presented in this chapter have demonstrated for the first time 
that cholesterol and Aβ42 can induce CD147 expression. Finally that adenoviral 
mediated CD147 expression protects neuronal cultures against Aβ42 induced oxidative 
stress only in the presence of CyPA. 
 
 
3.6: Discussion 
 
3.6.1: Cholesterol loading affects CD147 levels in vitro 
 
In the current study I demonstrated for the first time that cholesterol increases CD147 
expression dose dependently in primary neuronal cultures. The sterol carrier protein 
(SCP) which is involved in cholesterol uptake (McLean et al., 1989, Moncecchi et al., 
1996, Atshaves et al., 1999, Atshaves et al., 2009), intracellular transport (Kraemer et 
al., 1995, Ren et al., 2004), esterification (Murphy and Schroeder, 1997) and oxidation 
(Atshaves et al., 2009), reportedly affects CD147 expression by modulating 
transcription (Puglielli et al., 1995, Ko and Puglielli, 2007). This link suggests that 
cholesterol may influence SCP protein levels, thereby modulating CD147 expression. 
To investigate this relationship, I postulated that SCP protein levels change in response 
to cholesterol challenge.  However, attempts to detect SCP protein in culture lysates by 
western blot analysis were unsuccessful, despite trying 4 different commercially 
available antibodies.  Thus, I was unable to confirm or refute this hypothesis. 
 
As part of this study, I also confirmed that neuronal degeneration increased in response 
to cholesterol using LDH release as a marker of mitochondrial function and cellular 
health (Nixon, 2004, Feng et al., 2010, Metrailler-Ruchonnet et al., 2010, Zhang et al., 
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2010b). The increase in CD147 expression and LDH release suggested an association 
between CD147 regulation and the cells response to injury.  Oxidative stress is a major 
contributor to neuronal cell loss in a number of neurodegenerative disorders including 
AD, and there is strong evidence linking oxidative stress to Aβ. Oxidative stress occurs 
when reactive oxygen species (ROS), resulting from mitochondrial oxidative 
phosphorylation, exceed the cells naturally occurring antioxidant defence systems, lead 
to chemical damage of cellular structures and components. That this process occurs in 
AD is supported by the findings of Martins et al (Martins et al., 1986) who reported an 
increase in activity of enzymes from the hexose monophosphate pathways in post-
mortem brain samples compared to age-matched controls. Several reports have also 
shown extensive oxidative damage in AD, including lipid peroxidation (Sayre et al., 
1997, Kontush et al., 2001, Butterfield, 2002), oxidized proteins (Carney et al., 1994, 
Chan et al., 1999, Wang et al., 2003) nucleic acid damage  and advanced glycation end 
products (AGE) (Torreggiani et al., 2009). Oxidative damage in AD may be a direct 
result of Aβ peptide accumulation which causes neurotoxicity by producing reactive 
oxygen species (ROS) (Carney et al., 1994, Devi et al., 2006, Torreggiani et al., 2009) 
through interaction with metals, but mainly copper (Huang et al., 1999, Curtain et al., 
2001, Dong et al., 2003, Crouch et al., 2005). Specifically, the combination of Aβ and 
Cu ions generates hydrogen peroxide (H2O2) that causes damage to lipids and proteins. 
These findings clearly show that Aβ mediated generation of ROS is a potentially import 
contributor of neuronal cell death in AD.  
 
Thus, since elevated cholesterol is also associated with increased Aβ production (Refolo 
et al., 2000a, Wu et al., 2003, Fitz et al., 2010), I postulated that oxidative 
stress/reactive oxygen species (ROS) generation, induced by Aβ (Smith et al., 1998, Lin 
et al., 2001, Butterfield et al., 2002), might also account for the observed CD147 
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increase, independently of any SCP related mechanism.  Specifically, CD147 
expression has been linked to oxidative stress (Boulos et al., 2007).  As mentioned 
earlier, and in support of this idea, I noted that cultures treated with increasing 
cholesterol levels exhibited hallmarks of degeneration, indicating cellular stress. To test 
this hypothesis, I also measured Aβ levels in the supernatants of cholesterol treated 
cultures. However, despite using a highly sensitive commercial ELISA assay, I found 
that Aβ levels were undetectable.  Interestingly, Western blot analysis also revealed a 
steady, dose dependent decline in FL-APP protein levels with increasing cholesterol. 
These results are consistent with another study that previously reported a downward 
shift in FL-APP levels with increasing cholesterol levels (Galbete et al., 2000b), due 
apparently to a decrease in APP (sAPP) secretion caused by the disruption of the 
immature APP glycosylation by cholesterol. The disruption of FL-APP may account for 
the lack of detectable Aβ, as reduced FL-APP levels would have limited the amount of 
amyloid protein available for cleavage by gamma secretase and hence Aβ generation.  
 
 Cholesterol can reportedly increase oxidative stress by directly impacting on 
mitochondrial function (Homma et al., 2004, Oliveros et al., 2004, Lu et al., 2011, Mei 
et al., 2012), a process that may produce injurious levels of ROS, including hydrogen 
peroxide. In testing this possible association I exposed rat primary neuronal cultures to 
hydrogen peroxide and observed an increase in CD147 expression alongside increased 
LDH release.  Subsequently, I tested if the human Aβ42 toxic peptide species could 
similarly increase CD147 levels in neuronal cultures, given that it also induces 
H2O2/oxidative stress (Butterfield et al., 2002).  As postulated and for the first time, I 
demonstrated that, Aβ42 increases CD147 expression in a dose dependent manner, a 
potentially significant finding in AD, given that CD147 down regulation increases Aβ42 
(Zhou et al., 2005, 2006, 2007).  Furthermore and importantly, I demonstrated that 
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increased CD147 expression is not directly toxic to neurons in vitro. 
 
3.6.2: CD147 protects neuronal cultures form Aβ42 induced toxicity only in the 
presence of CYPA 
 
As part of this study I also investigated the behaviour of extracellular CYPA protein 
within the context of AD and Aβ toxicity and CD147 expression.  Recent reports 
indicate that CD147 depletion and/or knock down results in elevated Aβ peptide levels 
(Zhou et al., 2005) and that CyPA/CD147 signalling may protect neurons from 
oxidative and ischemic injury (Boulos et al., 2007). Furthermore, it is also reported that 
CD147 null mice exhibit neurological abnormalities such as spatial learning and 
memory deficits and that CD147 depletion affects embryonic development (Igakura et 
al., 1998, Muramatsu and Miyauchi, 2003, Chen et al., 2007). Taken together, these 
findings suggest that CD147 expression may protect against neuronal damage in vivo. 
The question arises, whether the biological effects attributable to CYPA would occur in 
vivo and additionally, if CYPA protein occurs within the extracellular compartment. 
Importantly, strong evidence indicates that CYPA secretion occurs in response to 
oxidative stress, which as alluded to earlier is a feature of the AD brain.  Indeed, 
endothelial cells and even neurons are known to secret CYPA at least in vitro.  
 
Whilst exogenous addition of recombinant CyPA protein reportedly protects neurons 
against oxidative and ischemic injury (Boulos et al., 2007), no studies have conclusively 
determined that protection against Aβ is mediated via the CD147 receptor.  In the 
current study, I showed for the first time that recombinant CYPA protein protects 
primary cortical neurons and human SH-SY5Y neuroblastoma cultures against Aβ42, 
via a CD147 dependent mechanism.  Importantly, although recombinant CYPA protein 
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appeared to increase the viability of cultures with basal CD147 expression, the level of 
protection only reached significance when CD147 was over expressed. These findings 
may be explained by a recent study, demonstrating that CYPA mediated biological 
effects require a threshold level of CD147 expression (Yang et al., 2008, Trachtenberg 
et al., 2011) cultures.  Nevertheless, these results support the notion that CYPA 
mediates its neuroprotective effects through the CD147 receptor, which is presumably 
imparted by increasing pro-survival signalling such as ERK1/2 activation (Boulos et al., 
2007), Bcl-2 up regulation (Biswas and Greene, 2002, Perkins et al., 2003, Metrailler-
Ruchonnet et al., 2010) and through Bax and caspase3 inhibition (Abdi et al., 2011).  
 
The impact of extracellular CYPA protein and CD147 signalling on AD may not just be 
limited to neuroprotective. CYPA/CD147 receptor signalling can also induce the 
production of matrix metalloproteinases (MMPs), including MMP9, which interestingly 
is known to be up regulated in AD brain (Backstrom et al., 1996, Lorenzl et al., 2003, 
Bruno et al., 2009, Romi et al., 2012).  Of particular significance, Vetrivel et al, (2008) 
postulated that CD147 may aid Aβ clearance, by somehow promoting its degradation.  
My findings linking Aβ, CD147 expression and extracellular CYPA may provide a 
potential mechanism by which this could occur.  
 
3.7: Conclusion 
 
Taken together, the findings of the present chapter identify potentially important 
relationships between cholesterol loading, CD147 expression, Aβ toxicity and the 
putative involvement of CYPA protein in neuroprotection, and possibly in Aβ clearance 
in AD.  
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CHAPTER 4 
 
A high fat/ high cholesterol diet does not affect CD147 levels in APPswe 
transgenic mice  
4.1: Introduction 
 
The previous chapter provided evidence that cholesterol levels can modulate CD147 
expression in culture as evidenced by elevated cellular CD147 levels under conditions 
of high cholesterol in the medium. The aims of the studies of this chapter involve 
extending these findings, in particular, determining the effect of increased cholesterol 
on CD147 levels in vivo.  
 
Cholesterol, a component of cell and organelle membranes, is essential for normal brain 
function. The brain contains the largest single pool of cholesterol that account for 25% 
of total body cholesterol and its derivatives (Dietschy and Turley, 2004, Vaya and 
Schipper, 2007). Cholesterol levels in the brain are maintained mostly by recycling 
brain cholesterol, however some transfer of cholesterol from the brain to the periphery 
does occur across the BBB, most likely following conversion to 24-OH cholesterol. 
Transfer from the blood to the brain can also occur. Excessive dietary cholesterol may 
upset this balance in many ways, both directly and indirectly via effects on general lipid 
metabolism, inducing insulin resistance and cardiovascular problems. Defects in 
cholesterol metabolism can induce neurological dysfunctions (Tint et al., 1994, Feng et 
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al., 2003).  Cholesterol accumulation has been shown to be toxic (Li et al., 2011) and 
can contribute to the development of age-related diseases (reviewed in Liu et al., 2010). 
 
A number of studies have assessed the impact of high fat/ high cholesterol diets on AD 
pathology in transgenic and non-transgenic animal models. Animals fed high 
cholesterol diets often suffer from increased Aβ deposition (Sparks et al., 1994b, Refolo 
et al., 2000b, Shie et al., 2002). For example,  hypercholesterolemic mice (Refolo et al., 
2000b)  demonstrate an increase in deposit sizes of Aβ (Refolo et al., 2000b), and in 
rabbits, a comparatively longer duration on a high cholesterol diet results in a more 
severe accumulation of brain Aβ (Sparks et al., 1994a). In another study, higher levels 
of Aβ deposition were observed in 12 month old TgAPPswe mice which had been fed a 
high fat/high cholesterol diet (HFHC) for 10 months (Shie et al., 2002), compared to 
TgAPPswe mice fed standard rodent chow.  
 
As APP itself and the enzymes involved in its cleavage are associated with membranes, 
particularly the trans-membrane γ-secretase enzyme, it is not surprising that much 
research has centred around membrane cholesterol levels and their effect on Aβ 
production. Cholesterol and sphingolipid-rich membranes microdomains (so called lipid 
rafts; (Lee et al., 1998, Wahrle et al., 2002) have been found to contain BACE1 and the 
γ-secretase complex, promoting Aβ production at these sites (reviewed in Cheng et al., 
2007).  Aβ40 and Aβ42 have been found to accumulate in the lipid rafts of aging 
Tg2576 mice (Kawarabayashi et al., 2004), and interestingly, there appears to be a 
sequence in the appearance of APOE and phosphorylated tau with the former increasing 
progressively from 12 months and the latter from 18 months of age in Tg2576 mice 
(Kawarabayashi et al., 2004).   
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Membrane cholesterol content can switch APP processing from the amyloidogenic 
pathway to the non-amyloidogenic pathway or vice versa. Although the mechanisms 
remain unclear, alterations in membrane cholesterol levels may modulate lipid fluidity. 
Depletion of membrane cholesterol has been shown to lead to a reduction in Aβ 
production, which is restored when cholesterol is replenished (Simons et al., 1998b, 
Wahrle et al., 2002). There is some controversy concerning these results however, as 
some researchers claim that the depletion of membrane cholesterol in many experiments 
is too severe for the effects to be physiologically relevant. It is thought that 
disorganization in the structure of the lipid bilayer could alter the α-secretase processing 
of APP by shifting the proximity of the secretase cleavage sites to the intramembrane 
domain of APP, and in vitro studies have demonstrated that high levels of cholesterol 
affect α-secretase and BACE activity and result in a decrease in soluble APP levels and 
an increase in Aβ production. However, it is still unclear how membrane cholesterol 
influences γ-secretase activity, thought to be concentrated to lipid rafts (Dickstein et al., 
2010). Some studies have shown that γ-secretase is dependent on lipid rafts but is not 
cholesterol-dependent, whereas others have shown that cholesterol can indeed modulate 
enzyme activity. Evidence has also been provided proposing that cholesterol plays a 
role in the conversion of soluble monomeric Aβ into insoluble aggregates (Schneider et 
al., 2006).  
 
Another mechanism that is explored in this chapter involves the regulation of some of 
the components of cholesterol metabolism. Many proteins have been linked to both 
cholesterol metabolism and AD, and one protein that is involved in both cholesterol 
metabolism and in CD147 function is the sterol carrier protein SCP-2. This protein 
plays a key role in cholesterol metabolism as it functions in cholesterol uptake (Hirai et 
al., 1994, Colles et al., 1995, Lipka et al., 1995, Moncecchi et al., 1996, Schroeder et al., 
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1998, Atshaves et al., 1999), intracellular transport (Puglielli et al., 1995), esterification 
(Murphy and Schroeder, 1997) and oxidation (Chanderbhan et al., 1986, Yamamoto et 
al., 1991).  In addition it has been shown to remodel lipid composition, structure and 
function of lipid rafts (Schroeder et al., 2007).  As described in chapter 1 (section 1.7.6) 
SCP facilitates CD147 transcription; it is therefore conceivable that changes in 
cholesterol homeostasis (i.e. under cholesterol loading) will alter levels of SCP, thereby 
impacting on CD147 levels and Aβ metabolism. Indeed cholesterol enrichment in rat 
aortic smooth muscle cells has been shown to result in an increase in SCP mRNA 
(Kraemer et al., 1995), providing evidence that cholesterol and its derivatives can 
regulate SCP expression. Whether this results in changes in CD147 levels, remains to be 
determined. 
 
4.2: Aims 
 
The overall aim of the current study was to determine if dietary cholesterol loading 
impacts on cerebral CD147 levels in vivo. To assess this, AD model transgenic mice 
(APPswe) were fed a normal chow diet or a high fat/high cholesterol diet and the 
following were determined.  
 
1)  The impact of a high fat/high cholesterol diet on body weight and plasma 
cholesterol levels. 
2)  The impact of a high fat/high cholesterol diet on CD147 levels in the brain and 
peripheral organs.  Any potential correlations between extent of changes and 
circulating cholesterol levels were also assessed. 
3) The impact of a high fat/high cholesterol diet on SCP mRNA levels in the brain. 
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4) The impact of a high fat/high cholesterol diet on cerebral levels of APP and its 
metabolites.   
 
4.3: Materials and methods 
4.3.1: Experimental animals and diets 
 
The APPswe mice were divided into 4 different groups, and fed for 10 weeks on either 
standard mouse chow (control) or a high fat/high cholesterol diet containing 10% fat, 
0.75% cholesterol, 0.3% cholate and additional vitamins (Fig.4.1). Baseline body 
weights were recorded, then mice were weighed once a fortnight. The average weight 
gain for each animal was calculated at the end of the study to determine the weight gain 
over the course of administering the diet. Following 10 weeks, mice were sacrificed and 
plasma, liver, brain and kidney tissues were collected; snap frozen and stored at – 80oC. 
The brains were divided into right (which were instantly snap frozen) and left (stored in 
RNA Later) hemispheres. 
 
4.3.2: Western blot and ELISA analyses 
 
Brain tissue homogenates underwent Western immunoblotting for CD147, FL-APP and 
the APP C-terminal fragments C-99 and C-83, whereas liver and kidney homogenates 
were immunobloted for CD147 only, as described in section 2.5.   Films of western 
immunoblots were scanned and optical density determined through the Bio-rad, 
Quantity One Software. Specifically film backgrounds were subtracted from optical 
density of individual protein bands. An internal control was run on each gel for inter-gel 
normalisation. Levels for the proteins of interest were represented as a ratio of the β-
actin, to control for inter sample loading differences and presented in scatter plots. 
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Western blots for all individual data points are presented in next to their corresponding 
scatter plots.  
ELISA was used for analysis of brain and plasma Aβ40 and Aβ42 levels as described in 
section 2.6.1. Total cholesterol levels were measured in plasma as described in section 
2.6.2. 
 
4.3.3: SCP-2 analysis 
 
To assess whether the high fat/high cholesterol diet led to changes in SCP-2 transcript 
levels, SCP-2 mRNA was extracted from 100mg of APPswe mice brains fed on a 
normal chow or a  high fat/high cholesterol diet using RNeasy Lipid Tissue Mini Kit 
(50) (Qiagen) according to the manufacturer’s instructions. SCP-2 forward 
(TGCGTTGGCTATGTGTATGG) and reverse (TGCCAGTCAGTCCCAAACTA) primers were designed 
using the Net Primer program and manufactured by Gene Works (Australia). Successful 
generation of the SCP-2 cDNA PCR product was confirmed by acrylamide gel 
electrophoresis. The cDNA amplification was performed using a 2-step cycling protocol 
(10 min at 95oC activation, 40 cycle of 15 sec at 95oC and 60 sec at 60oC, 60oC-95oC 
melt). The qRT-PCR reactions were performed using KAPA SYBR® FAST qPCR Kit 
Master Mix (South Africa) using the same primers on the Bio-Rad iCycler RT-PCR 
System using a total reaction volume of 20 µl. The optical densities were normalized 
against mTB House Keeping Gene. SCP-2 expression was determined by comparing 
relative ratio values of mice fed on a normal chow diet against those fed on a high 
fat/high cholesterol diet.  
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Figure.4.1: Experimental groups  
APPswe mice (n=36; 17 males, 19 females) were divided into two major groups. The 
first group (n=17; 7 males, 10 females) were fed a normal chow diet and the other 
(n=19; 10 males, 9 females) a high fat high cholesterol diet. 
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4.4: Results 
4.4.1: Impact of a high fat/high cholesterol diet on body weight and plasma 
cholesterol levels.  
 
Experimental mice were fed either a normal chow control or a high fat/high cholesterol 
diet for 10 weeks and weighed every fortnight. The body weight gain over the 10 week 
period is shown in Figure 4.2. As expected, all mice (either on the normal chow or high 
fat/ high cholesterol diet) gained weight over the treatment period, indicating that they 
were eating the diets provided.   
 
Following 10 weeks of administering the diets, mice were sacrificed and tissues and 
plasma collected. Total plasma cholesterol was measured in all mice and levels are 
shown in Fig. 4.3 Compared to mice fed on the normal chow control diet, those fed a 
high fat, high cholesterol diet had significantly higher plasma cholesterol levels. Female 
mice on the high fat/high cholesterol diet exhibited a greater (2 fold) increase in 
cholesterol level, than males (compare Fig. 4.3C with Fig.4.3B). Overall, the results 
indicate that the high fat, high cholesterol diet consumed by the mice significantly 
increased plasma cholesterol levels.  
 
To address the hypothesis that CD147 is altered in the presence of cholesterol in vivo, I 
then measured levels of this protein in the brain and peripheral organs of mice fed the 
different diets. 
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Figure 4.2: Body weights of APPswe mice fed on a normal chow and high fat/high 
cholesterol diets. 
Graphs represent body weight gain in (A) all mice, n=36, (B) males, n=17 and (C) 
females, n=19 during the course of study.  Mice were weighed at baseline (0) and every 
fortnight for 10 weeks after administering the diet. Data represents average body weight 
of mice at each of the measurement stages ± SD. ***, p<0.001, values significantly 
increased over baseline weights.   
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Figure 4.3: Total plasma cholesterol levels in APPswe mice following 10 weeks 
feeding with experimental diets. 
Plasma cholesterol levels in (A) all experimental mice on a normal chow (n=17) or a 
high fat/high cholesterol diet (n=19), (B) males on a normal chow diet (n=7) or a high 
fat/high cholesterol diet (n=10) and (C) females on a normal chow (n=10) or a high 
fat/high cholesterol diet (n=9). The data represents mean ± SE.  *p<0.05, **p<0.01; 
values significantly increased over those obtained from mice fed normal chow diet. 
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4.4.2: Cerebral CD147 protein levels are not significantly altered in APPswe mice 
fed a high fat/high cholesterol diet 
 
The CD147 protein levels of tissue homogenates were measured by Western 
immunoblot analysis using the rodent specific antibody EMMPRINE SC-9753 as 
described above. Although expression of CD147 in rodent brain tissue has been widely 
reported (Nahalkova et al., 2010, Xie et al., 2010, Agrawal and Yong, 2011), detection 
of this protein in the kidneys and liver has yet to be documented. Thus preliminary 
analysis was performed where expression in the peripheral organs was compared to that 
observed in homogenates of primary rat neuronal lysate, human brain and mouse brain 
(Fig 4.4). A protein band similar to that detected in rat primary neuronal lysate, was 
also detected at ~58 kDa in mouse brain, liver and kidney homogenates. However this 
protein band was absent from the human brain homogenates, indicating EMMPRINE 
SC-9753 antibody specificity for rodent CD147.   
 
Having established that CD147 can be detected in mouse brain, liver and kidneys, 
immunoblotting with this antibody was then performed on homogenates from all the 
experimental mice (Fig.4.5). Semi-quantitative analysis revealed no significant changes 
in CD147 level in either the males or the females. However, compared to mice fed on a 
normal chow diet, the data indicate an increasing trend in males (p=0.096) and a 
decreasing trend in females (p=0.201) fed on the high fat/high cholesterol diet 
(Fig.4.5C and D, respectively).  Analysis of CD147 protein levels in the peripheral 
organs (kidney and liver) revealed a significant reduction in the kidney tissue levels of 
CD147 in the males only (p=0.03) (Fig. 4.6).  No significant differences in CD147 
levels were observed in the liver samples (Fig.4.7) from either the male or the female 
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mice on the different diets. However, compared to mice fed the normal chow diet, a 
trend towards lower CD147 levels was observed in liver tissues from the male mice fed 
on the high fat/high cholesterol diet.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 151 
 
 
 
Figure 4.4: Immunodetection of CD147 using rodent EMMPRINE SC-9753 
antibody. 
Immunoblot of rat neuronal lysate (lane 1), human and mouse brain tissues (lanes 2-4) 
and mouse peripheral tissues (lanes 5-6). CD147 was detected in rat (lanes 1 and 3) and 
mouse (lanes 4-6) but not human (lane 2) tissue samples indicating the EMMPRINE 
SC-9753 antibody used is specific for rodent CD147.  
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Fig.4.5: Brain CD147 levels in brain tissue from APPswe mice following 10 weeks feeding with experimental diets. 
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Figure 4.5: Brain CD147 levels in brain tissue from APPswe mice following 10 weeks feeding with experimental diets. 
Western blot analysis of brain tissue from APPswe mice fed the normal chow diet or the high fat/high cholesterol diet for 10 weeks, males (A, C) and 
females (B, D). Western blots of brain homogenates run in duplicate show the 58 kDa CD147 protein levels and corresponding β-actin levels as a 
loading control in males (A) and females (B). Scatter plots of quantitated CD147 levels in males (C) and females (D) on the different diets. Individual 
points represent a specific mouse sample value (average of duplicate samples in adjacent lanes) with the group mean represented by a horizontal line. 
Compared to those fed on a normal chow diet,  data indicate a trend towards higher CD147 levels in males and a trend towards lower levels in females 
fed the high fat/high cholesterol diets respectively.  
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 Figure 4.6: CD147 levels in kidney tissue from APPswe mice following 10 weeks feeding with the experimental diets. 
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Figure 4.6: CD147 levels in kidney tissue from APPswe mice following 10 weeks feeding with the experimental diets. 
Western blot analysis of kidney tissue from APPswe mice fed the normal chow diet or the high fat/high cholesterol diet for 10 weeks, males (A, C) and 
females (B, D).  Western blots of kidney homogenates show the ~58 kDa CD147 and corresponding β-actin levels as a loading control in males (A) 
and females (B).  Scatter plots of quantitated CD147 levels from in males (C) and females (D) on the different diets. Individual points represent a 
specific mouse value with the group mean represented by horizontal line. Compared to mice fed the normal chow diet, data indicate a significant 
reduction in CD147 levels (*p<0.05) in the male mice fed the high fat/high cholesterol diet, with a trend towards lower levels in the female mice fed 
the high fat/high cholesterol diet.  
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  Figure 4.7: CD147 levels in liver tissue from APPswe mice following 10 weeks feeding with the experimental diets. 
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Figure 4.7: CD147 levels in liver tissue from APPswe mice following 10 weeks feeding with the experimental diets. 
Western blot analysis of liver tissue from APPswe mice fed the normal chow diet or the high fat/high cholesterol diet for 10 weeks, males (A, C) and 
females (B, D).  Western blots of liver homogenates run as single samples show the ~58 kDa CD147 levels and corresponding β-actin levels as a 
loading control in males (A) and females (B). Scatter plots of quantitated CD147 levels from males (C) and females (D) on the different diets. 
Individual points represent a specific mouse value (as quantitated from adjacent samples) with the group mean represented by a horizontal line. 
Compared to mice fed the normal chow diet, data indicate no significant change in CD147 levels. However there is a trend towards lower CD147 
levels in the males fed the high fat/high cholesterol diet. 
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4.4.3: Transcription of SCP-2 is not altered by a high fat/high cholesterol diet.  
 
The sterol carrier protein (SCP-2) plays a key role in a number of aspects of cholesterol 
metabolism (Hirai et al., 1994, Colles et al., 1995, Lipka et al., 1995, Moncecchi et al., 
1996, Schroeder et al., 1998, Atshaves et al., 1999) and is a key regulator of CD147 
expression (Ko and Puglielli, 2007).  Evidence exists that cholesterol can regulate SCP 
mRNA in rat aortic smooth muscle cells (Kraemer et al., 1995).  In the section above I 
have shown that the CD147 protein levels in the brain are not altered but increasing 
trend in males and decreasing trend in females were observed in mice fed on a high fat 
high cholesterol diet. To determine if this is associated with changes in SCP 
transcription, the brain tissue underwent quantitative RT-PCR analysis as described in 
section 4.3.  The mRNA was extracted from brain tissue stored in RNA later. Forward 
and reverse primers were designed against SCP as well as a housekeeping gene mTB 
(see section 4.3) and used to amplify the transcripts for quantitative RT-PCR. PCR 
analysis of cDNA using the primers (Fig. 4.8A) shows the presence of a ~173 bp 
transcript representing SCP-2 (lanes 3-6, blue arrow) and a ~175 bp transcript 
representing mTB (lanes 8-11, red arrow). These bands were absent in the control (lanes 
2 and 7), which consisted of master mix without cDNA template and indicates the 
absence of contaminating DNA. These results validated the use of the primers for 
quantitative RT-PCR analysis for amplification of the mRNA.  
 
Amplification curves show that SCP-2 was successfully amplified starting from cycle 
25 peaking at cycle 35 (Fig. 4.8B) with the amplification peak temperature of 80oC 
(Fig. 4.8 C and D).  The relative amounts of generated SCP-2 transcript, represented as 
a ratio of the MTB housekeeping gene is shown in Figure 5.9.  The results show that 
compared to mice fed normal chow control diet, SCP-2 transcript levels were not altered 
in brain tissue from mice fed a high fat/ high cholesterol diet (Fig.4.9).  
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Figure 4.8: Amplification of SCP-2 mRNA by RT-PCR in brain tissue from APPswe mice fed the experimental diets  
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Figure 4.8: Amplification of SCP-2 mRNA by RT-PCR in brain tissue from APPswe mice fed the experimental diets  
Agarose gel of PCR products of cDNA extracted from 4 samples of 100 mg brain tissue (2 from mice fed the normal chow diet and 2 from mice fed 
high fat/high cholesterol diet) (A).  The 100 bp DNA ladder is shown in lane 1, and the master mix without cDNA (negative control) is shown in lanes 
2 and 7.  SCP was successfully amplified and detected as a ~173 bp band (lanes 3-6, blue arrow). The mTB housekeeping gene was also successfully 
amplified and can be seen as a ~175bp band (lanes 8-11, red arrow). Representative charts of (B) amplification (C), melting curve and (D) melting 
peak of amplified SCP-2.   
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Figure 4.9: SCP-2 mRNA levels in brain tissue from APPswe mice fed the normal 
chow diet or the high fat/high cholesterol diet. 
Levels of SCP-2 mRNA were measured in brain tissue from (A) Male and (B) Female 
mice fed a normal chow diet or high fat/high cholesterol diets. Data was normalised  
against the housekeeping gene  mTB and levels are represented as a ratio of  that 
observed in brain tissue from mice fed the normal chow diet (indicated as a “relative 
ratio”).  Data are represented as mean  ±SD and show no difference in SCP-2 mRNA 
levels between mice fed on normal chow and high fat/high cholesterol diets. 
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4.4.4: Effects of the high fat/high cholesterol diet on APP and some of its 
metabolites.  
 
Studies investigating APP metabolism in transgenic mice fed high fat and/or high 
cholesterol diets have shown various effects on Aβ metabolism. Refolo et al. reported 
increases (Refolo et al., 2000a), Howland et al. reported a decrease (Howland et al., 
1998) and George et al. reported no change  in Aβ levels (George et al., 2004).  To 
determine if the diet used in this study impacted on levels of APP and its metabolites in 
mouse brain tissue, brain homogenate levels of full length APP and its C-terminal 
fragments (C83 and C99) were assessed by Western immunoblotting (as described in 
section 2.5). The C83 fragment is the C-terminal fragment of APP left in the membrane 
after α-secretase cleavage, whereas the C99 fragment is the membrane fragment of APP 
that is left after β-secretase cleavage. The results show a significant increase in FL-APP 
levels in brain tissue from both the male (p=0.026) and female (p=0.004) mice fed the 
high fat high cholesterol diet (Fig. 4.10).  Furthermore, the male mice fed the high 
fat/high cholesterol diet demonstrated significantly lower levels of the APP C83 
fragment (p=0.003) compared to those fed a normal chow diet (Fig. 4.12A and C). A 
trend towards lower levels of the APP C99 fragment was also observed in the brain 
tissue of male mice that had been fed the high fat/high cholesterol diet (Fig.4.11A and 
C), compared to those on the normal chow diet.  
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Figure 4.10: FL-APP levels in brain tissue homogenate from APPswe mice fed the normal chow diet or the high fat high cholesterol diet.  
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Figure 4.10: FL-APP levels in brain tissue homogenate from APPswe mice fed the normal chow diet or the high fat high cholesterol diet.  
Western blot analysis of brain tissue from APPswe mice fed the normal chow diet or the high fat/high cholesterol diet for 10 weeks, males (A, C) and 
females (B, D).  Western blots of brain homogenates run in duplicate showing the ~95-105 kDa FL-APP protein levels and corresponding β-actin 
levels as a loading control in males (A) and females (B). Scatter plots of quantitated FL-APP levels from males (C) and females (D) on the different 
diets. Individual points represent a specific mouse sample value (average of duplicates in adjacent lanes) with the group mean represented by a 
horizontal line. Compared to those fed the normal chow diet, data indicates significantly higher FL-APP levels (*p<0.05 respectively) in both males 
and females fed the high fat/high cholesterol diet.  
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Figure 4.11 Brain APP-C99 levels in APPswe mice after 10 weeks on the different diets 
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Figure 4.11 Brain APP-C99 levels in APPswe mice after 10 weeks on the different diets 
Western blot analysis of brain tissue from APPswe mice fed the normal chow diet or the high fat/high cholesterol diets for 10 weeks, males (A, C) and 
females (B, D).  Western blots of brain homogenates showing the ~10 kDa APP-C99 protein levels and the corresponding β-actin levels as a loading 
control in males (A) and females (B). Scatter plots of quantitated APP-C99 levels from males (C) and females (D) on the different diets. Individual 
points represent a specific mouse sample value (as quantitated from adjacent lanes) with the group mean represented by a horizontal line. Compared to 
those fed the normal chow diet, the data indicate no change in APP-C99 levels in either the male or female mice fed the high fat high cholesterol diet. 
However a trend towards lower levels of C99 fragments can be seen in the male mice fed the high fat/high cholesterol diet.  
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Figure 4.12 Brain APP-C83 levels in APPswe mice after 10 weeks on either the normal chow diet or the high fat/high cholesterol diet. 
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Figure 4.12 Brain APP-C83 levels in APPswe mice after 10 weeks on either the normal chow diet or the high fat/high cholesterol diet. 
Western blot analysis of brain tissue from APPswe mice fed the normal chow diet or the high fat/high cholesterol diets for 10 weeks, males (A, C) and 
females (B, D).  Western blots of brain homogenates showing the ~10 kDa APP-C83 protein levels and corresponding β-actin levels as a loading 
control in males (A) and females (B). Scatter plots of quantitated APP-C83 levels from males (C) and females (D) fed the different diets. Individual 
points represent a specific mouse sample value (as quantitated from adjacent lanes) with the group mean represented by a horizontal line. Compared to 
those fed the normal chow diet, data indicates a significantly lower levels of APP-C83 fragments (*p<0.01) in the males after being fed the high 
fat/high cholesterol diet.  
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4.4.5: Ratio of Aβ42/Aβ40 peptides in the brain and periphery of APPswe mice 
after 10 weeks on a high fat/high cholesterol diet or normal chow diet. 
 
To determine whether the high fat high cholesterol diet impacted on brain Aβ 
accumulation, brain levels of Aβ40 and Aβ42 peptides were measured by ELISA as 
described in section 2.6.1. As an increase in Aβ42 is indicative of greater pathology, the 
data is represented as a ratio of Aβ42/Aβ40 (Fig. 4.13).  Although not significant, a 
trend towards an increase in brain Aβ42/Aβ40 ratio is observed in mice fed high 
cholesterol/ high fat diet (Fig. 4.13 A-C), indicating a shift in Aβ production towards 
the longer more amyloidogenic form of Aβ (Aβ42), or perhaps indicating that less Aβ42 
was being cleared. It is noted however, that there is a large variation amongst those 
mice fed the high fat/high cholesterol diet. In particular a few mice (2 females and 3 
males) had ratios of much greater than 2, indicating more than 2-fold greater levels of 
Aβ42 compared to Aβ40 levels. Interestingly it should be noted that 3 of these mice had 
the highest levels of plasma cholesterol (>200nMol), suggesting plasma cholesterol 
levels can influence APP metabolism and/or Aβ42 production.  
 
Peripheral Aβ levels have been evaluated as a potential AD biomarker and have been 
used to assess a number of therapeutic agents including γ-secretase inhibitors or agents 
to promote amyloid clearance in preclinical studies using transgenic mice models 
(Kounnas et al., 2010, Wang et al., 2011, Winkler et al., 2010, Martone et al., 2009). 
Clinical studies have shown positive correlations between hypercholesterolaemia or 
body fat and peripheral Aβ levels (Balakrishnan et al., 2005, Hoglund et al., 2004, 
Smith et al., 2001). To determine if a high fat/ high cholesterol diet can induce changes 
in peripheral Aβ levels, plasma Aβ40 and Aβ42 levels were measured. The results are 
again shown as a ratio (Fig 4.14), and no overall significant change in plasma Aβ42/40 
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ratio was observed in the periphery of mice fed the high fat/ high cholesterol diet, 
compared to those fed the normal chow diet. 
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Figure 4.13: Brain Aβ42/40 ratios in APPswe mice fed on a high fat/high 
cholesterol diet compared to controls after 10 weeks. Representative scatter plots 
showing brain Aβ42/40 ratios:  (A) all mice, (B) males and (C) females. Individual 
points represent a specific sample value with the sample mean represented by horizontal 
line. There were no significant differences however results show that there is a trend 
towards an increase in the mice brain Aβ42/40 ratios, after being fed the high fat/high 
cholesterol diet for 10 weeks. 
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Figure 4.14: Plasma Aβ42/40 ratios in APPswe mice fed either a high fat/high 
cholesterol diet or a normal chow diet for 10 weeks.  
Representative scatter plots showing plasma Aβ42/40 ratios: (A) all mice, (B) males and 
(C) females. Individual points represent a specific sample value with the group mean 
represented by a horizontal line. Results indicate that plasma Aβ42/40 ratios were not 
altered. 
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4.5: Summary of results 
 
Overall the results presented in this chapter show associations between increases in 
plasma cholesterol with increases in brain FL-APP, and a trend towards a higher 
proportion of brain Aβ being the more amyloidogenic Aβ42 peptide. No changes in 
cerebral CD147 levels were detected as a result of high fat/high cholesterol diet, though 
significantly lower levels were detected in the male mouse kidney samples, and a trend 
towards lower CD147 levels was detected in the female mouse kidney samples. 
Observed changes do not appear to be mediated by changes in SCP-2 gene expression, 
as the high fat/ high cholesterol diet did not alter SCP-2 transcript levels. Although not 
significant, a trend towards increases in cerebral Aβ42 levels was observed in those 
mice fed the high fat/ high cholesterol diet, and there was also a trend towards lower 
levels of C-terminal fragments of APP, though only in male mice.  
 
4.6: Discussion 
 
The expression of CD147 is known to play an important role in a number of 
pathological diseases/disorders. Examples include facilitating metastasis of many 
cancers (lung, cervical and prostate cancers) through MMP induction (Zeng et al., 2011, 
Wu et al., 2011, Han et al., 2011 (Zhu et al.) and facilitating chemokine-mediated 
recruitment of inflammatory cells in pathological conditions involving inflammation 
(see chapter 1, (Kanyenda et al., 2011)). Roles of CD147 expression in the CNS are less 
established, however it appears to be important in neurodevelopment and 
neuroprotection (see chapter 1, (Kanyenda et al., 2011)).  With respect to AD, CD147 
expression has been shown to regulate Aβ levels in vitro and in vivo, for example RNAi 
knockdown of this gene results in Aβ accumulation (Zhou et al., 2005) and over-
expression results in a reduction in Aβ levels (Vetrivel et al., 2008b).  
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 Knockdown studies have shown that the sterol carrier protein is a major transcription 
factor that controls the expression of CD147. As shown and described in chapter 6, SCP 
binds CD147 within the promoter region and influences CD147 transcription.  The 
sterol carrier protein is a key protein involved in cholesterol metabolism where it has 
been shown to promote cholesterol uptake (Hirai et al., 1994, Colles et al., 1995, Lipka 
et al., 1995, Moncecchi et al., 1996, Schroeder et al., 1998, Atshaves et al., 1999), and 
facilitate cholesterol intracellular transport (Puglielli et al., 1995), esterification 
(Murphy and Schroeder, 1997) and oxidation (Chanderbhan et al., 1986, Yamamoto et 
al., 1991).  In addition it has been shown to remodel lipid composition, structure and 
function of lipid rafts (Schroeder et al., 2007). Given the importance of this protein in 
cholesterol metabolism, it is conceivable that SCP would respond to changes in 
cholesterol levels. Indeed Kraemer and colleagues (Kraemer et al., 1995) showed an up-
regulation of SCP in muscle cells treated with cholesterol.  
 
4.6.1: High fat/high cholesterol diet influences plasma cholesterol levels 
 
In the previous chapter, evidence was produced which showed that CD147 levels in 
primary neuronal cells were altered in a dose dependent manner following exposure to 
cholesterol (Chapter 3, section 3.4.2). In the current study, APPswe mice were fed a 
high fat/high cholesterol diet to provide an in vivo experimental model to assess the 
impact of a high cholesterol diet on CD147 protein expression, and to determine if there 
were any changes associated with alterations in SCP and APP metabolism. 
 
To raise peripheral levels of cholesterol, mice were fed a diet containing 10% fat, 0.75% 
cholesterol and 0.3% cholate, with controls feed on normal chow diet (SF08-020, 
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AIN93M Extra added vitamins) for 10 weeks. This led to a ~2 fold increase in plasma 
cholesterol levels (Fig.4.3). Previous studies on AD transgenic models have used 
similar high fat/high cholesterol diets however with cholesterol content ranging from 
1.25% to 5% ((Refolo et al., 2000b, Shie et al., 2002, Li et al., 2003a, Fitz et al., 2010).   
 
The composition of the diet was the same as that used in a study undertaken by a 
previous PhD student in our laboratory (Florence Lim) following changes from the 
initial composition of the diet. The student initially used a high fat/ high cholesterol diet 
comprising of 10% fat, 1% Cholesterol and 0.5% cholate, which was fed to APOE KI 
mice. The mice did not adapt well to the high fat/ high cholesterol diet, they did not find 
it palatable, most likely due to the bitter taste of cholate. The problem was rectified 
promptly by the addition of 7.5g fructose per 100 g of animal chow to make the food 
sweeter and to counteract the bitterness of the cholate. The percentages of cholesterol 
and cholate were also reduced (10% fat, 0.75% Cholesterol and 0.3% cholate). It is also 
important to note that when fructose was added to this high fat/high cholesterol diet, the 
sucrose content was also decreased slightly from 10g/100g feed (as in control rodent 
chow) to 7.5g/100g feed. In the presence of cholate, cholesterol can be more readily 
absorbed by the animal and therefore needs be included in the diet. Despite the lower 
dietary cholesterol content, significant fold increases in plasma cholesterol (2-3 folds) 
were observed in these previous experiments, compared to plasma levels of mice on the 
control diet. The same diet conditions were used in the current study and resulted in 
similar increases in plasma cholesterol.  
 
In previous studies, apart from the diet containing greater cholesterol content, the mice 
were maintained on the high fat/high cholesterol diets for a much longer period of time 
(4 months to 10 months). This may explain the slightly greater increase in serum 
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cholesterol levels (2-4 fold increase) than that observed in the current study. However, 
using such diets and treatment periods (7-10 months), some studies have shown similar 
increases to those shown in the current study (Shie et al., 2002, Mihovilovic et al., 2007, 
Fitz et al., 2010)). Despite the above-mentioned studies not showing dramatic increases 
in serum cholesterol, enhanced amyloid deposition was still evident, indicating that 
moderate increases in cholesterol can still lead to changes in pathology. As described 
below, despite the lower cholesterol content used and shorter duration of treatment in 
the current study, changes in Aβ levels were observed.   
  
Interestingly, the increase in plasma cholesterol in female mice was greater than that 
observed in male mice. Male and female mice exhibited a similar weight gain, 
suggesting that the amount of food ingested by the male and female mice was similar, 
thus it is unlikely that the male to female differences in serum cholesterol levels are due 
to the females eating significantly more than the males. Previous studies have reported 
sex differences in cholesterol metabolism and homeostasis. In a model of severe 
hypercholesterolaemia, where the peroxisome proliferator-activated receptor 
(PPARalpha) important for lipid metabolism and homeostasis was ablated, differences 
between female and male mice were observed where female mice showed higher 
cholesterol levels and deposited fat earlier than male mice (Costet et al., 1998). Another 
study provided evidence for a role for oestrogen, such that in the absence of this 
hormone (through ablation of aromatase), serum cholesterol levels were increased only 
in female mice. In contrast, under conditions of cholesterol loading, male mice showed 
reduced serum but increased hepatic cholesterol and this was associated with changes in 
expression of cholesterol transporters (Hewitt et al., 2004). Although differences in the 
severity of AD pathology have been reported in male and female AD transgenic mice 
 179 
 
models (Barrier et al., 2010, Carroll et al., 2010, Oikawa et al., 2010, Rosario et al., 
2010), whether differences in cholesterol metabolism contribute to this remains unclear.  
 
4.6.3: Increased cholesterol levels do not alter brain CD147 levels in vivo. 
 
To determine if the increases in serum cholesterol in those mice fed the high fat/high 
cholesterol diet were associated with changes in peripheral or cerebral CD147 levels, 
CD147 protein levels were measured in tissue homogenates by Western 
immunoblotting. The expression of CD147 in brain tissue has been widely reported 
(Nahalkova et al., 2010, Xie et al., 2010, Agrawal and Yong, 2011). Expression of  
CD147 has also been reported in many peripheral tissues including the lung, cervix, 
kidney and liver (Han et al., 2010, Kong et al., 2011, Wu et al., 2011, Zeng et al., 2011) 
and a soluble form has been indentified in human serum (Moonsom et al., 2010).   
 
The current study found that cerebral CD147 expression levels did not change 
significantly after 10 weeks on the high fat/high cholesterol diet, however, the male 
mice showed a trend towards higher CD147 levels and the female mice showed a trend 
towards lower CD147 levels in the brain after being on the high fat/ high cholesterol 
diet. In kidney tissue however, there were significant reductions in CD147 protein 
levels in the male mice and a trend towards lower levels in the female mice fed the high 
fat/high cholesterol diet. Whilst no significant changes in CD147 levels were observed 
in the liver, there was a trend toward a decrease in males fed the high fat/high 
cholesterol diet. Together, these results suggest that systemic increases in cholesterol do 
impact on the kidney. High dietary cholesterol may also alter cerebral CD147 levels and 
CD147 protein levels in other peripheral tissues, in particular if levels of soluble CD147 
are altered in the mice serum/plasma. Soluble CD147 can be detected in conditioned 
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media from human tumour cell cultures (Tang et al., 2004, Hanata et al., 2007), 
supernatant of human lipid loaded macrophages (Yue et al., 2009).  A quantitative 
ELISA assay to measure CD147 in human serum, has only recently been reported 
(Moonsom et al., 2010). Currently, there is a lack of suitable assays to measure soluble 
CD147 in rodent serum, and as is shown in Fig 5.4, specific antibodies and assays are 
required to detect CD147 from different species. Within the group of mice fed the high 
fat, high cholesterol diet, plasma cholesterol levels were found to be negatively 
correlated with brain CD147 levels, strengthening the notion of possible cholesterol 
mediated changes in brain CD147 levels. If these experiments were repeated with 
greater numbers of mice to increase the statistical strength of the results, or perhaps if 
mice were kept on these diets for a much longer period, it is possible that many of the 
trends seen here would be significant differences in such expanded or extended studies. 
 
4.6.4: A high fat/high cholesterol diet does not appear to affect SCP-2 transcript 
levels 
 
As mentioned above, CD147 transcription can be regulated by SCP-2.  In vitro evidence 
also indicates that cholesterol can alter SCP-2 transcription (Kraemer et al., 1995). 
There is yet no in vivo evidence that cholesterol mediated changes in SCP-2 occurs. To 
the best of my knowledge this is the first study to investigate whether dietary 
cholesterol can alter SCP-2 transcription. Thus, one aim of the work in this chapter was 
to determine whether the high fat/high cholesterol diet would increase SCP 
transcription. The results in Fig 5.10 show that the high fat/ high cholesterol diet did not 
alter brain SCP transcription. A previous, in vitro study has investigated the effects of 
cholesterol on SCP transcription.  In this study, smooth muscle cells harvested from rat 
thoracic aortas were treated with cholesterol (Kraemer et al., 1995) and it was found that 
under these conditions transcription of SCP was increased. Apart from the differences in 
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experimental models (in vitro vs in vivo), the study by Kraemer et al. also used 
cationised LDL cholesterol, a positively charged LDL cholesterol  which promotes a 
sterile inflammatory response in muscle and is a method used to measure cholesterol 
efflux (Tayler et al.).  Under in vitro conditions, concentrations of specific lipoproteins 
can be more readily controlled, in contrast to in vivo where increases in LDL and other 
lipoproteins occur as a result of increased dietary cholesterol.  The use of the type of 
LDL (native vs cationised) may also influence transcription (although there is no direct 
evidence of this as the Kraemer et al., study did not compare native versus cationised 
LDL). 
 
The particular isoform of SCP protein that may be up-regulated may also impact on 
CD147 transcription.  The SCP-2 gene is part of a fusion gene that contains two 
initiation sites encoding a 15.4 kDa (pro-SCP-2) and a 58.9 kDa (SCP-x) protein (Ohba 
et al., 1994, Ohba et al., 1995). The 58.9 kDa SCP-x protein undergoes a post-
translational cleavage process to yield a mature 12.9 kDa SCP-2 which has been shown 
to translocates to the nucleus and activate CD147 transcription (Ko and Puglielli, 2007). 
In contrast, expression of pro-SCP-2 has been shown to abolish activity of 12.9 kDa 
SCP-2 and inhibit CD147 transcription, resulting in an increase in Aβ production. In 
their study, Kraemer et al. assessed protein and mRNA levels of both 13 KDa SCP-2 
(~12.9 kDa) and 58 KDa SCP-x  (58.9 kDa) and showed that expression of SCP-2 
mRNA and protein, but not SCP-x, were increased (Kraemer et al., 1995) which would 
most likely lead to increased CD147 expression.  
 
It is conceivable that the high/ fat high cholesterol diet could alter CD147 levels, 
independent of any effects on SCP-2 expression. In addition to enhancing amyloid 
deposition, high fat/ high cholesterol diets fed to wild-type or transgenic mice have also 
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been associated with increases in cytokines/mediators and gliosis consistent with 
neuroinflammation (Thirumangalakudi et al., 2008) and increases in oxidative stress 
(Homma et al., 2004, Oliveros et al., 2004, Torreggiani et al., 2009). Changes in CD147 
expression have been reported in many pathological conditions, involving 
inflammation, including rheumatoid arthritis (Tomita et al., 2002, Zhu et al., 2006, 
Yang et al., 2008, Damsker et al., 2009) and atherosclerosis (Spinale et al., 2000, Choi 
et al., 2002, Yoon et al., 2005, Siwik et al., 2008) where it has roles such as the 
facilitation of chemokine-mediated recruitment of inflammatory cells or tissue repair 
through activation of MMPs (chapter 1, (Kanyenda et al., 2011)). Although a specific 
role for CD147 in neuroinflammation has yet to be established, the presence of CD147 
mRNA transcripts in microglia (Inoue et al., 1999) and astrocytes (Meeuwsen et al., 
2003), suggest a similar role in the brain. CD147 expression and particularly its 
interaction with CypA is known to protect against neuronal oxidative stress (Boulos et 
al., 2007). The inflammation and oxidative stress evident in AD model transgenic mice 
may be exacerbated by the high fat/ high cholesterol diet, subsequently impacting on 
CD147 expression. In this scenario, the observed decreasing trend in levels of CD147 
may be suggestive of a consequence of exacerbated AD pathology.  
 
4.6.5: CD147 influences on Aβ production 
 
Considering the roles that CD147 is currently believed to play in APP metabolism, in 
which it is thought to be capable of reducing Aβ levels, it was expected that an increase 
in CD147 levels would correlate with reduced Aβ load under conditions of the high-
cholesterol/ high fat diet. To assess this, levels of APP and its metabolites, including Aβ 
and the APP- C-terminal fragments C83 and C99 were assessed in brain tissues from 
mice fed the control chow diet or the high fat/ high cholesterol diet. As expected in 
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APPswe transgenic mice, significant increases in FL-APP levels were observed and 
decreases in one of the APP-C terminal fragments (C83) were also detected, although 
only in the male mice.  With respect to these particular APP-C83 results, the levels were 
particularly low in two of the mice, which most likely reduced the average to provide 
the overall significantly lower levels. Indeed, overall there was a large animal-to-animal 
variation in APP-C99 and C83 levels. All mice used in this study were confirmed to 
have the APP-transgene (by PCR, data not shown) and to express human APP protein 
(as confirmed by immunoblotting with human APP specific antibodies WO2 and 6E10, 
data not shown).   Thus the variation in C-terminal fragments and later in the Aβ 
peptide measurements were not due to some mice being non-transgenic.  
 
Variations were also observed in brain Aβ40 and Aβ42 levels as values spanned from 
<1 to 20 nmol/g levels in Aβ42 levels and <1 to 60 nmol/g in Aβ40 levels. The APPswe 
mice used in these experiments were relatively young mice (4.5 months). At this age, 
although Aβ40 and Aβ42 levels would begin to increase, plaque deposition would not 
be evident (plaque deposition occurs between 12-14 months of age). As the major aim 
of this study was to determine the effects of the high fat/ high cholesterol diet on 
CD147, the mouse age was chosen so that plaque/ AD pathology would not yet be 
evident. If the mice already had established AD pathology, any effects of the high 
fat/high cholesterol diet may have been masked by this pathology. The study was also 
aiming to examine changes in the initiating stages of the disease.  As a result of the age 
of the mice, since AD pathology should not have been present, the variation in Aβ 
levels cannot be attributed to variations in Aβ deposition.  
 
To normalise for animal variations in cerebral Aβ40 and Aβ42 levels, the ratio of 
Aβ42/40 was calculated for each animal and represented as a scatter plot in (Fig. 4.14). 
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This not only accounted for the large variations in the data but also provided a better 
indicator of whether the high fat high cholesterol diet increased levels of the more 
pathological Aβ42 species. Although not significant, there was a trend towards higher 
Aβ42/40 ratios (particularly in female mice). Although to a lesser degree (as explained 
above with differences in diets used), these results are consistent with previous reports 
in cholesterol fed transgenic APPswe mice, where cerebral amyloid load and Aβ levels 
are increased (Refolo et al., 2000b, Refolo et al., 2001, Shie et al., 2002, George et al., 
2004).  
 
A trend towards lower CD147 levels and increases in Aβ42 levels, following a period 
on a high fat/high cholesterol diet would be consistent with the notion that CD147 
negatively regulates Aβ levels.  The results presented in this chapter cannot determine if 
this is a consequence of increases in Aβ, a scenario in which progressive increases in 
Aβ would down-regulate CD147 levels, thereby allowing further accumulation of Aβ. 
This could occur either through a growing inability of CD147 to regulate γ-secretase 
activity or less inducement of enzymes that can degrade Aβ such as MMPs (Vetrivel et 
al., 2008b). The measurement of CD147 protein, relevant enzyme activities and Aβ 
levels in similar cholesterol fed mice at different ages could be performed in future 
studies to determine if changes in CD147 expression occur as Aβ accumulates. 
However, further studies aimed at deciphering how CD147 may (or may not) be 
involved in the early pathogenesis stages of AD would most likely be the most 
interesting.  
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4.7: Conclusions 
 
 
The results from this in vivo study have confirmed that a high fat/high cholesterol diet 
results in elevated circulating plasma cholesterol levels as evidenced by the elevated 
levels in both males and female fed on this diet. Although no significant increase in 
Aβ42/40 ratios were observed, a trend towards an increase in all mice fed on the high 
fat/high cholesterol diet was observed. The major finding observed in this study was a 
significant reduction in kidney CD147 protein levels in males combined with trends 
towards decreasing CD147 levels in brain, liver and kidney tissues from females fed the 
high fat/high cholesterol diet, compared to the control diet. In addition to changes in 
CD147 levels, the current study also identified significant increases in brain FL-APP 
levels and a significant reduction in APP-C83 fragments.  Although there were no 
changes in SCP transcript levels, changes in SCP protein isoforms (pro-SCP and SCP-x) 
cannot be ruled out. Whether the onset of AD results in changes in CD147 protein 
levels and if there is a correlation with AD pathology is addressed in chapter 5.   
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CHAPTER 5 
CD147 protein expression and localisation in AD brain tissue.  
5.1: Introduction 
 
The findings in chapters 3 and 4 describe the regulation of CD147 expression in vitro 
and in vivo. Together with evidence supporting a role for CD147 in regulating Aβ 
levels, either through regulating γ-secretase activity (Zhou et al., 2005) or Aβ 
degradation (Vetrivel et al., 2008b) warrants investigation of its expression in AD brain. 
In this chapter, expression levels of CD147 were assessed in brain tissue from controls, 
AD and Non-AD type dementia {dementia with Lewy Bodies (LBD) and frontal 
temporal dementia (FTD)} cases.   
 
The CD147 protein is expressed in many tissues including the brain (Seulberger et al., 
1990, Fan et al., 1998). The protein is expressed in a number of brain regions, including 
the frontal cortex and thalamus, and is particularly abundant in the hippocampus (Fan et 
al., 1998). CD147 expression has been reported in normal brain (in the vascular 
endothelium) and has been shown to be highly and widely expressed in gliomas, 
consistent with its role in tumour progression (Sameshima et al., 2000, Sameshima et 
al., 2003, Gu et al., 2009). Correlations between CD147 expression and BBB function 
have also been reported (Sameshima et al., 2000, Sameshima et al., 2003). Despite the 
number of studies describing CD147 expression in human brain, only one study has 
compared expression in the frontal cortex and thalamus form AD and control brain 
tissue (Nahalkova et al., 2010). The findings were inconclusive, as only a small number 
of samples were assessed (3 controls and 3 AD brains).  
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In this chapter I assessed CD147 protein expression analysis in a larger number of 
samples by immunohistochemistry (AD; n=17 and Controls; n=5), western blot (AD; 
n=14 and controls; n=4) and extended this analysis to hippocampal tissue. In addition, 
CD147 expression analysis was assessed in tissue from non-AD type dementias (LBD 
and FTD) to determine if any changes in expression is a result of general 
neurodegeneration. Furthermore, given evidence suggesting that CD147 expression 
regulates γ-secretase activity (Zhou et al., 2005) and although not a core component, 
interacts with the complex (Zhou et al., 2005, Winkler et al., 2009), expression of  the γ-
secretase core components, presenilins (PS1), nicastrin, and pen-2 were assessed and 
correlated with CD147 protein levels.  
 
5.2: Aims 
 
1) To determine if CD147 protein levels are altered in the frontal cortex or hippocampus 
of AD brain.  
 Assess tissue expression and localisation of CD147 protein in the frontal cortex 
from AD cases and compare with control and non-AD type dementia (LBD and FTD) 
cases. 
 
2) To determine if there is a correlation of CD147 protein levels with Aβ and that of the 
core components of the γ-secretase complex. 
 Assess protein levels of Aβ42 and the PS1, NCT, aph1 and pen2 in frontal 
cortex and hippocampus from control, AD and non-AD type dementia (LBD and 
FTD) cases.  
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5.3: Materials and methods 
5.3.1: Sourcing and preparation of tissues 
 
Tissue collection and analysis was approved by Hollywood Private Hospital and Edith 
Cowan University human ethics committees.  Western Australian Brain Bank Network 
(WABBN) supplied us with the frozen and formalin fixed frontal cortex and 
hippocampal tissues. Paraffin embedded tissue sections from formalin fixed tissues 
from ABBN were prepared in our laboratory (Table 5.1). Frozen hippocampal and 
frontal cortical tissues from controls (n=4; 4 males, no females), lewy body disease 
(LBD) (n=5; 3 males, 2 females =), frontal temporal dementia (FTD) (n=5; 3 males, 2 
females) and Alzheimer’s disease (AD) (n=14; 7 males, 10 females) were homogenised 
as described in section 2.3.3 prior to total protein estimation and expression analysis as 
described in sections 2.4.4 and 2.5 of the methodology chapter (chapter 2).  
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Table 5.1: List of IDs, pathology, age and sex of test samples 
 
 
 
 
 
 
ID Pathology Age Sex
WABBN
R10A 08A Alzheimers 74 M
R09A 33E Alzheimers 86 M
R09A 13L Alzheimers 57 M
R07A 32R Alzheimers 64 M
R07A 29L Alzheimers 60 F
R07A 27H Alzheimers 55 F
R07A 21T Alzheimers 91 F
R07A 09T Alzheimers 92 F
R07A 06A Alzheimers 76 F
R06A 20F Alzheimers 100 F
R06A 16K Alzheimers 93 F
R06A 06B Alzheimers 58 F
R05A 22L Alzheimers 76 M
R05A 20H Alzheimers 80 F
R05A 02T Alzheimers 83 M
R04A 36F Alzheimers 84 F
R04A 29P Alzheimers 73 M
R10A 11F Frontotemporal 78 F
R09A 19A Frontotemporal 58 M
R08A 19B Frontotemporal 63 M
R07A 38F Frontotemporal 60 M
R06A 18N Frontotemporal 63 F
R09A 35J Lewy Body Disease 79 F
R09A 32N Lewy Body Disease 82 M
R09A 02M Lewy Body Disease 88 F
R08A 15R Lewy Body Disease 78 M
R07A 28X Lewy Body Disease 77 M
R09A 11H Control 47 M
R07A 34X Control 67 M
R07A 33H Control 66 M
R07A 25D Control 46 M
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5.3.2: Western blot analysis 
 
CD147 protein levels were determined by SDS-PAGE gel electrophoresis in frozen 
hippocampal and cortical tissues as described in section 2.5 using anti goat EMMPRIN 
SC-9754 primary (Santa Cruz) specific for EMMPRIN of human origin, anti-Nicastrin 
(Sigma), anti-Presenilin (Kindly provided by Dr Paul Mathews, NYU), anti- PEN2 
(Sigma), β-Actin (AB8229)(Abcam – Australia) and anti goat HRP secondary 
antibodies. The CD147 (~55kDa), nicastrin (~78kDa), presenilin (~ 30kDa) and PEN2 
(~12kDa) and β-actin (~42kDa) protein bands were quantified using BioRad 
densitometry. Analysis of variance (ANOVA) with post-hoc analysis and Pearson’s 
correlation analysis were used to determine significant differences in levels of the 
proteins of interest among the test groups using SPSS software.  
 
5.3.3: Immunohistochemistry analysis 
 
In addition to western immunoblotting, CD147 protein levels were also determined by 
immunohistochemistry in formalin fixed and paraffin embedded tissue sections (4-5μ) 
from all cases analysed in this study. Sections were stained by EMMPRIN MAB2623 
primary antibody (Chemicon, USA) as described in section 2.18.  Stained sections were 
examined under light microscope (Olympus BX 51) fitted with Olympus DP71 Digital 
Camera. Two sets of pictures of each stained section were taken at the same light 
intensity and magnification. The first set was taken at x10 and the second set at x40 
magnifications. Image analysis to generate raw data was performed using ImageJ 
software (NIH). Images were first changed to HSB type for haematoxylin stained tissue 
analysis, then binary pictures generated to discriminate background staining and stained 
tissues. Particle analysis was performed and generated raw data values were converted 
using the following formula: 1/sample mean OD x 10000.  
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5.4: Results 
 
5.4.1: CD147 protein expression levels are not altered in brain tissue from 
Alzheimer’s disease (AD) cases. 
 
 In mouse brain, CD147 expression has been located in the hippocampus and upper 
layers of the cortex (Naruhashi et al., 1997, Higgins and Jacobsen, 2003, Richardson et 
al., 2003) where depletion in AD models results in increased Aβ deposition (Zhou et al., 
2007, Vetrivel et al., 2008b).  In human brain, expression of CD147 has been shown in 
the frontal cortex and thalamus (Sameshima et al., 2000, Nahalkova et al., 2009). Only 
one study has investigated expression of CD147 in control and AD brain, however no 
conclusive changes were observed due to the limited number of samples (Nahalkova et 
al., 2010).  Here, I analyse a larger cohort of cases and also compare expression in AD 
brain tissue to that from controls and non-AD type dementias. 
 
CD147 tissue expression and localisation was assessed using immunohistochemistry 
with a human specific EMMPRIN MAB2623 primary antibody (Chemicon, USA). 
Prior to immunohistochemical analysis, specificity of the CD147 was assessed (Fig 
5.1). Analysis was performed on a control and AD case. Melanoma and glioma tissue 
samples which are known to express high levels of CD147 (Liang et al., 2009, Han et 
al., 2010, Matsudaira et al., 2010, Kong et al., 2011, Wu et al., 2011) were used as 
positive controls . As expected, intensive staining was observed in the glioma (Fig 5.1, 
Bi) and melanoma (Fig 5. 1, Ci) tissues.  Staining was absent in tissue sections that 
were exposed to secondary antibody only, in the absence of primary antibody (Fig 5.1, 
Ai- ii),  indicating that the staining seen in the glioma or melanoma tissues is not 
background staining (Fig 5.1, Bi, Ci).  Staining was also evident in hippocampal and 
frontal cortex tissue of the control (Fig 5.1, Bii, and Cii) and AD (Fig 5.1, Biii, and 
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Ciii). Although staining was evident throughout the tissue, it was particularly prominent 
in the vascular endo-thelial cells (arrows).  Diffuse cytoplasmic staining with 
accentuation along the cell membrane was also observed. Of note is that staining 
appeared to be more intense in the AD brain tissue, compared with control (Fig 5.1, 
compare Bii and Cii, with Biii and Ciii).  Whether this held true in a larger sample size, 
was assessed next.  
 
Immunohistochemical analysis for CD147 was assessed in control, AD, FTD and LBD 
brain tissue. Representative figures of hippocampus and frontal cortex for each case at 
low (x10) and higher magnification (x40) are shown in Figures 5.2 and 5.4, 
respectively. As described above staining was evident throughout the tissue, it was 
particularly prominent in blood vessels/capillaries (arrows).  Diffuse cytoplasmic 
staining with accentuation along the cell membrane was also observed. A similar 
staining pattern has been observed in other studies of brain tissue (Sameshima et al., 
2000, Sameshima et al., 2003, Gu et al., 2009). Qualitatively, it appeared that compared 
to control tissue, overall staining and in particular the capillaries were more prominent 
in the AD, FTD or LBD frontal cortex or hippocampal tissue (Figures 5.2 and 5.4, 
compare B-D with A). Overall quantitation of staining using ImageJ software (NIH) 
(which measures both cytoplasmic and vascular staining) revealed similar levels of 
CD147 expression in control, AD, FTD and DLB tissue samples (Fig. 5.3 and 5.5). No 
regional differences were observed when levels were compared in the hippocampus and 
frontal cortex (Fig. 5.6).   
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Figure 5.1: Immunostaining for CD147 in melanoma, glioma and brain tissue. 
Cancer (i), brain tissue from a control (ii), and AD case (iii) underwent immunostaining 
with and without primary antibody. No or minimal background staining was observed in 
the antibody control tissues (A; i, ii and iii). CD147 staining was observed in frontal 
cortex (Bii) and hippocampal (Cii) tissues from the control sample.   Intensive CD147 
staining was observed in the glioma (Bi), melanoma (Ci) tissues, and frontal cortex (Bii) 
and hippocampal (Cii) tissues from the AD sample.   
 
i
Cancer ADNon - AD
i
i
A
B
C
iiiii
iiiii
iiiii
 194 
 
 
 
Figure 5.2: CD147 immunostaining in the hippocampus from control, LBD, FTD 
and AD brain tissue. Representative immunostained images at x10 (first column) or 
x40  magnification (second column) of  hippocampal tissue from controls (A), LBD (B), 
FTD (C), and AD (D). Scale bar represents 100 µm at 10x and 25µm at 40x 
magnifications respectively. Qualitatively, compared to control tissue (A), staining of 
the vascular endo-thelial cells (red arrows) was more prominent in the AD, FTD or 
LBD tissue (B-D). 
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Figure 5.3: Quantitation of CD147 immunostaning from hippocampus of control, 
LBD, FTD and AD cases. 
Cytoplasmic and vascular endothelial CD147 expression in the hippocampus tissue was 
assessed in all tissues and data is represented as mean ± SD.  Groups represent controls 
(n=4), LBD (n=5), FTD (n=5), AD (n=17).  Compared to controls results indicate no 
significant differences in CD147 expression. 
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Figure 5.4: CD147 immunostaining in the frontal cortex from control, LBD, FTD 
and AD brain tissue. 
Representative immunostained images at x10 (first column) or x40  magnification 
(second column) of  hippocampal tissue from controls (A), LBD (B), FTD (C), and AD 
(D). Scale bar represents 100 µm at 10x and 25µm at 40x magnifications respectively. 
Qualitatively, compared to control tissue (A), staining of the vascular endo-thelial cells 
(red arrows) was more prominent in the AD, FTD or LBD tissue (B-D) 
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Figure 5.5: Quantitation of CD147 immunostaining from frontal cortex of control, 
LBD, FTD and AD cases. 
Cytoplasmic and vascular endothelial CD147 staining in the frontal cortex was 
measured in all tissues and data is represented as mean ± SD.  Groups represent controls 
(n=4), LBD (n=5), FTD (n=5), AD (n=17). Compared to controls results indicate no 
significant differences of CD147 expression in LBD, FTD and AD, however there is a 
slight trend towards an increase observed in LBD and FTD. 
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Figure 5.6: A comparison of CD147 immunostaining in hippocampus and frontal 
cortex from control, LBD, FTD and AD cases.  
Cytoplasmic and vascular endothelial CD147 expression in hippocampal and frontal 
cortex tissue was assessed in all tissues and is represented as mean ± SD.  Groups 
represent control (n=4), LBD (n=5), FTD (n=5), AD (n=17). 
  
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
co LBD FTD AD
Hippo Cortex
CD
14
7 
pr
ot
ei
n 
Le
ve
ls
 
 199 
 
In order to more accurately quantitate total CD147 levels, brain homogenates from all 
cases underwent western blotting with EMMPRIN SC-9754 primary antibody (Santa 
Cruz). A ~ 55 kDa band representing CD147 was observed in the hippocampus and 
frontal cortex from all brain tissue samples (Fig 5.7A and C). Quantitation of the 
protein band, revealed no significant differences in total CD147 levels in hippocampal 
tissue from control, AD, LBD or FTD brain samples (Fig 5.7B). However a trend 
towards an increase was observed in hippocampus from AD brains. Similarly, no 
significant differences were observed in the frontal cortex from control, AD, FTD and 
LBD cases (Fig.5.7C and D).  
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Figure 5.7: CD147 levels in hippocampus and frontal cortex.  
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Figure 5.7: CD147 levels in hippocampus and frontal cortex.  
Western immunoblot analysis of CD147 protein levels in hippocampus (A and B) and frontal cortex (C and D). (A and C) Western blots of brain 
homogenates run in singles showing the ~55 kDa CD147 protein levels and corresponding β-actin levels as a loading control in hippocampus (A) and 
frontal cortex (C) in controls, LBD, FTD and AD. (B and D) Scatter plots representing CD147 levels in hippocampus and frontal cortex from controls, 
LBD, FTD and AD brain tissue. Individual points represent a specific sample value (as quantitated from adjacent blots) with the sample mean 
represented by horizontal line.  Compared to controls, data shows no significant differences of CD147 expression in both hippocampus and frontal 
cortex in LBD, FTD and AD.  
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5.4.2: Associations of CD147 protein expression with levels of Aβ42 and core 
protein components of γ-secretase. 
 
Although there was no overall changes in CD147 expression levels (see section above), 
as might be expected, there were large variations between samples, despite similar β-
actin levels. The close association of CD147 expression with Aβ levels and γ-secretase 
activity (Zhou et al., 2005) (Zhou et al., 2005, Winkler et al., 2009), prompted the 
investigation of  whether there was an association between CD147 levels and levels of 
Aβ42, and  expression of  the γ-secretase core components in the  brain tissue. Thus 
levels of Aβ42, PS1, NCT and Pen2 were measured in the brain tissue samples. 
 
Levels of Aβ42 were measured in the hippocampus and frontal cortex of control, FTD, 
LBD and AD brain tissue using ELISA. The results are shown in Figures 5.8 and 5.9. 
As expected compared to control tissue, Aβ42 levels were not altered in FTD brain 
tissue whilst levels were significantly increased in AD brain tissue (p<0.001) in 
hippocampus and (p=0.02) in the frontal cortex. Although there was large variation, 
compared to controls, levels were increased (p=0.004) in brain tissue from LBD 
dementia patients. A comparison of Aβ42 levels showed high levels in the frontal cortex 
(Fig.5.10). 
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Figure 5.8: Aβ42 levels in hippocampus.  
Aβ42 levels in brain tissue from the hippocampus of controls, lewy body disease 
(LBD), frontal temporal dementia (FTD) and Alzheimer’s disease (AD). Scatter plots 
representing Aβ42 levels in hippocampus from controls, LBD, FTD and AD brain 
tissue. Individual points represent a specific sample value with the sample mean 
represented by horizontal line. Compared to the controls data shows that Aβ42 levels 
are significantly increased in hippocampus from LBD and AD (***p<0.001 and 
*p<0.05 respectively) with AD showing the highest levels.  
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Figure 5.9: Aβ42 levels in frontal cortex.  
Aβ42 levels in brain tissue from the frontal cortex of controls, lewy body disease 
(LBD), frontal temporal dementia (FTD) and Alzheimer’s disease (AD). Scatter plots 
representing Aβ42 levels in frontal cortex from controls, LBD, FTD and AD brain 
tissue. Individual points represent a specific sample value with the sample mean 
represented by horizontal line. Compared to the controls data shows that Aβ42 levels 
are significantly increased in hippocampus from AD (*p<0.05).  
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Figure 5.10: Comparison of Aβ42 levels between hippocampus and frontal cortex.  
Aβ42 levels in hippocampus and frontal cortex from controls, lewy body disease 
(LBD), frontal temporal dementia (FTD) and Alzheimer’s disease (AD). Data is 
presented as ±SEM and indicate that frontal cortex has high Aβ42 expression compared 
to hippocampus.  
 
 
 
 
 
 
 
 
 
A
β4
2 
le
ve
ls 
(p
g/
m
g 
To
ta
l P
ro
te
in
)
0
400
800
1200
1600
CO FTD LBD AD
Hippocampus Cortex
 207 
 
Levels of the core protein components of γ-secretase including nicastrin, PS1 and PEN-
2 were assessed in the hippocampus and frontal cortex from all brain samples via 
western immunoblotting.  
 
Nicastrin, a type 1 transmembrane glycoprotein (Yu et al., 2000), plays a role in the 
assembly and intracellular trafficking of the γ-secretase complex (see chapter 1) (Shah 
et al., 2005, Zhang et al., 2005). Compared to controls, nicastrin levels were not altered 
in hippocampal (Fig.5.11A and B) and frontal cortex (Fig.5.11C and D) tissues from 
AD, FTD or LBD. However, though not significant, an increasing trend was observed in 
both hippocampus and frontal cortex tissues from AD.  
 
The presenilins are regarded as the core catalytic component of γ-secretase (L'Hernault 
and Arduengo, 1992, Levitan and Petersen, 1995, Martins et al., 1995, Xia et al., 1997) 
(Herreman et al., 1999)-(Palacino et al., 2000). Levels of PS1 were measured as recent 
evidence suggests that PS1 containing γ-secretase complexes are more active than PS2 
containing complexes (Stromberg et al., 2005, Hedskog et al., 2011, Yonemura et al., 
2011). Levels of PS1 were not significantly altered in hippocampal tissue from AD, 
FTD or LBD compared to controls (Fig.5.12A and B). However a trend towards and 
increase was observed in hippocampus tissue. A comparison between AD and LBD, 
showed significant difference of PS1 (p=<0.031) in hippocampus tissue.  In the frontal 
cortex, compared to controls, PS1 levels were not altered in tissue from AD subjects 
(Fig.5.12C and D) but an increasing trend was observed in AD and LBD. 
 
The Presenilin Enhancer 2 (PEN-2) is a ~12 kDa protein and has a critical role in the γ-
secretase complex as described in chapter 1,  where it facilitates end proteolysis of the 
presenilins (Crystal et al., 2003, Prokop et al., 2004, Steiner et al., 2002, Luo et al., 
2003, Takasugi et al., 2003, Hasegawa et al., 2004). Levels of this protein were 
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significantly increased in hippocampal tissue from AD tissue (p=0.014) compared to 
controls (Fig.5.13A and B). In the frontal cortex, PEN2 levels showed no significantly 
change in FTD, LBD or AD tissue, although a trend towards an increase was observed 
(Fig.5.13C and D). 
 
Overall, these results show that compared to control brain tissue Aβ42 levels were 
increased in AD tissue. In addition levels of components of the γ-secretase enzyme 
including, PS1 and PEN-2 were altered. To determine if there were associations 
between CD147 levels and levels of Aβ42 and the γ-secretase components, a bivariate 
Pearson’s correlation analysis was performed (Table 5.2). 
 
Strong significant positive correlations between CD147 and PS1 in hippocampus from 
controls (p=0.028), AD (p=0.002) and LBD (p=0.003); CD147 and NCT in AD 
(p=0.0001) and CD147 and PEN2 in controls (p=0.035) were observed. However, in 
the frontal cortex, significant correlations were observed in LBD (PS1, p=0.034; PEN2, 
p=0.003 respectively) and FTD (PEN2, p=0.042). Interestingly, there were similar 
correlations observed in LBD samples, which may reflect the presence of AD pathology 
in this type of dementia (Griffin et al., 2006, Maetzler et al., 2009).  However, as there 
were only five samples obtained of LBD tissue, the significant correlation may need to 
be confirmed in a larger sample.  There was no correlation between CD147 and Aβ42 in 
AD brains.   
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Table 5.2: CD147 correlations with nicastrin, presenilin1 and presenilin enhancer 2 in 
hippocampus and frontal cortex from AD, LBD and FTD brains. 
 HIPPOCAMPUS FRONTAL CORTEX 
Aβ42 NCT PS1 PEN2 Aβ42 NCT PS1 PEN2 
 
 
 
CD147 
 
CO 
-.017 
0.983 
.723 
0.277 
.972 
0.028* 
.965 
0.035* 
-.167 
0.833 
-.259 
0.741 
.764 
0.236 
-.629 
0.371 
AD .405 
0.151 
.824 
0.0001** 
.760 
0.002** 
.207 
0.478 
.211 
0.470 
.468 
0.091 
.386 
0.173 
.443 
0.113 
LBD .615 
0.385 
.763 
0.134 
.982 
0.003** 
.582 
0.304 
-.402 
0.598 
.025 
0.968 
.906 
0.034* 
.983 
0.003** 
FTD -.091 
0.909 
-.030 
0.970 
-.922 
p.078 
.491 
0.509 
.711 
0.178 
-.729 
0.271 
-.766 
0.234 
.958 
0.042* 
 
P-value calculated by bivariate Pearson’s correlation analysis. * Correlation is 
significant at the 0.05 level.  ** Correlation is significant at the 0.01 level (2-tailed). 
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Figure 5.11: Nicastrin levels in hippocampus and frontal cortex.  
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Figure 5.11: Nicastrin levels in hippocampus and frontal cortex.  
Western blots and data analysis of nicastrin in hippocampus (A and B) and frontal cortex (C and D). (A and C) Western blots of brain 
homogenates run in singles showing the ~75 kDa nicastrin protein levels and corresponding β-actin levels as a loading control in hippocampus 
(A) and frontal cortex (C) in controls, LBD, FTD and AD. (B and D) Scatter plots representing nicastrin levels in hippocampus and frontal 
cortex from controls, LBD, FTD and AD brain tissue. Individual points represent a specific sample value (as quantitated from adjacent blots) 
with the sample mean represented by horizontal line.  Compared to the controls, there was no difference in nicastrin levels observed in 
hippocampus and frontal cortex from LBD, FTD and AD respectively. However an increasing trend was observed in hippocampus and frontal 
cortex tissues from AD.  
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Figure 5.12: PS 1 levels in hippocampus and frontal cortex.  
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Figure 5.12: PS 1 levels in hippocampus and frontal cortex.  
Western blots and data analysis of PS1 levels in hippocampus (A and B) and frontal cortex (C and D). (A and C) Western blots of brain homogenates 
run in singles showing the ~38 kDa PS1 protein levels and corresponding β-actin levels as a loading control in hippocampus (A) and frontal cortex (C) 
in controls, LBD, FTD and AD. (B and D) Scatter plots representing PS1 levels in hippocampus and frontal cortex from controls, LBD, FTD and AD 
brain tissue. Individual points represent a specific sample value (as quantitated from adjacent blots) with the sample mean represented by horizontal 
line.  Compared to the control group, there is no significant difference in PS1 levels in hippocampus and frontal cortex. However in hippocampus there 
was significant difference in PS1 between AD and LBD (*p<0.05) with an increasing trend observed in frontal cortex from LBD.  
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Figure 5.13: PEN2 levels in hippocampus and frontal cortex.  
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Figure 5.13: PEN2 levels in hippocampus and frontal cortex.  
Western blots analysis of PEN2 protein levels in the hippocampus (A and B)) and frontal cortex (C and D). (A and C) Western blots of brain 
homogenates run in singles showing the ~12 kDa CD147 protein levels and corresponding β-actin levels as a loading control in hippocampus (A) and 
frontal cortex (C) in controls, LBD, FTD and AD. (B and D) Scatter plots representing PEN2 levels in hippocampus and frontal cortex from controls, 
LBD, FTD and AD brain tissue. Individual points represent a specific sample value (as quantitated from adjacent blots) with the sample mean 
represented by horizontal line.  Compared to the controls, PEN2 levels are significantly increased in hippocampus of AD patients (*p<0.05). A trend 
towards an increase is seen in the in frontal cortex from AD, FTD and LBD.   
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5.5: Summary of results: 
This chapter has shown the expression and localisation profile of CD147 in the frontal 
cortex and hippocampus of control, AD and non-AD type dementia subjects.  The 
results have shown cytoplasmic and particularly strong staining pattern surrounding the 
vascular endothelial cells which qualitatively appear to increase in intensity in AD brain 
tissue. Similar staining intensity was also observed in LBD and FTD brain tissue. 
Quantitatively measuring CD147 levels revealed no significant changes, however trends 
were observed. Highly significant positive correlations between CD147 and PS1 and 
CD147 and NCT were observed in hippocampal tissue from AD samples, suggesting 
tight associations between CD147 and core components of the γ-secretase complex.  
 
5.6: Discussion 
 
The expression of CD147 has been shown to impact on neuro-protection and 
modulating Aβ levels. Apart from in vitro over-expression and knock-down studies in 
proof-of-concept studies, the effects of CD147 transcription/expression on AD 
pathology have not been explored. Indeed, whether CD147 transcription or protein 
expression is altered in AD has not been fully examined.  Only one study has 
investigated CD147 protein expression levels in different regions in a small number of 
control and AD brain samples (Nahalkova et al., 2010). The numbers used (3 control 
and 3 AD brains) were too small to show significant differences, however qualitative 
analysis of immunostained tissue sections revealed that CD147 staining was more 
intensive in the neurons and capillaries in both frontal cortex and thalamus of AD brain 
compared to control brain. In this chapter a more detailed, qualitative and quantitative 
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analysis in a larger number of tissue samples (4 controls and 17 AD brains) was 
undertaken to determine if CD147 protein expression is significantly altered in AD. In 
addition, CD147 expression analysis was assessed in tissue from non-AD type 
dementias (LBD and FTD) to determine if any changes in expression is a result of 
general neurodegeneration. 
 
In mouse brain, CD147 expression has been located in the hippocampus and upper 
layers of the cortex (Naruhashi et al., 1997, Higgins and Jacobsen, 2003, Richardson et 
al., 2003). In human brain, expression of CD147 has been shown in the frontal cortex 
and thalamus (Sameshima et al., 2000, Nahalkova et al., 2009). The results presented in 
this thesis also show prominent CD147 expression in the hippocampus (See Fig 5.1 and 
5.2). Analysis of brain tissue by immunohistochemistry revealed a similar tissue 
localisation as reported by previous studies of human brain (Nahalkova et al., 2010) in 
both the hippocampus and frontal cortex. Immunostaining with an antibody specific to 
human CD147 showed that staining was evident throughout the tissue with diffuse 
cytoplasmic staining with accentuation along the cell membrane was also observed. 
Staining was particularly prominent in capillaries and blood vessels (Fig 5.2 and 5.4 at 
x40 magnification). This is in line with previous reports that have located CD147 
expression to the vascular endothelium and have suggested a role in BBB function 
(Sameshima et al., 2000, Sameshima et al., 2003, Gu et al., 2009). Indeed an MRI and 
immunohistochemical study of brain tumours has correlated CD147 expression in 
vascular endothelial cells with blood-brain barrier function (Sameshima et al., 2003). 
BBB function is known to be comprimsed in AD and other neurodegenerative diseases 
(Caserta et al., 1998, Clifford et al., 2007, Nagele et al., 2011) whether it correlates with 
vascular endothelial expression of CD147 levels in these disease states may provide 
insight into a possible marker of BBB dysfunction.  
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It was noted that compared to control brain tissue, there was a strong CD147 staining of 
the blood vessels or capillaries in AD (Fig 5.2 and 5.4 at x40 magnification).  CD147 is 
known to play a role in cerebral injury after ischemic stroke by stimulating endothelial 
cells to secrete matrix metalloproteases (MMPs) (Liebetrau et al., 2005). The blood 
vessels are the structures in the brain that contain ECM proteins known to be substrates 
for MMPs and take part in micro vascular damage. Abnormalities in brain vascular 
system and brain hypofusion are features of AD and are consistent with the vascular 
hypothesis of AD development (de la Torre, 2004) and although not to the extent of 
vascular dementia or AD, can also occur in other neurodegenerative diseases 
(Grammas, 2011). Indeed, CD147 staining within capillaries and blood vessels appeared 
to be increased in FTD and LBD compared to controls in the current study (Fig 5.2, B 
and D).  
 
As a more quantitative analysis of CD147 expression, brain homogenates underwent 
western immunoblotting. The study by Nahalkova et al., (2010) investigated CD147 
expression in the cortex and thalamus of 3 controls and 3 AD brain samples. Overall 
there was no significant changes as the number of sample assessed were small and there 
were variations in expression levels (increased, unchanged, and decreased).  In the 
current study, a greater number of control and AD samples were assessed to increase the 
statistical power of observing changes in CD147 levels. In addition to the frontal cortex, 
the hippocampus, where expression has been reported to be highest in rodent brain (Lee 
et al., 2003a, Lee et al., 2003b) was also assessed.   Quantitation by western 
immunoblotting of CD147 protein levels in the frontal cortex and hippocampus revealed 
no significant changes in mean protein values in AD brain compared to control brain, 
however there was an increasing trend observed in the hippocampus from AD.  
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Considering the reported roles of CD147 in modulating Aβ levels and interactions with 
core components of the γ-secretase complex, and that CD147 has been shown to 
partially co-localise with components of the complex, PS1, nicastrin and Pen-2 
(Nahalkova et al., 2010), correlations with levels of these proteins in the brain samples 
were assessed. Correlations would be indicative of potentially functional involvement of 
this protein in the pathological changes happening in AD brain.  
 
As expected Aβ42 levels were increased in the hippocampus and frontal cortex of the 
AD brain. Levels were also increased in both regions of brain tissue obtain from 
subjects with LBD. In addition to the wide-spread distribution of lewy bodies, subjects 
with LBD also show a variable burden of amyloid deposition and neurofibrillary 
tangles, a characteristic of AD (Gomperts et al., 2008, Armstrong and Cairns, 2000, 
2009). Although not to the extent of AD, Aβ42 is the predominant species deposited 
(Mann et al., 1998). In the current study, results have shown that Aβ42 does not 
correlate with CD147 which is consistent with the findings of Vetrivel (Vetrivel et al., 
2008b).  
 
5.6.3: PEN2 are increased in Alzheimer’s disease (AD) 
 
 Nicastrin is a type 1 transmembrane glycoprotein and a component of the γ-secretase 
enzyme complex (Yu et al., 2000).  In addition NCT plays a role in the assembly of the 
γ-secretase complex within the endoplasmic reticulum and its intracellular trafficking to 
the cell surface (Shah et al., 2005, Zhang et al., 2005). NCT also acts as a scaffold for 
the assembly of the γ-secretase enzyme complex that binds with APH-1 to form the first 
sub-complex (Morais et al., 2003, Periz and Fortini, 2004). Since γ-secretase enzyme is 
responsible for the production of Aβ, the current study investigated if NCT is altered in 
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hippocampus and frontal cortex tissues from controls, LBD, FTD and AD. Although not 
significant, our results have shown an increasing trend in nicastrin levels both in 
hippocampus and frontal Cortex from AD (Fig.5.11C and D). In addition to AD, 
increasing trends were also observed in hippocampus from FTD. Taken together these 
findings are suggestive of an increased γ-secretase enzyme activity during Aβ 
generation as NCT plays a role in its assembly. This is consistent with findings from 
other studies which reported increased NCT levels in Tg2576 mice (Chu et al., 2012, 
Gwon et al., 2012).  
 
The Presenilins (PS1 and PS2) are also transmembrane proteins (Sherrington et al., 
1995, Lehmann et al., 1997) which facilitates APP metabolism and processing and 
mutations in PS1 increase the production of the longer more pathological Aβ species 
(Martins et al., 1995, Xia et al., 1997).  In addition to Nicastrin, the current study also 
investigated PS1 expression levels in hippocampus and frontal cortex from controls, 
LBD, FTD and AD. Although not significant, increasing trends of PS1 levels in 
hippocampus and frontal cortex from FTD and AD were observed (Fig.5.12A and B). 
Interestingly though was the finding of a significant difference in PS1 levels between 
AD and LBD in hippocampus. This difference may have been influenced by one LBD 
sample that showed the lowest PS1 expression hence pulling down the mean of this 
group. The increasing trend in PS1 levels observed in AD in the current study are 
consistent to those reported in previous studies (Kodam et al., 2010, Chu et al., 2012) 
and is an indication of increased APP metabolism through the amyloidogenic pathway. 
This may also suggest a possible relationship between CD147 and PS1 expression 
levels in hippocampus. Since both CD147 and PS1 are transmembrane proteins, there 
may be possible interactions taking place during their biological functions at cellular 
levels, since CD147 is a multifunctional protein. There is therefore a need to investigate 
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further any possible interactions, not only between CD147 and PS1, but also with other 
members of the γ-secretase complex which will help explain further how CD147 and 
the γ-secretase complex interact to facilitate APP metabolism. 
 
Interaction of PEN-2 with other proteins results in the stability of the γ-secretase 
complex (Crystal et al., 2003, Prokop et al., 2004) and is required for stabilization of the 
presenilin N- and C-terminal fragments within the γ-secretase complex in addition to 
contributing to NCT maturation.  Reports have also shown that knocking down PEN-2 
expression results in marked decrease in Aβ production, suggesting  that PEN-2 is 
essential for γ-secretase activity (Steiner et al., 2002, Luo et al., 2003, Takasugi et al., 
2003). In addition to NCT and PS1 the current study also investigated PEN2 levels in 
hippocampus and frontal cortex from controls, LBD, FTD and AD. Our results have 
shown a significant increase of PEN2 levels in hippocampus from AD and an increasing 
trend in frontal cortex from AD, FTD and LBD (Fig.5.13A and B, and Fig. 5.13C and 
D). These findings are also consistent to those reported in other studies where increased 
PS1, NCT and PEN2 levels were observed (Kodam et al., 2010, Chu et al., 2012). The 
increased PEN2 levels observed in the hippocampus from AD may also be attributed to 
increased γ-secretase activity as PEN2 is responsible for its stability. Since PEN2 levels 
are increased in AD and we have also observed an increasing trend in CD147 level in 
hippocampus from AD, taken together these findings indicate a close relationship 
between PEN2 and CD147 that needs to be investigated further. 
 
It was interesting to observe that CD147, NCT, and PS1 levels showed an increasing 
profile in hippocampus and decreasing profile in some disease status in the cortex. I 
anticipated finding significant levels of these γ-secretase complex components in LBD 
and FTD that have similar manifestations as AD but this was not the case. These 
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findings are consistent with other studies that have reported mean differences between 
AD and age matched controls but with no statistical differences (Schonlein et al., 1993, 
Patel et al., 2006, Vetrivel et al., 2008a). In addition, our findings from hippocampal 
tissues are correct as it has also been reported that over expression of one member does 
not affect the whole complex (Edbauer et al., 2003, Kimberly et al., 2003, Takasugi et 
al., 2003) and that elevation of γ-secretase activity can only be achieved by over 
expressing all the components (Li et al., De Strooper, 2003). The cited studies support 
our findings where NCT, PS1, and currently CD147 showed increasing trends in 
addition to a significant increase in PEN2 
 
I have also reported decreasing trends in NCT, PS1 and PEN2 levels in the cortex which 
is consistent with TPM 21 findings by Vetrivel and colleagues. These findings confirm 
that γ-secretase complex components, including CD147, are reduced in the cortex and 
provide additional proof that CD147 is not elevated in cortex from AD brains as 
reported by Nahlakova et al (2010). Our data has shown increased PS1 and PEN2 levels 
with increasing trends of CD147 and NCT, in addition to a positive correlation between 
CD147 and NCT and PS1 levels in the hippocampus. These findings may indicate that a 
balance between CD147 and γ-secretase may be responsible for modulating Aβ levels in 
brains. 
 
5.7: Conclusion 
 
I report for the first time that CD147 is not altered in AD. However the observed 
increasing trends in CD147, PS1, nicastrin and significant increase and PEN2 levels in 
hippocampus from AD is an indication of increased γ-secretase activity. I also report for 
the first time that CD147 correlates with PS1 and NCT but not Aβ42 in hippocampus 
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from AD brains. Finally the findings confirm that CD147 is not part of the γ-secretase 
complex but rather that it may influence the γ-secretase complex activity indirectly by 
interacting with NCT, PS1, ALPH-1 and PEN 2 as it is a multifunctional protein.  
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CHAPTER 6 
Polymorphisms in the CD147 promoter region may influence 
Alzheimer’s disease (AD) pathology. 
 
6.1: Introduction 
 
The CD147 protein description and classification  (Biswas and Vonderhaar, 1987, 
Fossum et al., 1991, Miyauchi et al., 1991, Kasinrerk et al., 1992, Biswas et al., 1995), 
its role in MMPs production (Biswas et al., 1995, Guo et al., 1997) and it involvement 
in the development of the nervous system, spatial learning and memory, sensory inputs 
and retinal functions (Naruhashi et al., 1997, Muramatsu and Miyauchi, 2003, Zhou et 
al., 2005) have been reported. In addition its involvement in the development of cancer, 
tumour progression and AD pathogenesis (Nabeshima et al., 2006a, Winkler, 2008, 
Nahalkova et al., 2010), in particular regulating Aβ levels (Zhou et al., 2005, Vetrivel et 
al., 2008b) have also been reported.  
 
CD147 expression is facilitated by Sterol carrier protein 2 (SCP-2). The properties of 
SCP-2 have been discussed in Chapter 1 of this thesis, where I have described SCP-2 as 
part of a fusion gene with two initiation sites coding for a 15.4 kDa (pro-SCP-2) and a 
58.9 kDa (SCP-x) proteins (Ohba et al., 1994, Ohba et al., 1995).  In addition to its 
involvement in cholesterol trafficking and metabolism, SCP-x undergoes a post-
translational process yielding a mature 12.9 kDa DNA binding fragment in the nucleus 
where it regulates CD147 transcription (Ko and Puglielli, 2007).  This fragment is 
controlled by pro-SCP-2 which acts as a competitive regulator for CD147 transcription 
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(Ko and Puglielli, 2007).  SCP-2 was initially identified as a sterol carrier and a non-
specific lipid-binding protein.  However, subsequent studies have shown that SCP-2 
binds fatty acid and cholesterol and facilitates their translocation between membrane 
systems both in vitro and in vivo.  It has been established that SCP-2 is responsible for a 
rapid protein-mediated translocation of cholesterol in cells and tissues and that it alters 
cholesterol metabolism in the liver and plasma (Baum et al., 1997, Zanlungo et al., 
2000).   
 
The expression of pro-SCP-2 abolishes the transcriptional activity of 12.9kDa SCP-2 
which thereby shuts down CD147 transcription. The loss of CD147 expression (Ko and 
Puglielli, 2007) and deletion of CD147 in female knock- out mice (Zhou et al., 2006) 
lead to the increased production of Aβ.  In addition findings in chapter 3 of this thesis 
have shown that cholesterol loading affects CD147 expression in rat primary cortical 
neuronal cultures. Taken together these findings suggest that both cholesterol and SCP-
2 play a role in CD147 expression, which in turn has an impact on Aβ peptide levels.  
The findings in chapters 3 and 4 describe the regulation of CD147 expression in vitro 
and in vivo.  In addition findings in chapter 5 reveal CD147 expression in brain tissue 
from controls, AD and Non-AD type dementia (dementia with Lewy Bodies (LBD) and 
frontal temporal dementia (FTD)) cases and its association with the γ-secretase complex 
components. Taken together the in vitro and in vivo evidence supporting a role for 
CD147 in regulating Aβ levels, (either through regulating γ-secretase activity (Zhou et 
al., 2005) or Aβ degradation (Vetrivel et al., 2008b) warrants further investigation of its 
genotypic association with AD. It is not known if any polymorphisms in the CD147 
promoter region (where SCP-2 binds to initiate its transcription) influence AD 
development and pathology.  Thus in this chapter I investigated the presence of single 
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nucleotide polymorphisms (SNPs) within the CD147 promoter region, where SCP-2 
binds to initiate its transcription, that may be involved in AD pathology.  
 
6.2: Aims 
 
a) To confirm SCP-2 binding of CD147 DNA. 
b) To identify novel SNPs within the SCP-2 binding site on the CD147 promoter in 
addition to the already characterised SNPs reported in NCBI 
c) To determine an association between the identified SNPs and AD pathology. 
 
6.3: Material and methods 
 
The generation and purification of SCP-2 protein was performed as described in 
sections 2.4.2 and 2.4.3 of the methodology chapter. SCP-2 protein was generated using 
chemically competent KRX E.coli cell line transformed with pro-SCP and SCP-x DNA 
(1μl) and subcultured on Kanamycin agar plates over night. Following several steps of 
the transformation procedure protein expression was induced by the addition of 1mM 
IPTG and 0.1% Rhamnose. After approximately 18 hours of incubation the cell 
suspension was subjected to three passages of homogenization using a French press, 
followed by centrifugation at 10000g for 10 minutes. Inclusion bodies containing the 
desired protein were recovered from the homogenate as a pellet. The lysate was retained 
and further processed to recover recombinant proteins localized to the cytoplasm. 
 
The purification of pro-SCP and SCP-x cytoplasmic protein was achieved through 
immobilized metal ion affinity chromatography (IMAC) as described in section 2.4.3 of 
the methodology chapter. In brief the lysate was treated with 1ml of Ni-NTA agarose 
 228 
 
beads (Qiagen) and gently mixed at 4°C for 1 hour, centrifuged at 2000g for 5 minutes, 
and the supernatant removed. Four millilitres of wash solution was then mixed with the 
remaining beads, followed by centrifugation at 2000g for 5 minutes repeated 4 times. 
Protein was eluted by addition of 1ml of elution buffer to the beads, centrifuged for 5 
minutes at 2000g and the supernatant collected. The protein solution was transferred to 
dialysis tubing and dialysed against three 2 litre volumes of dialysis buffer solution at 
4°C, over a 24 hour period. The protein solution was then removed from the cellulose 
tubing, combined with glycerol (10%), filter sterilised (0.2µM) and stored at -80oC. 
Protein recovery was confirmed by western blot whereas SCP-2 binding of the CD147 
DNA was confirmed by electrophoretic mobility shift assay (EMSA) following the 
manufacturer’s instruction. 
 
The DNA binding properties of mature SCP-2 on an electrophoretic mobility shift assay 
(EMSA) following incubation of affinity-purified 12.9-kDa SCP-2 with PCR products 
corresponding to the CD147 promoter region has been described (Ko and Puglielli, 
2007) (Fig. 6.1). KO and Puglielli generated probes corresponding to nucleotides -492 
to -392, -392 to -242, -245 to -95 and -94 to 10 and used them to determine their 
binding capacity for the CD147 promoter DNA. They reported no binding observed 
with PCR products corresponding to nucleotides -492 to -392 and -94 to 10. However 
there was a strong mobility shift with the probe corresponding nucleotides to -245 to -
95 with a weak shift with the probe corresponding to nucleotides -392 to -242 when 
incubated with the transcriptionally active fragment of SCP-2 suggesting the existence 
affinity binding sites for SCP-2 on the CD147 promoter as shown in Figure 6.1. The 
471 bp EMMPRIN DNA used for EMSA as described by Liang et al. (Liang et al., 
2002) was kindly provided by Dr. Sherif Boulos of Australia Neuromuscular Research 
Institute (ANRI – Australia). 
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Fig.6.1: The schematic view of the 5’-Untranslated region of CD147 
CD147 promoter region showing SCP-2 binding site between nucleotides -392 and -95 
(adapted from (Ko and Puglielli, 2007)) 
 
 
 
 
 
 
 
 
 
 
 
 
CD147
SCP-2 binding site
CD147 promoter region
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Human genomic DNA samples (health controls; n=100 and AD cases, n=100) were 
sourced from the Australian Imaging Biomarker and Lifestyle (AIBL) study (Perth and 
Melbourne – Australia). A larger 709 bp fragment that covers the whole region 
sequenced by KO and Puglielli (Ko and Puglielli, 2007) as well as regions up and down 
stream of this region (Fig.6.3).  To generate the 709bp fragment a slowdown PCR was 
performed as described by Frey et al. (Frey et al., 2008). Approximately 30-50ng of 
genomic DNA was amplified by PCR in a reaction containing 400nM each primer 
(forward 5’ AGGCTCTGGGAGTACAGACG and reverse 5’ 
CCGGGAGGAACCTCTAGTC), 1.6μl MgCl2, 0.2 μl Taq polymerase, 4 μl 10x PCR 
buffer (Phusion), 1.5 μl 7-Deaza-dGTP, 2 μl dNTPS and 9.7 μl dH2O.  The thermal 
cycle conditions are as follows: 
 
• 1 cycle of 95oC for 5min., setting heating ramp to 2.5oC-1 and the cooling ramp 
rate for reaching annealing temperature to 1.5oCs-1 
• 48 cycles of 95oC x 30sec denaturation. 
o 30sec annealing with a progressively lowered temperature from 70-53oC 
at a rate of 1oC every third cycle and a primer extension of 40 sec at 
72oC. 
• 15 cycles of 58oC, 4oC hold. 
 
The 709bp product, which covers up- and down-stream of the putative SCP binding 
region (-392 to -95 nucleotides; (Ko and Puglielli, 2007), was verified by agarose 
electrophoresis and viewed under UV on a Biorad Gel doc prior to sequencing. 
 
Sequencing of the amplified region of the CD147 promoter was undertaken at Applied 
Genetic Diagnostics (APG), Department of Pathology-University of Melbourne.  The 
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provided 709bp product was verified by agarose electrophoresis before pre-sequencing 
cleanup using EXOSAP-IT (GE Healthcare) and a sequencing reaction with 5μM 
forward primer and Big Dye V3.1 terminators (Applied Biosystems).  The Qiagen 
DyeEx kit was used to clean up the product before capillary electrophoresis on an 
ABI3130xl Genetic Analyser with POP7 polymer. The product was amplified by PCR 
and sequenced by capillary electrophoresis on an ABI 3130xl Genetic Analyser and 
compared to the reference sequence NG_007468.1 using Mutation Surveyor Software® 
(Soft Genetics).   Results were confirmed by repeat sequencing. 
 
Linkage Dysequilibrium was estimated by D’ and r2 as implemented in Haploview V4.2 
software (Barrett et al., 2005). Allelic and haplotypic associations with clinical 
classification were undertaken using chi-squared (χ2) tests as implemented in 
Haploview. Corrections for multiple testing were considered if mandatory, 1000 
permutations as implemented in Haploview.  Genotype associations were then analyzed 
using IBM SPSS® Statistics version 19.  Analysis of association with categorical 
variables (i.e. clinical classification) was undertaken using χ2 analysis, whilst continuous 
variables were analyzed using either the Student’s T-test or One Way ANOVA, where 
appropriate. 
 
6.4: Results. 
 
6.4.1: SCP-x and pro-SCP bind CD147 DNA in vitro 
 
The two isoforms of SCP-2 protein (pro-SCP and SCP-x) were generated and purified 
as described in the methodology. In order to confirm its purity and production the 
protein was run on western blot and stained with His antibody. A positive 15kDa band 
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(Fig.6.2A) was identified and provided proof that the protein had been successfully 
produced and purified. For SCP to initiate transcription it has to bind to the CD147 
promoter region. Just like in the study by Ko and Puglielli (Ko and Puglielli, 2007) I 
also used the electrophoretic mobility shift assay (EMSA) to determine the SCP-2 
binding of the CD147 DNA and to confirm that the generated SCP isoforms were also 
binding CD147 DNA. I used yeast extract protein (lane 2), SCP-x and pro-SCP (lanes 3 
and 4 respectively), CD147 protein (lane 5) and yeast extract protein plus CD147 (lane 
6) as my controls. Compared to yeast extract protein (lanes 2 and 5), SCP protein minus 
CD147 DNA (lanes 3 and 4) and CD147 protein (lane 5), results showed positive 
CD147 DNA binding  as evidenced by reduced mobility of SCP protein isoforms (lanes 
7 and 8) on the gel (Fig.6.2B). 
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Figure 6.2: Purified SCP-2 protein and elctrophoretic mobility shift assay of SCP 
protein. 
Purified SCP protein separated by SDS-PAGE gel eletrophoretic method (A). 
Electrophoretic mobility shift assay (EMSA) (B) showing SCP isoforms binding CD147 
DNA. Compared to yeast extract protein (lanes 2 and 5), SCP protein minus CD147 
DNA (lanes 3 and 4) and CD147 protein (lane 5), results show positive SCP protein 
binding (lanes 7 and 8) of CD147 DNA as evidenced by reduced mobility of the SCP 
protein bands with SCP-x showing strong binding (red arrow). 
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6.4.2: CD147 promoter is a GC-rich region requiring special PCR technique to 
amplify. 
 
CD147 promoter region was amplified in human genomic DNA by polymerase chain 
reaction (PCR) as described above. Although PCR amplification of DNA has previously 
been reported (Mullis and Faloona, 1987, Saiki et al., 1988, Huh et al., 2011, Kang et 
al., 2011, Ramana et al., 2011), amplification of the GC-rich sequences have not been 
easy because they are refractory to amplification due to the formation of secondary 
intermolecular structures reported (Varadaraj and Skinner, 1994, Schwientek et al., 
2011). CD147 promoter region, as a regulatory domain, is a GC-rich region (Fig.6.3) 
requiring a special PCR method to amplify (Jung et al., 2002, Deng et al., 2010, Jensen 
et al., 2010, Wei et al., 2010). Thus preliminary amplification of the region was 
performed using the slowdown PCR as described in (Frey et al., 2008) in order  to 
ascertain that the GC-rich region was successfully amplified (Fig 6.4). Results have 
shown that compared to negative control (master mix minus DNA, lane 1) the promoter 
region was successfully amplified in the PCR products from 6 human brain test samples 
(lanes 2 – 7). Having established that CD147 promoter can be successfully amplified in 
human genomic DNA, the region was amplified in 200 DNA samples (n=100, controls 
and AD cases respectively) from the AIBL study cohort with the resultant product sent 
to Melbourne for sequencing as described above. 
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(Chr19:571680) 
CAGCGAGACCACTTTACTTGTACGGAAGGGGGCTGCCTGCGTGGGATGCAA
TCTCCAGAGCACACGGGACAAAGGAAGGGAGCTTCTGTTCCTCTGTCCTTTC
CCTGTTGGCTGGGGTTGGACGCCCACAATCTAAGCTGATCCCGGTTGGCTAA
AACTTAAAACTTTTTTAAAATAGGGTAAACGCGCCACCTGCGAGGAAAGAA
GAAGGGGGTAAGGTTGATTGACAACTTTAGACCTGGAAGTTGAGTTTCTGA
AGAGGAACTTACTTGTCCCAACCAAATGGTGCACAGGACGTTTATACTAAG
AAATTATTCATTTTCTGAGATCCAGATTCAAGTGCCCTTTAAGTATTTTTATT
TGGGCGGAGGAGGTCACTTCCTCCCACCTAATTTATTAATACGTTCATATAT
ATATATATATATGTACATTTTTAAAGGCAGAGATGTGCGTCTCGCCATGTTG
CCGCGTCTGGTCTCGAGCTCCCGGGCTCAAGCGATCTTCCCGCCTCGACCTC
CCAAGGCTCTGGGAGTACAGACGTGAGCCACAGCGGCCGGCCCGTGTTTAA
CTCAGATAAAATCTGGGTAACACACTTTCAACGCTTCAACCCCCTCGGGCGC
ACCGCTCTGCGCTCATTGCAACTTTGAAAGCAGGAAGGAAGAAATGCGCAG
GCTCCAGCCGCGTCCCCGCAGGCCCCACTCCCGTTTCCTAGCAACGCCGGGT
CACGTGCGCCGCCGCCCGGATTCCGTAGCGTGAGCCTGCCGGAGCCGGCGC
GTACATGCGAGCGTGTGCGCGCGTGCGCAGGCGGGGCGACCGGCGTCCCCG
GCGCTCGCCCCGCCCCCGAGATGACGCCGTGCGTGCGCGCGCCCGGTCCGC
GCCTCCGCCGCTNTTTTATAGCGGCCGCGNGGCGGCGGCGGCAGCGGTTGG
AGGTTGTAGGACCGGCGAGGAATAGGAATCATGGCGGCTGCGCTGTTCGTG
CTGCTGGGATTCGCGCTGCTGGGCACCCACGGAGCCTCCGGGGCTGGTGAG
GAGCGGGTAGGGGGCGGGGGTGCGGTCCTGCAGGGGCCGGGAATGGAGGC
CGCGGTGCCGACCCGAAGCCGACGGGAGCCTGGGGCCTCGGCGCGGGGCG
GCCTGGGGTGCGAAAGGCCGGCCCCGGGGGCTTCCCGCGCCAGCATGGAGC
TTGGGGGTGAAGTCCCAGGGTTTGAGGGGGGACTAGAGGTTCCTCCCGGCG
CGGCCTGCCGGGCTCCCCCGGGCGCT (Chr19:572934) 
 
 
Figure 6.3: Sequence of the CD147 promoter region 
Promoter region showing the GC-rich cis-elements, NCBI annotated SNPs (in red), and 
the region where SCP binds to initiate CD147 transcription (underlined).  In this thesis a 
total of 709bp was sequenced using primers (blue italics) to determine known SNPs and 
ascertain the presence of novel SNPs. 
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Figure 6.4: Slowdown PCR amplification of the CD147 promoter region 
Amplification of 709bp PCR product from the CD147 promoter region. Compared to 
negative control (master mix minus DNA, lane 1), results indicate successful 
amplification of the CD147 GC-rich promoter in human genomic DNA PCR products 
from 6 human brain test samples (lanes 2 - 7) by slowdown PCR method. 
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6.4.3: CD147 promoter contains two novel SNPs not previously reported. 
 
The CD147 promoter region sequenced in this thesis contains 16 SNPs that have been 
previously reported in NCBI with varying minor allele frequencies. Analysis of 
sequencing data failed to observe any sequence variation at 9 of these sites (potentially 
monomorphic in the cohort studied), whilst the remaining 7 SNPs already reported in 
NCBI were successfully identified, these being: rs4919859, rs145461969, rs11551906, 
rs28915407, rs142683396, rs28915408, and rs2072307. In addition to the previously 
reported SNPs results from the current study have identified two new novel SNPs that 
have not been previously reported. A comparison of minor allele frequencies in the 
current study is made to those reported in European populations from NCBI in Table 
6.1. 
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Table 6.1: Comparison of minor allele frequencies reported in European 
populations from NCBI and in the current study 
SNP Position MAF – NCBI* MAF – Current Study 
rs4919859 chr19:572317 0.333, 0.350 0.385 
rs145461969 chr19:572550 NA, NA 0.0025 
rs000001(c.-61A>G)** chr19:572574 Not reported 0.0025 
rs000002 (37C>G)** chr19:572672 Not reported 0.0025 
rs11551906 chr19:572680 NA, NA 0.02 
rs28915407 chr19:572811 0.087, NA 0.02 
rs142683396 chr19:572823 NA, NA 0.002 
rs28915408 chr19:572860 0.022, NA 0.032 
rs2072307 chr19:572878 0.022, NA 0.102 
 
*European population (PGA_CEPH-PANEL, HapMap-CEU): NA, not available in 
given population. Not reported, SNP has not been previously reported in NCBI 
database. 
**Novel SNP 
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The first of these, an A to G transition located 61 base pairs upstream (-61A>G) of the 
transcription initiation site, was identified in a single heterozygous healthy control 
individual and is subsequently referred to in this thesis as rs0000001.  A second novel 
SNP, a C to G transversion located 37 base pairs downstream (37C>G) of the 
transcription initiation site, was identified in a single heterozygous AD individual and is 
subsequently referred to in this thesis as rs0000002.  These SNPs need to be 
investigated further to determine if they have any influence on the development and 
pathology of AD or other neurodegenerative diseases. The 9 SNPs identified with minor 
allele frequency (MAF) greater than 0 were determined via Haploview and are 
presented with a plot of the relative D’ levels between each marker below (Fig.6.5). 
After identifying the SNPs, I then wanted to know if any of them is associated with AD. 
Results of this analysis are presented in the sections below. 
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Figure 6.5: Linkage disequilibrium for CD147 Single Nucleotide Polymorphisms in 
the AIBL cohort sample.  
Each of the 9 SNPs identified with MAF greater than 0 are presented with a plot of the 
relative D’ levels between each marker below, as determined via Haploview. 
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6.4.4: CD147 promoter SNPs are not associated with AD. 
 
SCP-2 binding to CD147 promoter has been reported (Ko and Puglielli, 2007) .  
However genetic variations within this region may alter SCP-2 binding which in turn 
may lead to alteration in CD147 expression leading to increased AD risk and pathology. 
As such, ascertaining the frequency of known genetic variations as well as the discovery 
of novel genetic variations within this region would be of interest.  In the current study a 
sample of 100 AD and 100 healthy controls from the AIBL cohort were utilised. Allelic 
and haplotypic associations were analysed using  Haploview V4.2 software (Barrett et 
al., 2005) and genotype associations were analyzed using IBM SPSS® Statistics version 
19 as described in section 6.3 of this chapter. Results from these experiments have 
shown no allelic (Table 6.2), genotypic (Table 6.3) and haplotypic (Tables 6.4) 
association with AD. 
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         Table 6.2: Allelic Frequencies   
SNP   
(major/minor) 
Risk 
Allele 
CTRL 
MAF 
AD 
MAF 
chisq p-value 
rs4919859         
(G/C) - 0.385 0.385 0.0 1.0 
rs145461969     (G/T) G 0.005 0.000 1.003 0.3167 
rs0000001         
(A/G) A 0.005 0.000 1.003 0.3167 
rs0000002         
(C/G) G 0.000 0.005 1.003 0.3167 
rs11551906       
(A/G) G 0.015 0.025 0.51 0.4751 
rs28915407       (G/T) G 0.03 0.01 2.041 0.1531 
rs142683396     
(G/A) A 0.000 0.005 1.003 0.3167 
rs28915408       
(G/A) G 0.04 0.025 0.716 0.3976 
rs2072307         (T/C) T 0.11 0.095 0.245 0.6209 
 
SNPs and minor (MAF) allele frequencies in controls and AD patients.  P-values ( 
range: 0.3167 – 1.0) for the 9 SNPs were calculated using chi-squared (χ2) tests as 
implemented in Haploview and indicating no association with AD 
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Table 6.3: Genotype association    
SNP Genotype Controls AD Chiq p-value* 
rs4919859 
GG 39 38  
.089 
 
.957 GC 45 47 
CC 16 15 
rs145461969 
GG 99 100  
.316 
 
1.00 GT 1 0 
rs0000001 
AA 99 100  
.316 
 
1.0 AG 1 0 
rs0000002 
CC 100 99  
.316 
 
1.0 CG 0 1 
rs11551906 
AA 98 95  
3.713 
 
.156 AG 1 5 
GC 1 0 
rs28915407 
GG 94 98  
2.083 
 
.149 GT 6 2 
rs142683396 
GG 100 99  
1.005 
 
.316 GA 0 1 
rs28915408 
GG 92 95  
.740 
 
.390 GA 8 5 
rs2072307 
TT 80 82  
.387 
 
.824 TC 18 17 
CC 2 1 
 
Genotype associations of the 9 SNPs in controls and AD cases were analyzed using 
IBM SPSS® Statistics version 19. P-values (range: 0.149 – 1.0) were calculated using 
chi-squared (χ2) tests as implemented in Haploview and indicating no association with 
AD 
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        Table 6.4: Manual Haplotype Associations 
Haplotype Freq AD Freq Ctrl 
Freq 
chisq p-value 
GGACAGGGT 0.438 0.461,  
 
0.416 0.819 0.3654 
CGACAGGGT 0.378 0.375,  
 
0.380 0.01 0.922 
GGACAGGGC 0.102 0.094,  
 
0.109 0.245 0.6204 
 
Haplotypic frequencies in health controls and AD patients and p-values (range: 0.3654 – 
0.922) calculated using chi-squared (χ2) tests as implemented in Haploview and 
indicating no association with AD. 
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6.4.5: CD147 promoter SNPs are not associated with Aβ, cholesterol and ApoE 
levels. 
 
Many potential risk factors for AD have been described which include, low levels of sex 
steroids (Pericak-Vance et al., 1991, Poirier et al., 1993, Strittmatter et al., 1993, 
Haskell et al., 1997, Lambert et al., 1998, Short et al., 2001), increased levels of 
gonadotropins (Smith et al., 1998, Bowen et al., 2000, Short et al., 2001), head injury, 
physical inactivity, stroke, diabetes, hypertension, and hypercholesterolemia. In addition 
age and possession of the ε4 allele of the Apolipoprotein E gene (APOE ε4) are some of 
the major risk factors for most of the population (Martins et al., 2006). Thus the current 
study investigated associations between the CD147 promoter SNPs and plasma Aβ40, 
Aβ42, cholesterol and ApoE levels. No association analysis of the new identified SNPs 
was done as they appear in only 1 health control and AD case respectively. However an 
association analysis of the other SNPs showed that these SNPs are not associated with 
Aβ40, Aβ42, cholesterol and ApoE levels (Table 6.5). 
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Table 6.5: SNPs association with Aβ, cholesterol and ApoE Levels 
SNP Genotype n Mean Std. Dev p-value 
Aβ40 
rs4919859 
GG 
GC 
CC 
77 
92 
31 
114.3451 
112.3340 
111.8019 
79.03767 
70.09841 
77.30048 
.982 
rs11551906 AA AG 
193 
6 
114.0789 
91.2300 
78.27700 
29.46459 .477 
rs28915407 GG GT 
192 
8 
113.2423 
107.8288 
78.37106 
47.42792 .847 
rs28915408 GG GA 
187 
13 
109.4164 
164.9454 
71.81514 
126.60262 .143 
rs2072307 
TT 
TC 
CC 
162 
35 
3 
109.4405 
126.8474 
145.3800 
73.89005 
90.85050 
77.30048 
.371 
Aβ42 
rs4919859  
GG 
GC 
CC 
77 
92 
31 
38.4395 
37.9095 
34.0903 
18.64391 
17.18257 
22.06179 
.526 
rs11551906  AA AG 
193 
6 
37.7050 
33.4433 
18.80707 
6.20001 .581 
rs28915407  GG GT 
192 
8 
37.4291 
39.7400 
18.84739 
7.93448 .731 
rs28915408  GG GA 
187 
13 
37.0856 
43.7931 
17.76225 
27.53798 .208 
rs2072307  
TT 
TC 
CC 
162 
35 
3 
36.3743 
42.2791 
43.9700 
17.55477 
22.26998 
18.99478 
.193 
Cholesterol 
rs4919859  
GG 
GC 
CC 
77 
91 
31 
5.3727 
5.4967 
5.2258 
1.05539 
1.02604 
1.12041 
.437 
rs11551906  AA AG 
192 
6 
5.4156 
4.8167 
1.05531 
0.41673 .168 
rs28915407  GG GT 
191 
8 
5.4230 
5.0125 
1.06252 
0.66641 .280 
rs28915408  GG GA 
186 
13 
5.3995 
5.5077 
1.06418 
0.87793 .721 
rs2072307  
TT 
TC 
CC 
161 
35 
3 
5.4379 
5.2686 
5.3333 
1.04319 
1.08784 
1.36137 
.686 
ApoE 
rs4919859  
GG 
GC 
CC 
77 
87 
30 
14.5928 
15.1154 
15.4358 
2.92177 
2.52136 
2.20916 
.255 
rs11551906  AA AG 
187 
6 
14.9600 
14.8298 
2.64031 
3.44908 .906 
rs28915407  GG GT 
186 
8 
14.9972 
14.0350 
2.65860 
2.43816 .316 
rs28915408  GG GA 
181 
13 
14.9955 
14.4298 
2.68765 
2.08612 .459 
rs2072307  
TT 
TC 
CC 
156 
35 
3 
14.8645 
15.2719 
14.9576 
2.56049 
3.11273 
0.93808 
.532 
Association analysis CD147 SNPs (n>1 in ≥2 genotypes) with Aβ40, Aβ42, cholesterol 
and ApoE levels were undertaken using χ2 analysis, whilst continuous variables were 
analyzed using IBM SPSS® Statistics version 19 with either the Student’s T-test or One 
Way ANOVA, where appropriate. P-values (range: 0.143 – 0.982) showing no 
association of the SNPs with Aβ40, Aβ42, cholesterol and ApoE levels 
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6.4.5: CD147 promoter SNP rs11551906 is associated with AD pathology.  
 
Imaging techniques using radio labelled positron emission tomography (PET) tracers 
that bind to Aβ peptides in amyloid plaques are currently being used to assess relative 
brain amyloid plaque pathology in AD (Lee et al., 2003a, Mistur et al., 2009, Mosconi 
et al., 2009, Jagust et al., 2010, Kadir et al., 2011). The AIBL study performed PET 
scans on a subset of the study participants and the current study did a genotype 
association analysis of the CD147 promoter SNPs with the standard uptake value ratios 
(SUVR) of the radio labelled tracer (Pittsburgh Compound B, PiB) used in the AIBL 
study. Results have shown a positive association with rs11551906 SNP (*p<0.05) 
(Table 6.6) indicating that presence of the minor allele of this SNP is associated with 
increase cerebral amyloid burden.  
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Table 6.6: Genotype association with SUVR 
SNP GENOTYPE n MEAN SD p-value 
rs11551906 
AA 40 1.7850 .56186 
.010* 
AG 2 2.1300 .08485 
rs28915407 
GG 39 1.8364 .55135 
.141 
GT 3 1.3467 .40377 
rs28915408 
GG 39 1.7936 .54587 
.745 
GA 3 1.9033 .77106 
 
Genotypic association of the 3 SNPs with SUVR in AD patients were analyzed using 
IBM SPSS® Statistics version 19. P-values (range: 0.010 – 0.745) p-values indicating a 
significant association of rs11551906 with SUVR (*p<0.05) 
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6.5: Summary of results 
 
Overall the results presented in this chapter show that SCP-2 binds CD147 DNA and 
based on previous studies this is likely to be within the promoter region, specifically in 
the region -392 to -95 as identified by Ko and Puglielli (Ko and Puglielli, 2007). 
Sequencing of a 709bp fragment covering this region identified 2 novel SNPs within the 
CD147 promoter that have not been reported before in NCBI. There was neither an 
association between the 9 identified polymorphic SNPs and AD risk or with changes in 
plasma cholesterol, Aβ40, Aβ42 and ApoE levels. However, a significant association 
between the rs11551906 minor allele and elevated cerebral amyloid burden, as 
determined by PiB-PET SUVR, (*p<0.05) was observed.  
 
6.6: Discussion 
6.6.1: SNPs association with AD 
 
Genetic mutations or polymorphisms linked to AD development and severity (Prince et 
al., 2003, Greeve et al., 2004, Frey et al., 2008, Ringman et al., 2010) and AD risk 
factors such as sex steroids (Pericak-Vance et al., 1991, Poirier et al., 1993, Strittmatter 
et al., 1993, Haskell et al., 1997, Lambert et al., 1998, Short et al., 2001)), 
gonadotrophins (Smith et al., 1998, Bowen et al., 2000, Short et al., 2001) and 
possession of the APOE ε4 allele (Martins et al., 2006) have been reported. The current 
study investigated SNPs in the CD147 promoter region, where SCP-2 binds to stimulate 
CD147 transcription and determined their association with AD. Allelic (Table 6.2), 
genotypic (Tables 6.3) and Haplotypic (Table 6.4), association analysis were 
undertaken and showed no association with AD. These findings cannot completely rule 
out the possible association of the identified SNPs with AD as only a small subset of 
samples were utilised for sequencing experiments.  Due to the small sample size the 
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possibility remains that there was not sufficient power to identify any associations.  
Further, as the focus of this study was on the promoter region of CD147 it cannot be 
ruled out that an untyped variant downstream from the sequenced region, within the 
coding region of the gene, may impart risk for AD. Previous studies have associated 
differences in CD147 expression with Aβ levels (Zhou et al., 2005, Vetrivel et al., 
2008b) and deficits in memory and behaviour functions (Naruhashi et al., 1997) where a 
number of behavioural tasks were carried out in mice lacking CD147. Compared to 
wild-type and heterogeneous (Basigin +/-) mice, the CD147 null mice (Basigin -/-) 
performed worse in memory and learning tasks (e.g. Y-maze and water finding tasks). 
In addition CD147 null mice were less sensitive to light, pain, and induced electric 
shock, reflecting the importance of CD147 in sensory functions.  As such, genetic 
variation within the CD147 promoter may likewise be associated with AD biomarkers 
and abnormal limbic system function. 
 
To address the above question the current study investigated any associations between 
these SNPs and plasma Aβ40, Aβ42, cholesterol and ApoE levels.  Due to previous 
links between CD147 expression and the aforementioned biomarkers it was anticipated 
that some association with these parameters linked to AD pathology would be observed. 
However, there were no associations revealed for the identified SNPs with levels of 
Aβ40, Aβ42, cholesterol and ApoE in plasma (Table 6.4) despite these being amongst 
the most potent reported AD risk factors (Martins et al., 2006) (Jarvik et al., 1995, 
Igbavboa et al., 1996). The findings may suggest that genetic variations in the CD147 
promoter do not play a role in AD pathology as seen in those in the APP and ApoE 
genes. However, it may also be hypothesised that CD147 promoter mutations play a 
role in AD pathology only when SCP-2 binds the promoter region that may result in 
increased Aβ generation as reported by Ko and Puglielli (Ko and Puglielli, 2007). 
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Further, this study did not investigate any proximal or distal regulatory elements, which 
may also impact on CD147 expression levels and in turn impact upon regulation of Aβ 
generation. However these hypothesises need to be proved further in future studies. 
 
6.6.2: SUVR is associated with rs11551906  
 
The uses of PET scans that utilise tracers that bind to Aβ peptides in amyloid plaques to 
assess relative brain amyloid plaque pathology in AD have been reported (Lee et al., 
2003a, Mistur et al., 2009, Mosconi et al., 2009, Jagust et al., 2010, Kadir et al., 2011). 
The AIBL study also used a similar technique on the study subjects as reported in the 
previous studies. A subset of 42 individuals from the 200 AIBL subjects sequenced in 
this thesis underwent PiB-PET scans and genotype association analysis of SNPs within 
the sequenced CD147 promoter region with PiB-PET derived SUVR. Only 3 SNPs 
from those identified could be analysed due to the frequency of identified genotypes. 
Out of the 3 SNPs only 1 (rs11551906) is associated with SUVR (Table 6.5) indicating 
its association with increase cerebral amyloid burden.  
 
CD147 knock down studies reported increased Aβ levels (Zhou et al., 2005, Vetrivel et 
al., 2008b) and that SCP-2 binding of CD147 promoter facilitates CD147 transcription 
(Ko and Puglielli, 2007). Expression of pro-SCP-2 has been shown to abolish activity of 
12.9 kDa SCP-2 and inhibit CD147 transcription, resulting in an increase in Aβ 
production (Ko and Puglielli, 2007).  Furthermore the current study has shown that 
rs11551906 is associated with SUVR. Taken together these findings may suggest that 
this SNP interferes with SCP-2 binding to the CD147 promoter or facilitates pro-SCP-2 
expression which in turn shuts down CD147 transcription resulting in increased Aβ 
generation. This may explain why this SNP is associated with SUVR. It is not known if 
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the other SNPs would also show an association if a larger cohort is used, thus a follow-
up study is required to better answer this question. 
 
6.6.3: Novel SNPs within the CD147 promoter 
 
In addition to the already NCBI reported SNPs (Table 6.1), the main aim for 
sequencing the CD147 promoter region described in this thesis was to identify novel 
SNPs that may be associated with AD development and pathology. At the time of 
writing the NCBI database identifies 16 SNPs within the region sequenced and only one 
of these (rs28915404 an -/G deletion-insertion variation) located within the putative 
SCP binding region. However, no additional SNPs were identified in the region where 
SCP-2 binds to initiate CD147 transcription that later influences Aβ levels in vivo. 
Interestingly though was the discovery of the 2 novel SNPs within the promoter region 
but outside the region where SCP-2 binds. These were an A to G transition located 61 
base pairs upstream (-61A>G) of the transcription initiation site and a C to G 
transversion located 37 base pairs downstream (37C>G) of the transcription initiation 
site. These novel genetic variations were identified in a single heterozygous healthy 
control individual and a single heterozygous AD individual, respectively.  It is not 
known if -61A>G SNP may provide some protection whereas 37C>G SNP may be a 
risk factor for AD, however a comprehensive study using a larger and well 
characterized sample cohort has to be undertaken to prove this hypothesis.  
 
 Taken together that GC-rich sequences are difficult to amplify (Varadaraj and Skinner, 
1994, Schwientek et al., 2011) and that CD147 promoter is a GC-rich region (Fig.6.3) 
requiring special PCR method to amplify (Jung et al., 2002, Deng et al., 2010, Jensen et 
al., 2010, Wei et al., 2010), warrants a robust sequencing of the entire CD147 promoter 
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to identify other novel SNPs that have not been identified yet. This will also further help 
in the investigation of the roles such SNPs may play in disease pathology including the 
2 currently reported in this thesis despite being identified in one health control and AD 
patient only. 
 
6.7: Conclusion 
 
I report for the first time that the CD147 promoter region sequenced in this study 
contains 2 novel SNPs that have not been reported before in NCBI. I also report for the 
first time that out of the 9 SNPs identified in this region only one (rs11551906) is 
associated with AD biomarker SUVR.  
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CHAPTER 7 
General discussion 
7.1: The link between CD147 protein and AD pathology. 
 
 There are several theories regarding AD development and pathogenesis with the 
amyloid cascade hypothesis being the most widely accepted and studied one. The 
amyloid cascade hypothesis proposes that the aggregation and deposition of β-amyloid 
(Aβ) is the initial pathological event in AD, which leads to the formation of amyloid 
plaques and then to NFT, neuronal cell death, and ultimately dementia. However, the 
reasons for Aβ aggregation and additional factor(s) involved in the amyloid cascade are 
not properly understood and need to be established. Oxidative stress, inflammatory 
processes, reduced Aβ clearance, dys-regulated lipid metabolism, reduced oxygen levels 
and hormonal changes have all been suggested, either directly or indirectly, to initiate or 
to promote the initial stages of Aβ aggregation. For example, age-related losses of 
oestrogen in women and testosterone in men are risk factors for AD, possibly due to 
hormone influences on Aβ production and degradation, neuron viability, and oestrogen 
signalling mechanisms (Li et al., 2000b, Pike et al., 2009). 
   
Possibly the majority of studies on factors that may influence risk of AD have emanated 
from the early genetic studies which found links between AD and possession of 
apolipoprotein E4 alleles (Holtzman et al., 2012). This was soon followed by studies 
that found links between cardiovascular diseases and AD (Sahathevan et al., 2012). 
There is now also substantial evidence that conditions such as stroke, hypertension, 
diabetes and lipid disorders are independently associated with an increased risk of AD 
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and vascular cognitive impairment. As part of these studies, cholesterol and diet have 
been extensively studied. Due to this research, elevated cholesterol levels and high fat 
diets have now been associated with increased Aβ production and have been classified 
as AD risk factors. 
  
The brain represents only about 2 percent of your body weight, but actually has about 
20 percent of your body's cholesterol. Cholesterol is important for normal brain function 
- it is important for synaptic function and is also an essential component of cell 
membranes in the brain. Defects in cholesterol metabolism are associated with serious 
neurological and mental dysfunctions (Tint et al., 1994). Alterations in general 
cholesterol metabolism have been implicated in AD pathogenesis (Jarvik et al., 1995, 
Igbavboa et al., 1996) as evidenced by reported higher plasma cholesterol levels in 
people who subsequently develop AD compared to people who don’t (Notkola et al., 
1998). Some early longitudinal studies of cholesterol-reducing drugs (statins) found that 
statins such as lovastatin or simvastatin could reduce the risk of developing AD (Miida 
et al., 2005). 
 
By competitive inhibition of hydroxymethyl co-enzyme A-reductase, statins reduce the 
production of cholesterol and isoprenoid intermediates including geranyl and farnesyl 
pyrophosphate. In vitro studies also found that statin-induced depletion of cellular 
cholesterol reduces Aβ production and secretion (Simons et al., 1998a), whereas 
cholesterol supplementation results in increased production of Aβ40/42, suggesting that 
intracellular cholesterol levels can influence APP processing. The reason for this may 
be that membrane cholesterol content influences the activity of γ-secretase, the APP 
cleavage enzyme found in cholesterol rich microdomains of the cell membrane, and that 
is unusual due to its intra-membrane cleavage site.  More recent reviews of the clinical 
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statin data, however, have found that statins have no effect on incidence of AD 
(McGuinness et al., 2009), or alternatively that the results are just too variable to make 
any conclusions (Shepardson et al., 2011a, b). The variability in the results of statin 
studies has been put down to differences in the blood-brain barrier permeability among 
statins, the stage of AD at which statins were administered, and/or drug pleiotropic 
metabolic effects. Nevertheless, the interest in cholesterol metabolism and the effect of 
cholesterol on Aβ production has prompted much research into lipids and AD. From 
this research, a high fat diet has now also been implicated in the aetiology and 
development of AD as evidenced by the findings that AD incidence is higher in 
countries with high-fat/high-calorie diets (Kalmijn et al., 1997), and that the risks for 
cardiovascular diseases such as elevated blood cholesterol and triacylglycerol 
(triglyceride) levels, obesity, diabetes, lack of exercise and hypertension are also risks 
for developing AD (Fillit et al., 2008).   
 
Other interesting studies have reported changes in Aβ peptide generation due to cellular 
CD147 alterations, an indication of a possible link between CD147 and Aβ. CD147 is a 
member of the immunoglobulin superfamily, it was first identified as a tumour surface 
protein capable of inducing matrix metalloproteinase (MMP) expression in fibroblasts, 
and thus it is also known as EMMPRIN (extracellular matrix metalloproteinase 
inducer). CD147 is a transmembrane glycoprotein, and increased expression of CD147 
occurs in many tumours, however the protein is also critical in foetal development and 
retinal function and it has been shown to play a role in thymic T cell development, as 
well as many neurological processes ranging from the development of the nervous 
system to involvement in spatial learning (Iacono et al., 2007). 
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Cancer studies of CD147-null animals found that a lack of CD147 leads to a dramatic 
reduction in accumulation of the monocarboxylate (lactate) transporters (MCT)-1 and -4 
proteins, which indicated a role for CD147 in targeting these transporters to the plasma 
membrane. Continued association of these proteins is required for function, and high 
levels of these proteins are found on aggressive tumour cells, both of these 
characteristics are potentially necessary to meet the high glycolytic needs of 
transformed (cancer) cells (Iacono et al., 2007).  Other studies more relevant to AD 
have reported that CD147 expression levels influence Aβ generation and that a lack of 
CD147 can cause cognition defects similar to those seen in AD (Zhu et al., 2006, Zhou 
et al., 2007).  CD147 has been shown to be a regulatory co-factor for the γ-secretase 
complex and that depletion of CD147 from the γ-secretase complex through RNA 
interference in cell lines results in an increase in Aβ production (Zhou et al., 2005). 
 
These results suggested that CD147 levels could modulate Aβ generation. However, 
other studies have found that the levels and localization of CD147 in fibroblasts, as well 
as the postnatal expression and distribution of CD147 in the brain, are distinct from 
those of integral γ-secretase subunits. It has also been found that membranes isolated 
from CD147-depleted cells fail to elevate Aβ production in in vitro γ-secretase assays 
(Vetrivel et al., 2008). Instead, Vetrivel et al. found that CD147’s influence on Aβ 
levels was more likely due to extracellular degradation by matrix metalloproteinases 
(MMPs), the levels of which have been previously reported to be stimulated by CD147 
(Vetrivel et al., 2008b). From other studies of γ-secretase, it appears only a small 
fraction of the cellular pool of CD147 or p23 (also known as TMP21, involved in 
vesicular trafficking between the ER and Golgi) remains complexed with γ-secretase at 
steady state, and the precise mechanisms by which these proteins modulate γ-secretase 
activity remain obscure. 
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A major role for CD147 in the brain is supported by studies that have demonstrated 
neurological abnormalities such as spatial learning and memory deficits in CD147 null 
mice (Naruhashi et al., 1997, Higgins and Jacobsen, 2003, Richardson et al., 2003). 
However, there is still little literature on CD147 effects on neuronal health and Aβ 
production and/or clearance, whereas many studies have been carried out to establish its 
involvement in cancer metastasis.  
 
The recent CD147 studies that have attracted the attention of researchers in the AD field 
are those which have looked into the regulation of CD147 as a potential strategy to 
reduce the risk of AD via the modulation of γ-secretase activity, or via the modulation 
of extracellular enzymes (possibly MMPs) that can degrade extracellular Aβ (Zhou et 
al., 2007, Vetrivel et al., 2008b). In addition to the siRNA CD147 knock down studies 
in transgenic mice which have shown CD147 reduction causes a dose-dependent 
increase in Aβ production (Zhou et al., 2005), CD147’s involvement in AD pathology is 
also supported by studies which have shown increased levels of the protein in the 
frontal cortex of AD affected individuals (Nahalkova et al., 2009, 2010).  
 
The current study has attempted to characterise further the ways in which CD147 may 
contribute to AD development and pathogenesis, and the results of these studies are 
outlined in chapters 3 – 6 of this thesis. In summary CD147 protein levels were 
measured in rat primary neuronal cultures in the presence and/or absence of endogenous 
cholesterol and Aβ42 peptide, whilst CD147 neuronal protection against oxidative stress 
and Aβ toxicity was also investigated, as reported in chapter 3. In addition to these in 
vitro experiments, the current study has also measured CD147 levels in brain tissues 
from APPswe transgenic mice fed on normal chow or a high fat/high cholesterol diet to 
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investigate the impact of diet on CD147 protein expression. The findings of these 
studies are reported in chapter 4. CD147 levels in human brains from control, frontal 
temporal dementia, Lewy body disease, and Alzheimer’s disease cases were measured 
to characterise any differences in CD147 levels between aged control brains and brains 
with the various neurodegenerative disorders. The findings of these experiments are 
reported in chapter 5. In chapter 6, sequencing studies were carried out to investigate 
known and any novel polymorphisms in the CD147 gene promoter region, which may 
also contribute to the development and/or pathology of AD. The findings from all these 
experiments listed are discussed in detail below. 
 
7.2: Cholesterol and Aβ42 loading increases CD147 protein expression in vitro  
 
Brain cholesterol can be produced by glial cells, although in adult brains, most brain 
cholesterol is believed to be recycled. Neurons, which are especially enriched with 
cholesterol, are believed to obtain their cholesterol by uptake of apoE/cholesterol 
complexes via receptors of the LDLR family.  Neurological and mental dysfunctions 
due to defects in cholesterol metabolism have been reported (Tint et al., 1994). There is 
now significant in vitro evidence to indicate a role of cholesterol in AD pathology and 
recent clinical findings also support the notion that progressive deterioration of 
cholesterol homeostasis is a central player in AD pathophysiology. Firstly, 
polymorphisms in several proteins and enzymes involved in cholesterol or lipoprotein 
transport and metabolism have been linked to the risk of AD. Secondly, enzymatic 
production of Aβ is affected by membrane cholesterol levels, thought to be due to 
effects on γ-secretase. However, studies that have led to this conclusion have often been 
studies of statin effects, and more recent studies have suggested that due to the high 
number of pleiotropic effects of statins, novel molecular mechanisms that account for 
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the beneficial effect of statins on AD might be discovered in the future.  Thirdly, 
cholesterol has been shown to affect APP maturation (Galbete et al., 2000a), and 
alterations to cholesterol metabolism are likely to affect this step in APP metabolism.  
 
To maintain cholesterol homeostasis in the brain, some excretion occurs following 
enzymatic conversion of cholesterol to the oxysterol 24-OH cholesterol. Another 
oxysterol found in the brain is 27-OH cholesterol, although this is believed to derive 
mostly from the circulation. The brain levels of these oxysterols influence expression of 
many enzymes involved in lipid homeostasis in the brain such as the sterol regulatory 
element binding proteins (SERBP), apoE (via the liver X receptor) and ABCA1 and 
ABCG1 (ATP binding cassette transporters, cholesterol efflux transporters) (Martins et 
al., 2009). CSF 24-OH cholesterol has been found to be higher in AD individuals, and 
cholesterol efflux appears to be elevated and related to the increased risk for AD 
(Papassotiropoulos et al., 2002, Koldamova et al., 2003). 
 
In chapter 3 of this thesis the studies demonstrate that cholesterol and Aβ42 loading in 
rat primary cortical neuronal cultures altered CD147 and FL-APP expression levels. In 
primary cultures of rat neurons, cholesterol loading increased CD147 protein levels 
(Fig.3.1) and reduced FL-APP protein levels (Fig. 3.2). These findings suggest that 
CD147 protein expression can increase under conditions of hypercholesterolemia. It is 
possible that a similar scenario happens in human brains in relation to AD 
development/pathogenesis. Further investigations are required to establish the detailed 
mechanism(s) through which cholesterol exerts its influence on CD147 protein 
expression levels at the cellular level.   
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In order to determine the cause of the higher CD147 expression, cell viability was 
investigated by measuring LDH release into the culture supernatants. A significant 
increase in LDH release (Fig. 3.3) was found, indicating that the cholesterol loading 
caused stress to the neuronal cultures. It is therefore likely that cellular stress was 
responsible for the observed increased CD147 expression. Our findings are consistent 
with findings from previous studies that have reported that protein production can be 
affected in cells undergoing environmental stress (Yao and Tabas, 2001, Matsuda et al., 
2002, Nilsson and Sunnerhagen, 2011).  
The results in this chapter have also shown a reduction in FL-APP levels in response to 
cholesterol loading, at high concentrations of cholesterol. In a study by Galbete and 
colleagues (Galbete et al., 2000b), it was shown that increased cholesterol levels cause a 
decrease in the secretion of the α-secretase-cleaved form of soluble APP by interfering 
with glycosylation in the protein maturation pathway. It was concluded that although 
APP was probably being inserted in the membrane, a proportion was not being 
glycosylated, and was not being cleaved by α-secretase (Galbete et al., 2000b). At much 
higher concentrations of cholesterol, cellular toxicity is likely to have reduced APP 
production in the cells, which is what we have observed. The findings suggest that 
increased cholesterol levels can affect APP production and maturation, and the other 
results of this section of chapter 3 shows that cholesterol loading can induce cell 
oxidative stress in rat primary cortical neuronal cultures as evidenced by the elevated 
LDH release, and result in the over-expression of CD147 protein. The observed 
increased CD147 protein levels in the presence of increased cholesterol loading are 
most likely due to cell stress induced by exogenous cholesterol. These findings support 
the notion that CD147 is a marker of inflammation. In this case it could be hypothesized 
that increased cholesterol levels, which in turn activated the apoptotic pathway, 
triggered the inflammatory process.  
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7.3: Aβ42 induced oxidative stress increases CD147 protein expression in vitro  
 
As mentioned previously, CD147 levels have been shown to influence levels of Aβ, 
either by modulating γ-secretase activity, or by stimulating the production of the MMPs, 
which have been shown to degrade Aβ. CD147 has also been shown to protect neuronal 
cells against oxidative stress and injury (Boulos et al., 2007),  and the Aβ42 addition 
experiments in chapter 3 were designed to provide further evidence that oxidative stress 
leads to increased CD147 protein production.  As can be seen from the results, there 
was a significant increase in CD147 expression (Fig.3.6, chapter 3) and significantly 
reduced FL-APP (Fig.3.7 chapter 3) levels in the neuronal cells following exposure to 
high extracellular levels of Aβ42 peptide. LDH release (Fig.3.5, chapter 3) also 
increased in the neuronal cultures treated with Aβ42, indicating cellular oxidative stress 
was being induced by the peptides. These experiments involved the addition of high 
concentrations of Aβ42, and the LDH release results indicate that cellular toxicity 
occurs at even the lowest Aβ42 level used (1 µM, Fig. 3.5). The FL-APP bands on the 
Western blot suggest that APP maturation is affected at the lower Aβ42 concentrations, 
and that FL-APP production is significantly reduced at higher levels of Aβ42. The 
effects at the higher levels of Aβ42 (~ 5 – 15 µM) are most likely due to cytotoxicity 
(Fig. 3.7), as LDH levels were 4  - 5 fold above control (untreated) levels at these Aβ42 
concentrations.  The levels of CD147 did not show any significant change till higher 
concentrations were utilised, at which point the increase in CD147 protein levels was 
highly significant. Other studies have provided evidence that CD147 is a regulatory 
component of the γ-secretase complex (Zhou et al. 2005, 2007), by showing that 
depletion of CD147 from the γ-secretase complex through RNA interference in cell 
lines results in an increase in Aβ production without affecting expression levels of the 
other γ-secretase components. However, as follow-up studies have indicated, instead of 
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regulating Aβ production, CD147 may play a role in its degradation and clearance 
(Vetrivel et al., 2008b), it may be that the high Aβ concentrations have induced an 
increase in CD147 production, in an effort to remove the Aβ and reduce the oxidative 
stress. Nevertheless, the Aβ42 concentrations that appear to be required to induce the 
increase in CD147 (5-15 µM) are not physiologically relevant, thus the increase in 
CD147 may be simply due to cytotoxicity. It also needs to be remembered that the 
CD147 neuronal protection may require the presence of cyclophilin A (CyPA) as 
reported by Boulous et al (2007).  
 
The discovery that CD147 is a signalling receptor for CyPA has provided a novel 
function for CD147 (Yurchenko et al., 2002). Activation of the CD147 receptor by 
CyPA has been shown to stimulate the phosphorylation of ERK1/2, which activates the 
anti-apoptotic proteins Bcl-2 (Riccio et al., 1999) and Bag-1 (Perkins et al., 2003) and 
phosphorylation-mediated inactivation of pro-apoptotic proteins such as Bim (Biswas 
and Greene, 2002) and Bad (Bonni et al., 1999, Zhu et al., 2002).  These downstream 
pro-survival signalling events may be one mechanism through which CyPA/CD147 
interaction protects neurons from toxic insults. To investigate the involvement of CyPA 
in protection against Aβ42, a different in vitro assay system was devised, as discussed 
in the next section.  
 
7.4: Adenoviral mediated CD147 over expression protects neuronal cell against 
Aβ42 induced oxidative stress only in the presence of CyPA in vitro 
 
Researchers have studied the effect of reducing CD147 levels – for example the RNAi 
in vitro studies mentioned in the previous section and in vivo studies which have 
reported neurological abnormalities such as spatial learning deficits and memory 
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deficits in CD147 null mice (neurological problems that also occur in mouse models of 
AD) (Naruhashi et al., 1997, Higgins and Jacobsen, 2003, Richardson et al., 2003). 
Other in vitro studies have shown that CD147 is a component of the γ-secretase 
complex and that depletion of CD147 results in elevated Aβ levels (Zhou et al., 2005, 
2007), possibly due to effects on the γ-secretase complex. However other studies which 
have also shown that depletion of CD147 increases extracellular Aβ levels, found that 
the levels and localisation of CD147 in fibroblasts, as well as the postnatal expression 
and distribution of CD147 in the brain, are distinct from those of integral γ-secretase 
subunits (Vetrivel et al., 2008b). 
 
In other experiments, CyPA-CD147 protein interaction has been reported to protect 
neurons in vitro from oxidative stress (induced by cumene hydroperoxide) and ischemia 
(induced by oxygen glucose deprivation) through the ERK1/2 pathways (Boulos et al., 
2007). Oxidative stress can be induced by elevated Aβ levels and is thought to play a 
role in AD pathogenesis. It may be that CyPA-CD147 protein interaction may reduce 
Aβ-induced oxidative stress, thus protecting cells. This provides another reason for low 
levels of CD147 being detrimental to neuronal health, and suggests that inducing higher 
levels of CD147 may protect against AD-related neuropathology. Other studies which 
suggest higher levels of CD147 may be advantageous are those which have shown that 
CD147 is capable of inducing matrix metalloproteases (MMPs), enzymes capable of 
degrading Aβ peptides.   
 
In order to characterise further the possible protective effect of CD147 against oxidative 
stress, CD147 protein was over-expressed using recombinant adenoviruses in vitro. Rat 
primary neuronal cultures and SH-SY5Y human neuroblastoma cultures were 
transduced with recombinant adenoviruses (AdRSV-Empty as a control and AdRSV-
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CD147) to over-express CD147 protein.  Cells were exposed to Aβ42, with or without 
prior exposure to CyPA. The purpose of these studies was to examine the effect of 
increased levels of CD147, as well as the possible involvement of CyPA, on neuronal 
protection against Aβ42-induced oxidative stress.  
 
In the first stage of this work, it was shown that CD147 protein was successfully over-
expressed in rat primary (Fig.3.9) and SH-SY5Y neuronal (Fig.3.12) cultures. The 
results of the next stage of the experiments suggest that neuronal cultures exposed to 
CyPA prior to Aβ42 exposure are protected from Aβ42-induced oxidative stress 
(Fig.3.10 and Fig.3.11). The results also show that adenoviral mediated CD147 over-
expression alone does not achieve the protective effect seen when the protein is used in 
combination with CypA (Fig.3.11 and Fig.3.13). These results are consistent with those 
reported by Boulos et al. (Boulos et al., 2007) where it was shown that the 
CyPA/CD147 combination can protect neurons against oxidative stress and ischemia. 
Our results are also consistent with the notion that CD147 protein requires interaction 
with other proteins to achieve its cellular role. This is supported by a study which has 
reported that the functional effect of CD147 at the cellular level is integrin-dependent 
and requires the physical association of integrins with CD147 (Berditchevski et al., 
1997). It is interesting to note that CD147- associated α6β1 integrins bind Aβ peptides 
and initiate a signal transduction cascade in microglial cells (Bamberger et al., 2003). 
This is yet another association that may explain how CD147 protein may be involved in 
Aβ metabolism (Vetrivel et al., 2008b).  
 
In summary, the results presented in chapter 3 show that exposure to high cholesterol or 
high Aβ42 loading may induce CD147 protein expression and support the theory that 
these agents cause oxidative stress and can be neurotoxic, as evidenced by elevated 
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LDH release. The studies also support the hypothesis that the CD147/CyPA 
combination may be of major significance in the protection against oxidative stress. 
CD147 protein is quite abundant in regions of the brain affected early in AD, such as 
the CA1 region of the hippocampus. It could therefore be argued that CD147 is well-
placed to play a role in reducing AD pathology indirectly by reducing oxidative stress 
when in combination with CyPA protein.  
 
In order to characterise further the influence of cholesterol on CD147 protein expression 
reported above, the current study also investigated its levels in the AD model APPswe 
transgenic mice fed on either a normal chow or a high fat/ high cholesterol diet. Results 
from these in vivo experiments are discussed below. 
 
7.5: CD147 levels are not altered by high fat/high cholesterol diet in vivo 
 
Transgenic and non-transgenic animal models of AD fed high fat/ high cholesterol diets 
exhibit increased AD pathology – in particular increased Aβ deposition (Sparks et al., 
1994b, Refolo et al., 2000b, Shie et al., 2002). A comparatively longer duration on a 
high cholesterol diet leads to more severe accumulation of Aβ in rabbit brains (Sparks et 
al., 1994a). Furthermore, TgAPPswe mice fed a high fat/high cholesterol diet for 10 
months have increased Aβ deposition compared to standard chow-fed control mice, and 
the Aβ deposition levels correlate inversely with HDL levels (Shie et al., 2002).  Aβ40 
and Aβ42 appear to accumulate initially in the lipid rafts of aging AD model Tg2576 
mice brains (Kawarabayashi et al., 2004). Interestingly, after dimeric Aβ accumulates in 
the lipid rafts of the Tg2576 brain, apolipoprotein E (ApoE) and then phosphorylated 
tau accumulate, suggesting Aβ aggregation and accumulation is the initial pathology to 
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develop, and emphasizing the importance of trying to prevent Aβ accumulation 
(Kawarabayashi et al., 2004).   
 
In chapter 4, studies were carried out to assess the impact of a high cholesterol/high fat 
diet on CD147 expression in AD-model transgenic mice. Results presented in this 
chapter have first confirmed that a high fat/high cholesterol diet affects body weight. All 
experimental mice gained weight by the end of the study; however this was more 
evident in the APPswe mice fed a high fat/high cholesterol diet (Fig.4.2, chapter 4). It 
was also noted that males gained more body weight than females suggesting that the 
males were eating more than the females. Secondly, compared to controls, results also 
confirmed that a high cholesterol diet affects circulating plasma cholesterol in vivo as 
evidenced by a significant increase in circulating cholesterol levels in the mice fed the 
high cholesterol diet (Fig.4.3, chapter 4). Interestingly, female mice exhibited a 2-fold 
cholesterol increase compared to the males indicating a gender-based difference in 
cholesterol metabolism.  These results are consistent with the findings from previous 
studies that have also reported sex differences in cholesterol metabolism and 
homeostasis, where female mice have tended to show higher cholesterol levels and to 
deposit fat earlier than male mice (Costet et al., 1998). Other studies have reported that, 
following high cholesterol diets, male mice show reduced serum but increased hepatic 
cholesterol and that these changes are associated with changes in expression of 
cholesterol transporters (Hewitt et al., 2004). Similarly, sex based differences have also 
been reported in the severity of AD pathology in male and female AD transgenic mice 
models (Barrier et al., 2010, Carroll et al., 2010, Oikawa et al., 2010, Rosario et al., 
2010).  
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Lastly the results from this chapter have shown that mice fed on high fat/high 
cholesterol diet showed an increasing trend in brain CD147 protein levels in males with 
females expressing the reduced levels (Fig. 4.5, chapter 4) and that CD147 correlates 
with plasma cholesterol. Furthermore, although not significant, Aβ42/40 ratios showed 
increasing trends in mice on a high fat/high cholesterol diet. These findings are also 
consistent with other studies that have reported increased Aβ levels in conditions of 
high cholesterol (Sparks et al., 1994b, Refolo et al., 2000b, Shie et al., 2002) and 
depleted CD147 protein (Zhou et al., 2007) levels. Taken together these findings 
suggest that the increasing trend of CD147 in males may be due to higher intake of the 
diet as they also showed a higher weight gain. The females may have shown reduced 
levels due to not eating the diet more as evidenced by their body weight as compared to 
males on the same diet. It can therefore be concluded that high cholesterol diet has some 
influence on CD147 expression in vivo. To further understand the mechanism through 
which CD147 may be influenced by a high cholesterol diet, the current study also 
investigated the influence of this diet on SCP, a protein which stimulates CD147 
transcription. The outcomes of these in vivo experiments are discussed below. 
 
7.6: High fat/high cholesterol diet did not affect SCP-2 levels in vivo 
 
The importance of cholesterol homeostasis in brain function and its devastating effects 
when its metabolism and circulating levels are altered have been reported before, as 
discussed earlier in this thesis (Tint et al., 1994, Jarvik et al., 1995, Igbavboa et al., 
1996, Notkola et al., 1998). Most studies have investigated the association between a 
high fat/high cholesterol diet and AD in relation to Aβ generation and cognitive 
function. However there has been very little research done on the influence of diet on 
SCP-2 protein expression levels. Recently a study by Ko and Puglielli reported that 
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SCP-2 influences CD147 transcription (Ko and Puglielli, 2007). Since SCP-2 regulates 
cholesterol transport to the cell membrane and that increased cholesterol loading results 
in increased CD147 protein levels in vitro, the current study investigated the effects of a 
high fat/high cholesterol diet on SCP-2 protein levels in APPswe transgenic mice.  
 
SCP-2 levels were measured in APPswe mice fed a normal chow and a high fat/high 
cholesterol diet by RT-PCR. Results are presented in chapter 4 of this thesis (Fig. 4.8, 
chapter 4) and  show that SCP-2 was successfully amplified and that a high fat/high 
cholesterol diet did not alter SCP-2 mRNA levels (Fig. 4.9, chapter 4). These results are 
different from those reported by Kraemer et al., who showed that expression of SCP-2, 
but not SCP-x, was increased in conditions of increased cholesterol loading in muscle 
cells (Kraemer et al., 1995). The difference may be attributed to the type of cholesterol 
used, the tissue in which SCP-2 was measured and the type of experiment under which 
SCP-2 protein was determined. In the next stage of these studies, the effect of a high 
cholesterol/high fat on SCP-2 mRNA levels in the brain were examined in vivo, using 
the AD model APPswe mice.  Our results showed that a high cholesterol/high fat diet 
did not alter SCP-2 levels.  In the in vitro studies by Kraemer et al., (1995) cationized 
cholesterol was used. This could not be used in vivo as it influences cholesterol efflux 
from muscle tissues. These differences in the experimental design and methodology 
may explain the differences between the SCP-2 levels reported here and those reported 
by Kraemer et al. In addition, it is likely that SCP-2 mRNA/protein levels in different 
tissues are not the same, and due to the systemic changes to lipid metabolism that a high 
cholesterol diet is likely to bring about, a more comprehensive study of SCP-2 levels in 
several tissues including the brain will be needed to determine whether such differences 
exist. There is therefore a need for further study to establish conclusively whether 
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CD147 expression alters in muscle, brain, liver, or any other tissue in the presence of 
increasing cholesterol levels in the diet. 
 
In the next stage of this thesis, CD147 levels in the hippocampus and frontal cortex of 
health controls, Lewy Body dementia (LB), fronto-temporal dementia (FTD) and AD 
were investigated. In addition, possible associations of single nucleotide polymorphisms 
(SNPs) within the CD147 promoter region (where SCP-2 binds to initiate CD147 
transcription) and AD pathology were also investigated. Results from these experiments 
are discussed below.  
 
7.7: CD147 protein levels are not altered in Alzheimer’s disease (AD) 
 
Some evidence has been reported to indicate a role for CD147 in the pathogenesis of 
AD and that CD147 may have neuroprotective actions (Boulos et al., 2007). CD147 
protein has been detected in the hippocampus, especially in the CA1 region, a brain 
region that plays a key role in memory and learning and that is most vulnerable in AD 
(Hrabovszky et al., 2000, Rao, 2001). Recently, elevated CD147 levels have been 
reported in AD/dementia (Nahalkova et al., 2009, 2010). This is in addition to its 
possible influence on Aβ production via the γ-secretase enzyme (Zhou et al., 2005, 
2006, 2007) and the potential influence on extracellular Aβ degradation through MMP 
induction (Vetrivel et al., 2008b). Taken together these reports indicate that CD147 may 
play an important role in APP processing and/or Aβ clearance. However there is little 
information concerning CD147 distribution in the various cells of the brain, thus the 
current study measured CD147 expression levels in hippocampal and frontal cortex 
tissue from lewy body disease, frontal temporal dementia and Alzheimer’s disease cases 
and compared to age-matched control brain tissue.   
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The immunohistochemistry and Western blot analysis results presented in chapter 5 of 
this thesis show that CD147 protein is not elevated in AD (Fig.5.2 and 5.7). However, 
although not significant, there were trends towards higher CD147 levels observed in the 
hippocampus and frontal cortex of AD, FTD and LBD brains (Fig.5.2, 5.5.4 and 5.7). 
Increased Aβ peptide accumulation that leads to senile plaque deposition in Lewy body 
disease pathology and dementia (Gomperts et al., 2008, Armstrong and Cairns, 2009, 
Foster et al., 2010) has been reported before. The current study has also shown 
significant Aβ levels in AD and LBD which is consistent with findings from the 
previous studies mentioned above. The observed positive correlation between CD147 
and NCT and PS1 levels in hippocampus from AD brains and PS1 from LBD (Table 
5.1) is suggestive that CD147 interacts with the γ-secretase complex components. 
Although not significant, the trend towards higher levels of CD147, nicastrin and PS1 
levels and the significant increase of PEN2 levels observed in hippocampus from AD 
cases, with a trend towards an increase in CD147 levels in the frontal cortex of AD 
cases, is an indication of increased γ-secretase activity in dementia that is likely to lead 
to increased Aβ production and accumulation and provides further evidence that CD147 
is involved to some extent in AD pathogenesis.  
 
As discussed in chapter 5, findings of the current study agree with Nahalkova and 
colleagues who reported elevated CD147 levels in AD patients (Nahalkova et al., 2009, 
2010). However Nahalkova reported increased CD147 levels in the cortex while our 
findings have shown only trends towards an increase in CD147 levels in the 
hippocampus and frontal cortex. These differences may be due to the different sample 
sizes used. Nahalkova’s findings may have been compromised due to a small sample 
size (n=3) which did not give his study a required statistical power. The current findings 
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of CD147 expression in the AD are possibly more reliable due to the bigger sample size 
(AD, n=14) for Western blot and (n=17) for immunohistochemistry. For statistical 
analysis to be applied, this was a big enough sample size to give the study the required 
power. As a recent study has provided evidence that CD147 may not influence Aβ 
production by being an integral part of the γ-secretase complex (Vetrivel et al., 2008b), 
an increase in expression of CD147 in the hippocampus and frontal cortex in AD may 
be more the result of increased Aβ accumulation which initiates oxidative stress. Thus 
higher levels of CD147 may be a reaction to this oxidative stress, either in an attempt to 
reduce stress by inducing production of degradative enzymes (MMPs), or possibly as a 
result of cellular toxicity and death (apoptosis). Members of the monocarboxylate 
transporter (MCT) family of proteins, MCT1 and MCT4, require CD147 as a chaperone 
for their expression at the plasma membrane, CD147 has also been associated with 
integrin, γ-secretase, caveolin-1, and cyclophilins, as mentioned earlier in this thesis 
(Iacono et al., 2007). This variety of potential functional roles for CD147 makes it very 
difficult to come to simple conclusions concerning its likely role in AD. Many more 
studies will be required to understand the functions of CD147, the roles this protein has 
in lipid and cholesterol metabolism, and the involvement of any of these roles in AD.   
 
7.8: Incidence of known CD147 SNPs and discovery of 2 novel CD147 SNPs  
 
In order to examine other potential aspects of CD147 involvement in AD pathology, the 
current study also investigated the incidence of known SNPs and the possibility of novel 
SNPs in the promoter region of CD147. This was carried out on human genomic DNA 
samples obtained from both control and AD-affected cases. Results presented in chapter 
6 of this thesis have shown no association between SNPs in the sequenced region and 
AD. This further supports the notion that CD147 is not directly associated with AD 
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pathology but rather interacts with several proteins whose outcomes may be linked to 
factors associated to AD development and pathology. There does appear to be some 
association between possession of the rs11551906 minor allele with elevated cerebral 
amyloid burden, warranting further investigation in future studies.  Interestingly though 
was the discovery of the 2 novel SNPs within the promoter region, outside the region 
where SCP-2 binds. These were an A to G transition located 61 base pairs upstream (-
61A>G) of the transcription initiation site and a C to G transversion located 37 base 
pairs downstream (37C>G) of the transcription initiation site. These novel genetic 
variations were identified in a single heterozygous healthy control individual and a 
single heterozygous AD individual, respectively.  It is not known if -61A>G SNP may 
provide some protection whereas 37C>G SNP may be a risk factor for AD. However, a 
comprehensive study using a larger and well characterized sample cohort has to be 
undertaken to investigate this hypothesis.  
 
7.9: Future directions 
 
The work presented in this thesis has provided further evidence that CD147 is a 
multifunctional protein whose roles and expression may be influenced by other factors 
including cholesterol, oxidative stress and SCP-2. The relationships between CD147 
and these factors, as well as others such as MMPs, γ-secretase and MCT proteins, all 
require further investigation. As many of the proposed functions of this protein have 
been linked to AD pathogenesis, further research into this protein may yield important 
information concerning the development and potential prevention of AD pathology. 
Some of the proposed future studies include, but are not limited to the following: 
 
 A larger sample size of AD cases with similar disease severity as classified by 
the Braack Staging method, together with age-matched control cases, should be 
 274 
 
assembled in order to compare more effectively CD147 expression levels in AD 
and age-matched control brains. 
 It may be beneficial to sequence a larger portion of CD147 promoter region in a 
well characterized cohort in order to identify other possible CD147 promoter-
related SNPs that may be associated with AD pathology. 
 The effects of the newly discovered -61A>G and 37C>G CD147 SNPs on AD 
pathology and on the transcription/translation of CD147 protein should be 
investigated, to help characterise further the role(s) of CD147.   
 
7.10: Conclusions 
 
This study has reported that (a) increasing cholesterol and Aβ42 loading affect cell 
viability, induce CD147 expression and that adenoviral mediated CD147 expression 
protects neuronal cultures against Aβ42 induced oxidative stress and injury only in the 
presence of CyPA. (b) that there is an association between high fat / high cholesterol 
diet and plasma cholesterol with a trend towards increasing cerebral CD147 levels and a 
positive correlation between CD147 and plasma cholesterol levels. (c) that CD147 
protein levels are not significantly elevated in AD. In addition, we report that (d) SNPs 
within the CD147 promoter region are not associated with AD and finally (e) that two 
novel SNPs (-61A>G and 37C>G) within the CD147 promoter region (not listed in the 
NCBI) have been identified.  
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